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ABSTRACT	
	
Introduction	
RNA	 viruses	 are	 economically	 important	 pathogens	 of	 fish,	 and	 among	 these	 viruses,	
infectious	pancreatic	necrosis	virus	(IPNV)	is	of	particular	concern	for	the	aquaculture	industry,	
especially	for	farmed	rainbow	trout	(Oncorhynchus	mykiss)	and	Atlantic	salmon	(Salmo	salar).	
This	non-enveloped	aquatic	virus,	which	was	 first	 isolated	 in	 the	UK	 in	1971,	belongs	 to	 the	
family	of	Birnaviridae	and	has	a	bi-segmented	dsRNA	genome	of	about	6kb.	IPNV	is	classified	
in	 6	 genogroups	 with	 correspondence	 to	 10	 known	 serotypes	 and	 an	 additional	 proposed	
genogroup	of	marine	aquabirnaviruses	(MABV).	
IPNV	 causes	 high	 mortality	 in	 fry	 and	 a	 reduced	 mortality	 in	 adult	 fish,	 respectively.	 Fish,	
which	 survive,	 can	 become	 carriers	 and	 this	 can	 lead	 to	 a	 clinical	 outbreak	 by	 releasing	
infective	material	into	water	or	by	vertical	transmission	via	oocytes,	milt	and	seminal	fluids.	
	
Methods	
This	project	aimed	at	determining	the	phylogeny	and	genomic	changes	of	IPNV	in	Scotland	by	
whole	genome	sequence	analysis	of	IPNV	isolates	(diagnostic	TCID50	supernatants)	spanning	3	
decades	since	1982,	using	next	generation	sequencing	technology.	Viral	RNA	of	IPNV	culture	
supernatant	(CHSE-214	and	TO	cell	culture)	was	processed	for	next	generation	sequencing	on	
an	 Illumina	MiSeq	 platform.	 Library	 preparation	was	 performed	 using	 the	 Nextera	 XT	 DNA	
Library	 Kit,	 prior	 to	 sequencing	 according	 to	 the	 manufacturer’s	 MiSeq	 Reagent	 Kit	 v3	
(150cycles)	 protocol.	 To	 optimize	 whole	 genome	 next	 generation	 sequencing	 for	 IPNV,	 we	
compared	 two	 RNA	 processing	 protocols,	 the	Glasgow	 (GLAP)	 and	 the	Goettingen	 protocol	
(GOEP)	 with	 focus	 on	 missing	 terminal	 nucleotides	 after	 a	 de	 novo	 genome	 assembly.	
Sequences	were	used	to	determine	the	phylogeny	and	selection	pressure	on	the	genome	as	
well	as	a	possible	virus-host	adaptation.	
	
Results	
The	 results	 showed	 that	 both	 protocols	 were	 able	 to	 give	 full	 length	 genomes	 as	 well	 as	
genomes	with	missing	terminal	nucleotides.	
The	phylogenetic	analysis	of	57	sequenced	 IPVN	 isolates	 shows	 that	78.95	%	of	 the	 isolates	
group	within	genogroup	V,	which	includes	serogroup	Sp	and	5.26	%	within	genogroup	I	which	
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includes	 serogroup	 Ja.	 Segment	 A	 of	 15.79	 %	 of	 the	 isolate	 grouped	 within	 genogroup	 III,	
which	includes	serotype	Ca1	and	Te	but	only	7.02	%	of	the	segment	B	isolates	grouped	in	the	
genogroup	III.	The	remaining	8.77	%	of	segment	B	groups	within	genogroup	II,	containing	the	
Ab	serotype.	
Previous	research	has	shown	that	residue	substitutions	at	positions	217	and	221	in	the	major	
capsid	protein	VP2	have	an	impact	on	the	virulence	of	the	virus,	leading	to	different	virulence	
types:	virulent	(T217,	A221),	low	virulence	(P217,	A221),	avirulent	(T217,	T221)	and	persistent	
(P217,	T221).	Whole	genome	sequence	results	show	that	58.93	%	of	the	sequenced	 isolates	
belong	to	the	persistent,	32.14	%	to	the	low	virulent	type,	only	one	isolate	was	of	a	virulent	
type	and	7.15	%	had	not	virulence	assigned	amino	acid	compositions	in	positions	217	and	221.	
The	selection	pressure	analysis	showed	that	especially	VP2	is	experiencing	selection	pressure	
in	the	variable	region.	 In	the	VP1	protein	we	see	two	sites	under	positive	selection	pressure	
within	specific	motifs.	VP5	showed	positive	selected	sites	mostly	within	the	truncated	region	
of	the	protein.	Other	proteins	showed	no	particular	interesting	sites	of	selection.	
The	codon	adaptation	analysis	showed	highest	adaptation	index	for	VP2.	Besides	VP5,	which	
had	an	CAI	index	below	one,	therefore	showing	negative	adaptation,	other	IPNV	proteins	had	
an	CAI	of	barely	above	the	value	of	1.	
The	 dinucleotide	 abundance,	 focussing	 on	 CpG,	 showed	 that	 CpG	 is	 underrepresented	 in	
segment	A	and	B.	
	
Discussion	
Phylogenetic	 analysis	 of	 the	 sequenced	 IPNV	 strains	 shows	 separate	 clustering	 of	 different	
genogroups.	 Genetic	 reassortment	 is	 observed	 in	 segment	 B	 showing	 a	 grouping	 within	
genogroup	III	and	II	although	the	segment	A	of	these	isolates	was	grouping	exclusively	within	
III.	
We	 found	that	over	50	%	of	 the	 isolates	belong	 to	 the	persistent	and	over	30	%	to	 the	 low	
virulent	type,	assuming	that	due	to	not	sterilising	vaccination	these	types	were	selected	in	the	
vaccinated	population.		
The	results	from	the	CAI	calculations	indicate	an	adaptation	of	IPNV	to	its	host.	Together	with	
the	 findings	 that	CpG	 is	underrepresented	 in	 IPNV	 it	 suggests	 that	 this	 leads	 to	an	 immune	
escape.	 Especially	 since	 the	 selection	 pressure	 analysis	 showed	 positive	 selection	 in	 VP2	
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within	 the	 virulence	 determination	 sites	 of	 the	 protein,	 indicating	 that	 IPNV	 “tries”	 to	
downregulate	immune	recognition.	
The	prevalence	of	mostly	persistent	type	of	isolates	indicates	together	with	the	assumption	of	
adaptation	and	immune	escape	that	IPNV	is	evolving	with	the	host	in	order	to	ensure	survival.	
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1 Introduction	
1.1 Infectious	pancreatic	necrosis	virus	
1.1.1 The	disease	
Infectious	 pancreatic	 necrosis	 virus	 (IPNV)	 is	 a	 wide-spread	 pathogen	 of	 aquatic	 animals	
(Munro	and	Midtlyng	2011)	 that	has	been	 isolated	worldwide.	The	regions	with	 the	highest	
IPNV	reports	are	 the	ones	with	 intensive	aquaculture.	The	virus	and	 the	disease	patterns	 in	
Atlantic	salmon	(Salmo	salar)	as	the	host	organism	are	described	in	the	following.	As	this	work	
is	about	the	molecular	evolution	of	IPNV	I	will	mainly	focus	on	these	aspects,	while	only	briefly	
describing	disease	patterns,	diagnostic	and	preventive	measurements.	
IPNV	 causes	 a	 high	mortality	 of	 up	 to	 100	%	 in	 salmonid	 fry	 in	 freshwater,	 and	 a	 reduced	
mortality	 in	adult	 fish.	Fish,	which	survive,	can	shed	 the	virus	 for	up	 to	6	years	as	 IPNV	can	
persist	 in	 B-cells,	 neutrophils	 and	 head	 kidney	 derived	 salmon	 leucocytes	 (Ronneseth,	
Pettersen,	and	Wergeland	2012)	(Ahne	and	Thomsen	1986).	Horizontal	transmission	by	IPNV	
virions	 shed	 into	 the	 water	 by	 persistently	 infected	 fish	 or	 vertical	 IPNV	 transmission	 via	
oocytes,	milt	and	seminal	fluids	can	lead	to	new	infections	in	naïve	fish.	
Infectious	pancreatic	necrosis	(IPN)	mostly	occurs	 in	young	animals	and	can	be	symptomatic	
or	asymptomatic.	The	symptom	can	differ	and	not	every	infected	fish	develops	all	described	
symptoms.	Infected	young	Atlantic	salmon	lose	appetite,	are	lethargic	and	show	an	abnormal	
swimming	pattern.	Furthermore,	 they	are	darker	 in	appearance,	present	 internal,	as	well	as	
external	lesions,	abdominal	swelling,	pale	gills,	haemorrhages	and	necrosis	of	pancreatic	cells	
(Wood,	Snieszko,	and	Yasutake	1955)	(Wolf	1988)	(Smail	et	al.	1992)	(McKnight	and	Roberts	
1976,	Roberts	and	McKnight	1976).	
The	severity	of	IPNV	depends	on	factors	such	as	age,	feeding,	stress	and	temperature.	Smolts	
are	most	susceptible	4-12	weeks	after	transfer	into	sea	water	(Wolf,	Dunbar,	and	Pyle	1961)	
(Wolf,	 Fish,	 and	 Research	 1966)	 (Smail	 et	 al.	 1992)	 (Roberts	 and	 Pearson	 2005)	 (Skjelstad	
2003)	 and	 IPN	 develops	 after	 an	 incubation	 period	 of	 10-14	 days,	 depending	 on	 the	
temperature	(Ramstad	et	al.	2007)	(Okamoto	et	al.	1993,	Okamoto	et	al.	1987)	(Wetten	et	al.	
2007).	
	
1.1.2 Virus	characteristics	
IPNV	was	first	isolated	in	the	US	during	an	outbreak	in	rainbow	trout	(Onchorhynchus	mykiss)	
fingerlings	in	1955	(Wood,	Snieszko,	and	Yasutake	1955).	This	isolate	was	given	the	reference	
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number	 VR299.	 It	 appears	 that	 the	 first	 description	 of	 the	 disease	 was	 already	 published	
earlier	 by	M’Gonigle	 in	 Canada	 in	 the	 1940s.	 In	 Europe	 IPNV	was	 first	 detected	 in	 1964	 in	
southern	France	(Besse	and	de	Kinkelin	1965).	From	1968	on	IPNV	was	isolated	also	in	other	
European	countries	(Jorgensen	and	Bregnballe	1969).	The	first	isolation	in	the	UK	was	in	1971	
from	rainbow	trout	on	a	farm	in	Scotland	(Ball	et	al.	1971).	
	
1.1.2.1 IPNV	virion	
IPNV,	as	seen	in	Figure	1,	is	a	member	of	the	genus	Aquabirnavirus	in	the	family	Birnaviridae,	
has	a	non-enveloped,	single-shelled	capsid	of	a	T=13	icosahedral	symmetry	composed	of	260	
trimeric	 subunits	of	VP2	peptides	 (Lightner	and	Post	1969)	 (Hulo	et	al.	2010).	 It	 is	60	nm	 in	
diameter	 (Cohen,	 Poinsard,	 and	 Scherrer	 1973)	 and	 has	 a	molecular	weight	 of	 55	 x	 106	Da	
(Dobos	1995a,	b).	
	
	
Figure	 1.	 IPNV	 in	 FHM	 cells;	 short	 arrow	 indicates	
virus-specific	 tubules;	 long	 arrow	 shows	 crystalline	
arrays	of	virions.	Scale	represents	200nm	(Crane	and	
Hyatt	2011).	
	
The	 stability	 and	 infectivity	 of	 the	 virus	 depends	 on	 water	 temperature,	 salinity	 and	 the	
presence	 of	 microbial	 flora	 (Mortensen,	 Nilsen,	 and	 Hjeltnes	 1998)	 (Ahne	 1982)	 (ToReNzo	
1983).	 Studies	 have	 shown	 that	 IPNV	 is	 stable	 at	 salinity	 ranges	 from	 0	 to	 40	 %	 and	 at	
temperatures	from	-80	°C	to	+40	°C,	with	a	reduction	of	infectivity	above	20	°C.	Freezing	and	
thawing	was	shown	to	decrease	the	virus	titre	(Mortensen,	Nilsen,	and	Hjeltnes	1998)	(Barja	
et	al.	1983),	with	differences	between	the	IPNV	strains	(McMichael,	Fryer,	and	Pilcher	1975).	
Taken	together,	greatest	 IPNV	stability	 is	achieved	 in	filter-sterilised	or	autoclaved	estuarine	
water	at	15	°C	(Barja	et	al.	1983)	(ToReNzo	1983).	
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1.1.2.2 IPNV	genome	
The	 IPNV	 genome	 is	 a	 bi-segmented,	 double-stranded,	 RNase	 resistant	 RNA	 genome	 of	
5,881kb	(Jasper	strain)	(Duncan	et	al.	1987)	which	is	composed	of	a	3097	bp	long	segment	A	
and	 a	 2784	 bp	 long	 segment	 B	 (NC_001915.1;	 NC_001916.1).	 Each	 segment	 is	 linked	 to	 a	
Serine	residue	at	the	5’-end	of	the	genome-linked	protein	(VPg/VP1)	and	has	no	3'-poly-A	tail	
(Dobos	1995a,	b).	
Segment	A	contains	two	overlapping	open	reading	frames	(ORFs)	that	are	read	through	leaky	
scanning,	where	the	40	S	ribosome	subunit	skips	the	first	ORF	and	continues	scanning	until	it	
gets	 to	 the	 second	 overlapping	 ORF.	 The	 larger	 first	 ORF	 encodes	 a	 106	 kDa	 polyprotein	
composed	of	5’-pVP2-VP4-VP3-3’.	The	second	(small)	overlapping	ORF	encodes	the	Arginine-
rich	 non-structural	 15	 kDa	 VP5	 protein	 (Dobos	 1995a,	 b).	 Segment	 B	 is	 monocistronic	 and	
contains	only	one	ORF	that	encodes	the	RNA-dependent	RNA	polymerase	(RdRp/VP1),	in	form	
of	a	94	kDa	VP1/VPg	protein	(Duncan	and	Dobos	1986,	Duncan	et	al.	1987)	(Dobos	1995a,	b).	
	
	
Figure	 2.	 Segment	 A	 and	 B	 of	 IPNV;	 VP1	 is	 bound	 to	 each	 5’-end	 of	 the	 bi-
segmented	dsRNA	genome,	which	encodes	the	proteins	VP2,	VP3,	VP4	and	VP5	 in	
segment	A	and	VP1	in	segment	B	(Dobos	1995a).	
	
1.1.2.3 IPNV	proteins	
IPNV	encodes	 five	proteins,	 four	 located	on	segment	A	and	one	 located	on	segment	B.	The	
proteins	VP2,	VP3	and	VP4	derive	from	one	polyprotein	as	shown	in	Figure	2	and	Figure	5.	This	
polyprotein	generates	first	the	62	kDa	protein	pVP2,	which	is	further	cleaved	during	the	virus	
maturation	to	the	54	kDa	VP2	protein	and	the	propeptides	p1-3,	that	are	associated	with	the	
virion,	and	the	31	kDa	VP3.	This	is	achieved	via	post-translational	modification	by	the	29	kDa	
Serine-Lysine	 protease	VP4	 (Figure	 5	 and	 Table	 1)	 (Huang	 et	 al.	 1986)	 (Duncan	 et	 al.	 1987)	
	 18	
(Nagy	 et	 al.	 1987)	 (Manning	 and	 Leong	 1990);(Petit	 et	 al.	 2000)	 (Galloux,	 Chevalier,	 Henry,	
Huet,	Da	Costa,	et	al.	2004).	
	
Table	1.	IPNV-protein	overview.	
Protein	 Segment	 Size	(kDa)	 Function	
VP1/	VPg	 B	 94	 RdRp/	genome-linked	VP1	
Polyprotein	 A	 106	 precursor	of	VP2,	VP3	and	VP4	
pVP2	 A	 63	 pre-VP2	
VP2	 A	 54	 major	capsid	protein	
VP3	 A	 31	 minor	capsid	protein	
VP4	 A	 29	 Serine-Lysine	protease	
VP5	 A	 15-17	 anti-apoptosis/	non-structural	protein	
	
1.1.2.3.1 VP1/	RdRp	
VP1	 is	encoded	on	segment	B	and	 is	a	RNA-dependent	RNA	polymerase	 (RdRp,	VP1)	with	a	
GTP-binding	region	(G	motif)	and	6	conserved	motifs	 I	–	VI	 (I=F;	 II=C;	 III=A;	 IV=B;	V=D;	VI=E;	
GTP	 binding	 motif=G),	 which	 performs	 RNA	 transcription	 and	 genome	 replication.	 The	
polymerase	sequence	motifs	are	 II	–	 III	–	 IV	with	ADN	being	 the	catalytic	 residue	 in	motif	 II	
(Graham	et	al.	2011).	It	 is	 larger	compared	to	the	polymerases	of	other	RNA	viruses.	 In	vitro	
experiments	 showed	 that	 this	 polymerase	 acts	 as	 a	 primer	 and	 uses	 a	 semi-conservative	
(displacement)	mechanism	for	RNA	replication.	Furthermore,	it	is	active	in	the	virion	without	
any	processing	such	as	proteolysis.	The	optimal	enzymatic	activity	was	shown	to	be	at	30	°C,	
pH	 of	 8.0	 and	 in	 the	 presence	 of	 6	 mM	 Mg2+-ions,	 although	 the	 pH	 and	 the	 Mg2+	
concentrations	were	not	 critical	 for	 the	polymerase	activity	 (Mertens,	 Jamieson,	 and	Dobos	
1982).	 Further	 studies	 showed,	 that	 the	 IPNV	 polymerase	 also	 has	 a	 terminal	
(deoxy)nucleotide	 transferase,	 RNA-dependent	 DNA	 polymerase	 (reverse	 transcriptase)	 and	
template-independent	self-guanylylation	activity	(Graham	et	al.	2011).	
It	was	 also	 shown	 that	 the	 IPNV	RdRp	 exists	 in	 two	 forms	within	 the	 virion:	 as	 VPg,	which	
binds	 to	 the	 5’-end	 of	 each	 genome	 segment	 by	 a	 N-terminal	 Serine-5’-
guanosinemonophosphate	phosphodiester	bond	(Calvert	et	al.	1991)	which	occurs	only	in	the	
Birnaviridae	 dsRNA	 family,	 and	 as	 a	 free	 polypeptide	 VP1	 that	 functions	 as	 a	 RdRp.	
Comparison	of	RdRps	of	other	dsRNA	viruses	showed	that	the	RdRp	of	IPNV	does	not	have	the	
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Glycine-Aspartic	acid-Aspartic	acid	(GDD)	motif,	which	is	typical	for	this	enzyme	family	but	a	
structurally	similar	Alanine-Aspartic	acid-Asparagine	(ADN)	motif	(Dobos	1995a,	b,	Graham	et	
al.	2011,	Gorbalenya	et	al.	2002).	
Additionally,	VP1	is	the	only	protein	in	the	virion	that,	as	VP1pG,	auto-catalyses	in	a	template-
independent	manner	 the	 addition	 of	 a	 GMP	 to	 a	 Serine	 residue	 (within	 the	 N-terminal	 27	
residues)	 so	 it	 can	 act	 as	 a	 primer	 for	 the	 replication	 during	 the	 viral	 ssRNA(+)	 synthesis	
(Dobos	 1993)	 (Xu,	 Si,	 and	 Dobos	 2004)	 (Graham	 et	 al.	 2011).	 The	 catalytic	 binding	 site	 is	
conserved	within	the	Birnaviridae,	which	makes	it	a	general	feature	of	the	polymerases	of	this	
virus	family.	Protein	structure	studies	revealed	that	the	N-terminus	(Serine	2)	of	VP1	interacts	
with	its	active	site	and	is	ligated	to	the	nascent	RNA	daughter	strand	during	RNA	replication.	
This	finding	provides	a	model	for	the	mechanism	of	viral	genome-polymerase	association	that	
is	observed	in	vivo.	It	is	suggested	that	the	N-terminus	of	the	polymerase	domain	plays	a	role	
in	 recruiting	 dNTPs,	 since	 it	 was	 observed	 close	 to	 the	 (d)NTP	 entry	 tunnel	 (Graham	 et	 al.	
2011).	Since	we	know	that	VP1	has	a	reverse	transcriptase	activity	it	can	utilise	dNTPs	beside	
NTPs	and	form	RNA/DNA	hybrids.	
Genetic	comparison	experiments	of	 the	 IPNV	Jasper/genogroup	 I	and	Sp/genogroup	V	RdRp	
revealed	 that	 there	 is	 an	 88	 %	 homology	 between	 each	 other,	 but	 only	 41	 %	 with	 the	
Birnavirus	 Infectious	 Bursal	 Disease	 Virus	 (IBDV)	 RdRp.	 Nevertheless,	 homologues	 regions	
exist	within	the	central	part	of	the	proteins	(Duncan	et	al.	1991).	
	
1.1.2.3.2 VP2	
When	Santi	et.	al.	(2004)	compared	the	sequences	of	different	IPNV	Sp/	genogroup	V	isolates,	
they	found	that	the	major	capsid	protein	VP2	is	more	variable	in	the	coding	region	than	VP1,	
VP3	and	VP4	 sequences.	VP2	 contains	a	 variable	domain	 in	 the	 central	 region	between	 the	
residues	 183-335,	 which	 is	 an	 important	 antigenic	 site	 (Blake	 et	 al.	 2001)	 and	 two	
hypervariable	 region	 between	 the	 residues	 239-257	 and	 271-284.	 Further	 experiments	
revealed	 that	a	Threonine	 (Thr)	 instead	of	Proline	 (Pro)	at	position	217	and	Alanine	 (Ala)	at	
position	 221	 are	 characteristic	 for	 virulent	 IPNV	 Sp	 isolates	 (Santi,	 Vakharia,	 and	 Evensen	
2004b).	 Interestingly,	 both	 residues	 are	 located	 within	 the	 hypervariable	 region.	 The	
observation	of	the	Ala/Thr	change	at	position	221	was	always	made	after	2	passages	in	CHSE-
214	 cell	 culture,	 which	 probably	 shows	 an	 attenuation	 of	 the	 virus	 in	 cell	 culture	 (Santi,	
Vakharia,	and	Evensen	2004b),	it	was	however	not	shown	in	RTG-2	cell	line	even	after	several	
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passages	 (Song	 et	 al.	 2005).	 However,	 it	 is	 assumed	 that	 Alanine	 at	 position	 221	 reduces	
binding	affinity	to	cell	receptors,	resulting	in	more	effective	virus	release	and	therefore	higher	
replication	(Mutoloki	et	al.	2016).	
As	previously	mentioned,	the	capsid	of	the	virion	is	made	of	260	VP2	subunits.	Each	subunit	is	
folded	 into	 three	 domains,	 base	 (B),	 shell	 (S)	 and	 projection	 (P)	 (see	 Figure	 3).	 Domain	 P	
harbours	loops,	which	are	the	most	exposed	part	of	the	VP2	trimer	and	contain	the	antigenic	
sites	and	virulence	factors.	
	
	
Figure	3.	 IPNV	and	IBDV	VP2;	(A)	Ribbon	diagram	of	 IBDV-VP2	with	nuanced	domains	B,	S	and	P.	(B)	Ribbon	
diagram	 of	 IPNV-VP2	 with	 nuanced	 domains	 B,	 S	 and	 P.	 (C)	 Alignment	 of	 IPNV	 (blue)	 and	 IBDV	 (red)	 VP2	
subunits.	Blue	and	red	stars	highlight	 residues	decisive	 for	virulence	of	 IPNV	and	 IBDV,	respectively.	The	 line	
indicates	the	molecular	3-fold	axis.	Boxes	highlight	regions	structural	divergence	and	stars	show	the	position	of	
the	amino	acid	residues	associated	with	virulence	in	IPNV	(blue;	217	and	221)	and	in	IBDV	(red;	253,	279,	284)		
(Coulibaly	et	al.	2010,	Coulibaly	et	al.	2005).	
	
1.1.2.3.3 VP3	
The	multifunctional	VP3	protein,	which	is	found	in	the	inner	layer	of	the	virus	capsid,	is	a	self-
binding	 protein.	 It	 also	 interacts	 with	 VP1	 and	 the	 dsRNA	 genome	 segments	 and	 seem	 to	
activate	 the	 RdRp	 (Pedersen,	 Skjesol,	 and	 Jørgensen	 2007)	 (see	 Figure	 4).	 The	 VP1-VP3	
interaction	does	not	require	the	presence	of	dsRNA.	 Interestingly,	 the	binding	between	VP1	
and	VP3	occurs	before	the	mature	virion	formation.	This	 interaction	could	play	a	role	 in	the	
assembly	process	of	IPNV	(Pedersen,	Skjesol,	and	Jørgensen	2007).	Furthermore,	VP3	inhibits	
IFNα	 induction	 in	 salmon	 cells	 by	 targeting	 the	 RIG-I/MDA5	 pathway	 to	 block	 immune	
response	during	infection	(Lauksund	et	al.	2015).	
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Figure	4.	Model	for	self-interaction	and	VP1	and	dsRNA	binding	sites	of	
the	IPNV-VP3	protein	(Pedersen,	Skjesol,	and	Jørgensen	2007).	
	
1.1.2.3.4 VP4	
The	 VP4	 protein	 is	 a	 Serine633-Lysine674	 protease	 that	 is	 essential	 for	 the	 polypeptide	
processing.	 It	cleaves	the	(Ser/Thr)-X-Ala	ê	 (Ser/Ala)-Gly	motif	of	the	polyprotein	at	 its	own	
N-terminal	site	at	amino	acid	position	508-509	of	the	pVP2-VP4	junction	and	at	its	C-terminal	
site	at	position	734-735	of	the	VP4-VP3	junction,	as		shown	in	Figure	5	(Petit	et	al.	2000).	As	
VP3,	VP4	also	has	an	immune	response	blocking	activity	by	inhibiting	the	IFNα1	promotor	in	
salmon	cells	(Lauksund	et	al.	2015).	
	
	
Figure	5.	Segment	A	encoded	polyprotein	with	VP4	cleavage	sites	(Munro	and	Midtlyng	2011).	
	
1.1.2.3.5 VP5	
VP5	 is	 a	 non-structural	 Arginine-rich	 anti-apoptosis	 protein	 and	 is	 expressed	 early	 in	 the	
replication	cycle.	It	shares	homologous	domains	with	Bcl-2	and	shuts	off	the	host’s	apoptosis	
system	by	down	regulation	of	Mcl-1,	which	induces	cells	to	undergo	apoptotic	cell	death.	This	
way	 IPNV	 enhances	 cell	 survival	 for	 the	 benefit	 of	 viral	 proliferation	 (Hong,	 Gong,	 and	Wu	
2002).	Besides	that,	together	with	VP4,	VP5	inhibits	the	IFN	expression	facilitated	by	the	Mx	
promoter	and	has	an	antagonistic	effect	(Skjesol	et	al.	2009).	The	small	ORF,	which	encodes	
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the	 protein,	 shows	 a	 high	 level	 of	 variation	 within	 the	 genome	 of	 different	 IPNV	 Sp	
serotype/genogroup	V	isolates	with	an	additional	in-frame	stop	codon	at	nucleotide	position	
472,	 that	 creates	 a	 12	 kDa	 version	 of	 the	 VP5	 protein	 and	 at	 nucleotide	 position	 496	 that	
results	 in	 an	 additional	 alternative	 (truncated)	 form	of	 VP5.	 It	was	 shown	 that	 IPNV	with	 a	
truncated	 VP5	 is	 virulent	 but	 this	 feature	 could	 not	 be	 confirmed	 in	 other	 challenge	
experiments	(Santi,	Sandtrø,	et	al.	2005,	Santi,	Song,	et	al.	2005,	Song	et	al.	2006,	Song	et	al.	
2005),	 where	 fish	 challenged	 with	 IPNV	 virions	 containing	 a	 truncated	 VP5	 showed	 only	
moderate	mortality.	The	fact	that	some	isolates	did	not	even	encode	the	VP5	protein	but	still	
induced	mortality,	 supports	 the	 findings	 that	 absence	of	VP5-expression	does	not	 influence	
the	 viral	 growth	 and	 virulence	 (Heppell	 et	 al.	 1995)	 (Weber	 et	 al.	 2001,	 Santi,	 Song,	 et	 al.	
2005).	
	
1.1.2.4 IPNV	classification	
Wolf	 and	Quimby	 found	 in	 1971	 (Wolf	 and	Quimby	 1971)	 that	 antibodies	 against	 the	 IPNV	
isolate	VR299	only	partly	deactivated	European	isolates.	Through	further	experiments	Hill	and	
Way	 suggested	 a	 classification	 of	 aquatic	 Birnaviruses	 in	 serotypes	 A	 and	 B	 and	 divided	
serogroup	A	 in	A1-A9,	 due	 to	 results	 in	 reciprocal	 cross-neutralisation	 assays	 (Hill	 and	Way	
1995).	 IPNV	belonging	 to	 serotype	A	 are	 found	worldwide,	whereas	 serotype	B,	which	was	
first	 described	 in	 the	mussel	Tellina	 tenuis	by	Underwood	 et	 al.	 in	 1977	 (Underwood	 et	 al.	
1977),	seems	to	be	endemic	primarily	in	the	North	Sea	close	to	Denmark.	
Although	 studies,	 which	 were	 done	 with	 polyclonal	 antibodies,	 confirm	 the	 9	 different	 A	
serotypes,	 experiments	 with	monoclonal	 antibodies	 (MAb)	 in	 an	 ELISA	 assay,	 targeting	 the	
major	 neutralisation	 epitopes	 within	 VP2	 (Frost	 et	 al.	 1995)	 showed	 that	 they	 could	 not	
distinguish	 between	 them.	 Until	 now,	 there	 are	 no	 suitable	 MAb-assays	 available	 to	
determine	the	serotype	of	an	IPNV	isolate	(Christie,	Ness,	and	Djupvik	1990,	Frost	et	al.	1995,	
Melby	and	Christie	1994).	
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Table	2.	Classification	of	IPNV	based	on	seroneutralization	and	genotyping	proposed	by	Hill	and	Way,	1995	(serotype)	and	Blake	et	al.,	2001	(genogroup).	Hosts	were	listed	
according	to	the	publications	(Hill	and	Way	1995,	Blake	et	al.	2001).	
Serotype	Nomenclature	 Serotype	
Name	
Genogroup	
Nomenclature	
Host	 Origin	Country	
A1	 West	Buxton	(WB)	 I	 Trout	 USA	
A1	 Buhl	 I	 Trout	 USA	
A1	 Reno	 I	 Trout	 USA	
A1	 VR299	 I	 Trout	 USA	
A1	 Jasper	(Ja-Dobos)	 I	 Trout	 Canada	
A1	 Dry	Mills	(DM)	 I	 Trout	 USA	
A2	 Sparajub	(Sp)	 V	 Trout	 Denmark	
A2	 N1	 V	 Atlantic	salmon	(Salmo	salar)	 Norway	
A3	 Abild	(Ab)	 II	 Trout	 Denmark	
A4	 Hecht	(He)	 VI	 Pike	 Germany	
A5	 Tellina	(Te)	 III	 Tellina	 UK	
A6	 Canada1	(C1)	 III	 Trout	 Canada	
A7	 Canada2	(C2)	 IV	 Trout	 Canada	
A8	 Canada3	(C3)	 IV	 Arctic	char	(Salvelinus	alpinus)	 Canada	
A9	 Jasper	(Ja)	 I	 Trout	 Canada	
B1	 Tellina	virus	(TV-1)	 III	 Tellina	 UK	
MABV	(Marine	Aquabirnavirus)	(Zhang	and	
Suzuki	2004,	Nishizawa,	Kinoshita,	and	
Yoshimizu	2005)	
Yellowtail	virus	(Y-6,	YT-01A)	 VII	 Yellowtail	 Japan	
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On	the	other	hand,	sequencing	the	genome	of	IPNV	can	be	used	to	genogroup	IPNV.	Based	on	
the	large	ORF	in	segment	A	and	the	VP2	region,	IPNV	is	now	classified	in	6	genogroups	with	
correspondence	to	the	known	10	serotypes	as	shown	in	Table	2	with	an	additional	genogroup	
for	Marine	Aquabirnavirus	as	proposed	by	Zhang	and	Suzuki	in	2004	(Zhang	and	Suzuki	2004)	
(Hill	and	Way	1995)	(Blake	et	al.	2001)	(Cutrin	et	al.	2004).	
Nevertheless,	 since	 Romero-Brey	 reported	 a	 natural	 reassortment	 between	 two	 different	
strains	in	2009,	due	to	coinfection	of	two	different	strains	in	one	fish,	where	segment	A	from	
one	strain	and	segment	B	from	another	strain	rearranged	together	in	a	new	virion.	Therefore,	
both	segment	A	and	B	should	be	sequenced	for	better	genomic	characterisation	of	each	IPNV	
isolate	(Romero-Brey	et	al.	2009).	Further	research	showed	that	reassortment	in	IPNV	is	not	
random	and	 that	 some	 segments	 replicate	more	efficiently	 than	others	 in	 a	 cell-dependent	
manner	and	that	it	can	as	well	influence	the	virulence	(Lago	et	al.	2017).	
	
1.1.2.5 IPNV	replication	model	
IPNV	replicates	in	the	cytoplasm	of	a	host	cell.	Since	eukaryotic	cells	do	not	produce	dsRNA,	
they	 recognise	 the	 viral	 dsRNA	 as	 a	 pathogen	 associated	 molecular	 pattern	 (PAMP)	 and	
inactivate	 it,	 which	 leads	 to	 development	 of	 immune	 escape	 mechanism	 due	 to	 mutation	
pressure	initiated	by	the	immune	system	of	the	host.	This	will	be	discussed	in	detail	further	in	
the	thesis,	especially	in	the	discussion.		
One	replication	cycle,	as	first	shown	in	details	in	CHSE-214	cells,	takes	approximately	16-20	h	
depending	on	the	temperature,	although	the	RdRp	is	active	even	at	temperatures	above	30	°C	
(Mertens,	 Jamieson,	 and	 Dobos	 1982).	 In	 some	 cells,	 researchers	 observed	 a	 persistent	
infection	with	a	very	low	viral	replication	without	any	cytopathic	effect	(CPE)	probably	due	to	
the	overproduction	of	defective	interfering	particles	(MacDonald	and	Kennedy	1979)	(Hedrick	
and	 Fryer	 1981).	 IPNV	 enters	 the	 host	 through	 gills,	 skin	 and	 gut	 penetrating	 the	 cell	 by	
binding	VP2	 to	polypeptides	on	 the	cell	 surface	 (Dobos	1995a,	b)	 (Kuznar	et	al.	1995)	 to	be	
adsorbed	 into	 the	 cell	 through	 endocytosis	 (Couve,	 Kiss,	 and	 Kuznar	 1992).	 For	 CHSE-214	
specifically	 it	 was	 shown	 that	 IPNV	 enters	 via	 macropinocytosis	 (Levican	 et	 al.	 2017).	 It	 is	
assumed	that	the	virion	is	not	being	uncoated	during	the	entry	process	(Cohen	1975,	Patton	
and	 Spencer	 2000)	 and	 that	 during	 the	 replication	 cycle,	 the	 genome	 of	 dsRNA	 viruses	
remains	within	the	capsid,	to	protect	the	viral	genome	from	Rig-I	like	receptors	(RLRs)	of	the	
innate	 immune	response,	 in	the	presence	of	the	active	RdRp	inside	the	virion.	At	2-4	h	post	
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infection	a	first	transcription	intermediate	can	be	detected	as	well	as	the	viral	mRNA	and	viral	
polypeptides	after	4-6	hours.	The	maximum	amount	of	viral	mRNA,	which	does	not	have	a	5’	
poly	 A	 tail,	 is	 found	 after	 8-10	 hours	 and	 decreases	 after	 14	 h	 (Somogyi	 and	 Dobos	 1980)	
(Dobos	 1995a,	 b).	 Viral	 proteins	 are	 produced	 in	 approximately	 the	 same	 proportions	
between	3	and	14	h	after	 infection	 (Dobos	et	 al.	 1977,	Dobos	1977).	 The	viral	particles	are	
formed	from	non-infectious	premature	provirions	that	contain	pVP2.	The	maturation	process,	
which	 involves	 the	 cleavage	 of	 pVP2	 to	 VP2	 by	 the	 VP4	 protease,	 creates	 then	 mature	
infectious	virions	(Villanueva	et	al.	2004).	
	
	
Figure	 6.	 IPNV	 replication	 model	 proposed	
by	Villanueva	et	al.,	showing	different	steps	
in	 the	 infective	 cycle,	 considering	
intermediates	 possibly	 such	 as	 defective	
interfering	particles	(Villanueva	et	al.	2004).	
Further	 in	 vitro	 experiments	 showed,	 that	 transcription,	 which	 is	 primed	 via	 VP1	 and	 is	
proceed	 as	 an	 asymmetric,	 semi-conservative	 strand-displacement	 mechanism,	 results	 in	
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synthesis	of	only	 (+)	strands	of	 the	genome	segments	 that	are	attached	to	 the	template	via	
base	pairing	(Dobos	1995a,	b).	Produced	viral	mRNA	functions	as	template	for	translation	to	
produce	 viral	 proteins	 and	 replication	 of	 the	 viral	 genome.	 Villanueva	 and	 colleagues	
proposed	a	model	of	IPNV	replication	based	upon	the	research	done	so	far,	which	shows	the	
different	steps	of	the	replication	(Villanueva	et	al.	2004).	
	
1.1.3 Pathogenicity	
Cell	 culture	 is	 a	diagnostic	method,	 that	provides	proof	of	 the	presence	of	 infectious	 intact	
IPNV	at	the	time	of	sampling.	Usually,	the	pathogen	achieves	high	titres	in	infected	tissues	and	
there	is	no	known	stage	of	the	disease	at	which	the	virus	is	not	detectable	in	cell	culture.	
An	infection	with	IPNV	results	in	a	clear	visible	cytopathic	effect	(CPE)	in	cells.	Many	cell	types	
are	susceptible	to	IPNV	infection.	Several	cell	lines	are	used	for	IPNV	detection	and	isolation.	
For	 best	 results	 the	 CHSE-214	 cell	 line	 should	 be	 used	 (Lorenzen,	 Carstensen,	 and	 Olesen	
1999).	It	was	further	shown	that	IPNV	does	attenuate	(undergoes	mutations	which	lead	to	a	
weaker	virus	type)	in	CHSE-214	cells	but	not	in	RTG-2	cell	culture	(Song	et	al.	2005)	even	after	
several	passages	(see	1.1.2.3.2).	Another	difference	between	cell	lines	is	the	cellular	immune	
response	to	IPNV.	RTG-2	cells	produce	interferon,	whereas	CHSE-214	do	not,	so	IPNV	in	CHSE-
214	 results	 in	 higher	 virus	 titres.	 Therefore,	 CHSE-214	 is	 mostly	 used	 for	 IPNV	 growth	
(MacDonald	 and	 Kennedy	 1979,	 Dobos	 1995a).	 IPNV	 grows	 in	 cell	 culture	 at	 10-25	 °C,	
dependent	on	the	cell	line	used.	CHSE-214	cells	are	cultured	in	the	dark	at	21°C	and	5	%	CO2.	
Another	 cell	 line	 used	 for	 IPNV	 infection	 is	 the	 TO	 cell	 line	 derived	 from	 head	 kidney	
leucocytes	of	 the	Atlantic	 salmon	cultured	at	20	 °C	with	5	%	CO2	 (Wergeland	and	 Jakobsen	
2001).	
	
1.1.4 IPNV	diagnostics	
Standard	diagnosis	of	IPN	disease	is	carried	out	by	isolating	IPNV	on	cell	culture	followed	by	
antibody-based	detection.	However,	this	 is	time	(up	to	three	or	four	weeks)	and	 laboratory-
space	 consuming	 and	 needs	 specially	 trained	 technicians	with	 cell	 culture	 experience.	Over	
the	years	immunological	and	molecular	techniques	have	been	developed	that	allow	a	faster,	
more	sensitive	and	even	quantitative	detection	of	IPNV	(Table	3).	
The	 diagnostic	 criteria	 for	 an	 aquatic	 pathogen	 are	 defined	 by	 the	World	 Organization	 for	
Animal	 Health	 and	 American	 Fisheries	 Society	 (OIE	 2000).	 Sampling	 for	 IPNV	 diagnostics	 is	
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different	for	each	method	and	the	size	of	the	fish	but	most	methods	require	the	sampling	of	
the	liver,	kidney	and	spleen.	
	
Table	3.	Overview	of	methods	for	IPNV	diagnosis	(Munro	and	Midtlyng	2011).	
Technique	 Concept	
Cell	culture	 Viral	isolation	
Neutralisation	Assay	 	
	
	
Antibody	binding	assays	
FAT	
ELISA	
Immunohistochemistry	
Immunodot	blot	
Flow	cytometry	
Coagglutination	test	
RT-PCR	 	
Amplification	and	detection	
of	viral	nucleic	acid	
real-time	PCR	
RT-LAMP	
In	situ	hybridisation	
	
1.1.5 Epidemiology	
First	disease	outbreaks	caused	by	IPNV	on	Atlantic	salmon	farms	in	Europe	were	reported	in	
Norway	 in	 the	 1980s	 (Christie	 et	 al.	 1988)	 and	 later,	 in	 the	 1990s,	 in	 Scotland	 (Smail	 et	 al.	
1992).	 It	 is	assumed	that	 IPNV	 infects	a	wide	range	of	up	to	100	hosts,	 including	fish,	water	
birds	and	crustaceans	(Munro	and	Midtlyng	2011)	and	has	been	detected	worldwide.	It	is	the	
most	important	disease	in	its	impact	on	farmed	salmon	production	in	the	European	Union	and	
in	 Norway	 (Ariel	 and	 Olesen	 2002)	 (Murray,	 Busby,	 and	 Bruno	 2003).	 There	 are	 no	
publications	available	that	provide	statistics	about	losses	in	aquaculture	due	to	IPN,	although	
the	Fish	Health	Report	for	Norway	reports	a	reduction	on	IPNV	positive	tested	salmon	farming	
sites	 from	 223	 in	 2009	 to	 27	 in	 2016	 (Hjeltnes	 et	 al.	 2017).	 A	 study	 done	 by	 the	 Marine	
Laboratory	in	Aberdeen,	UK,	estimates	that	Scottish	farms	lost	up	to	2	M	GBP	(Murray,	Busby,	
and	Bruno	2003)	 and	 the	 loss	 in	 Ireland	was	up	 to	 €	 31	M	after	 an	 IPNV	outbreak	 in	 2006	
according	 to	 the	 Marine	 Institute	 in	 Galway,	 Ireland	 (Geoghegan,	 Ó	 Cinneide,	 and	 Ruane	
2007).	 Furthermore,	 all	 waters	 in	 Shetland	 are	 thought	 to	 be	 IPNV-contaminated.	 As	 the	
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disease	can	stay	for	up	to	3	months	in	post-	transfer	fish	and	can	be	shed	via	oocytes,	milt	and	
seminal	 fluid,	 this	 lead	 to	 the	 expansion	 of	 IPNV	 down	 the	 coast	 of	 Scotland	 by	 2001	 and	
reaching	Ireland	in	2002	possibly	through	trading	and	transmission	of	the	virus	into	the	wild	
fish	population.	To	prevent	huge	losses	farms	can	use	specific	post-transfer	diets	and	transfer	
systems	which	are	 less	stressful	for	the	stocked	fish.	There	are	also	IPN	resistant	fish	strains	
and	vaccines	available	(Roberts	and	Pearson	2005).	
Today	we	 know	 that	 certain	 IPNV	 strains	 are	 less	 virulent	 than	others.	 In	 2004	 Santi	 et	 al.,	
2004,	 described	 that	 certain	 amino	 acid	 positions	 in	 the	 VP2	 gene	 determine	 the	
pathogenicity	of	different	IPNV	strains	(Santi,	Vakharia,	and	Evensen	2004b).	
Today	we	differ	between	virulent	(T217	A221),	persistent	(P217	T221),	avirulent	(T217	T221)	
and	low	virulent	(P217	A221)	types	with	less	than	10	%	mortality.	The	virulent	strains	have	a	
high	 morbidity	 and	 mortality	 (Santi,	 Vakharia,	 and	 Evensen	 2004b)	 (Song	 et	 al.	 2005).	
Persistent	strains	 induce	a	high	morbidity	and	 in	general	no	mortality	but	may	 induce	some	
mortality	 later	 in	 the	 disease	 (Mutoloki,	Munang'andu,	 and	 Evensen	 2013)	 (Julin,	Mennen,	
and	Sommer	2013).	This	pattern	was	not	shown	in	a	big	study	of	Scottish	IPNV	isolates	where	
some	 of	 the	 PT	 isolates	 induced	 high	 mortalities	 (Bain,	 Gregory,	 and	 Raynard	 2008)	 as	
mentioned	 previously.	 Isolates	with	 the	 residues	 T217	 T221	 have	 only	 a	mortality	 of	 15	%,	
compared	to	T217	A221	with	>60	%	mortality	(Song	et	al.	2005).	
	
1.1.6 IPNV	vaccine	
Vaccines	are	an	important	measure	to	prevent	disease,	especially	when	there	is	no	treatment	
available,	as	it	is	mostly	the	case	for	viral	diseases.	There	are	different	types	of	vaccines,	such	
as	non-replicating	(inactivated	whole	virus	or	subunit	vaccines),	replicating	and	DNA	vaccines.	
Non-replicating	vaccines	contain	killed	pathogens	or	parts	of	pathogens	that	are	extracted	or	
synthesized,	 for	 example,	 a	 specific	 site	 of	 a	 protein.	 They	 are	widely	 used	 as	 they	 cannot	
cause	 the	disease	after	vaccination.	However,	 they	 require	higher	amount	of	 the	antigen	of	
interest,	 they	 have	 to	 be	 administered	 with	 adjuvants	 to	 increase	 the	 immune	 response,	
which	is	a	B-cell	response	that	results	in	antibody	production	against	the	administered	antigen	
(humoral	immunity)	and	they	result	in	a	shorter	protection	compared	to	replicating	vaccines.	
Replicating	vaccines	on	the	other	hand	simulate	a	natural	infection	and	therefore	are	capable	
of	 inducing	a	humoral	and	a	cellular	 immune	response.	The	administered	virus	 replicates	 in	
host	cells	and	is	therefore	presented	on	the	cell	surface	as	well.	This	results	in	a	much	longer	
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protection	than	given	by	non-replicating	vaccines.	DNA	vaccines	contain	a	genetic	sequence	of	
the	 antigen	 of	 interest	 that	 is	 embedded	 in	 a	 genetic	 delivery	 system	 like	 a	 plasmid	 and	 is	
expressed	 in	 the	 host	 cell	 to	 stimulate	 humoral	 and	 cellular	 immune	 response	 (Flint	 et	 al.	
2015,	Gudding,	Lillehaug,	and	Evensen	2014).		
First	vaccine	trials	were	launched	in	the	1970s	with	inactivated	or	attenuated	IPNV	and	failed	
to	 protect	 against	 the	 virus	 (Dorson	 1988).	 Then	Manning	 and	 Leong	 showed	 that	 the	 VP2	
coding	region	has	an	immunogenic	effect	able	to	induce	immunity	(Manning	and	Leong	1990).	
After	 that	 several	 recombinant	 vaccines	 were	 launched,	 such	 as	 in	 1995	 in	 Norway.	 IPN	
vaccines	 available	 today	 include	 either	 the	 main	 immunogenic	 protein	 VP2	 and	 other	
components	of	the	virus	(Rimstad	2014)	or	are	 inactivated	vaccines	(Gomez-Casado,	Estepa,	
and	Coll	2011).	However,	 there	 is	an	 issue	as	 fish	are	most	 susceptible	 to	 IPNV	before	 they	
reach	 their	 immunocompetent	age,	 so	 the	administration	of	a	vaccine	would	 result	 in	a	 full	
protection	(Rodriguez	Saint-Jean,	Borrego,	and	Perez-Prieto	2003).	
Quite	 often	 vaccine	 trial	 results	 as	 well	 as	 details	 on	 the	 exact	 antigen	 used	 were	 not	
published.	The	protection	shown	in	the	trials	were	said	to	be	more	than	80	%	but	this	was	not	
the	case	in	the	field	and	it	didn’t	stop	IPNV	outbreaks.	DNA	vaccines	were	developed	as	well	
but	they	could	not	be	administered	on	a	bigger	scale	due	to	regulatory	issues.	
Vaccines	 are	 administered	 via	 injection,	 submersion	 bath	 or	 per	 os	 to	 salmonids	 in	 the	
seawater	 stage	 (post-smolts).	 The	 best	 results	 were	 achieved	 by	 vaccination	 via	 injection	
although	that	is	difficult	due	to	the	size	of	the	vulnerable	fish	and	tissue	damage	caused.	
IPN	 outbreaks	 in	 Norway	 continued	 up	 to	 2010	 and	 dropped	 from	 2011	 onward,	 when	
commercial	 IPN	 resistant	 salmon	 breed	 became	 available	 (Olsen	 and	 Hellberg	 2012).	 It	 is	
possible	 to	 assume	 a	 similar	 scenario	 for	 the	 UK	 as	 IPN	 resistant	 salmon	 with	 identified	
quantitative	 trait	 loci	 (QTL)	 for	 IPN	 resistance	 (Houston,	 Bishop,	 et	 al.	 2009,	Houston	 et	 al.	
2008)	 also	were	 available	 from	 2010s	 on	 (Gheyas	 et	 al.	 2010).	 The	 IPNV-resistant	 QTL	 has	
been	shown	to	block	the	entry	of	the	T217,	A221	variant	(virulent	type)	in	infected	cells	and	in	
infected	fish	(Moen	et	al.	2015,	Houston,	Haley,	et	al.	2009).	
IPN	resistant	fish	seem	to	be	more	promising	than	vaccines	as	vaccines	show	a	big	variation	in	
terms	of	protection	depending	on	the	fish’s	immune-genetic	background	and	the	IPNV	strain	
involved	(Ramstad	and	Midtlyng	2008).	Initial	reports	from	northern	Norway	indicate	that	in	
recent	 years	 IPNV	 has	 evolved	 to	 overcome	 this	 resistance	 (O.	 Evensen,	 personal	
communication).	 	
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1.2 Next	generation	sequencing	(NGS)	
1.2.1 Overview	
Next	generation	sequencing	describes	high	throughput	sequencing	technology.	With	its	higher	
throughput,	 the	 ability	 to	process	multiple	whole	 genomes	 from	different	 organisms	 at	 the	
same	 time	 and	 lower	 costs	 than	 Sanger	 sequencing	 it	 provided	 a	 next	 level	 tool	 for	 basic	
research.	Furthermore,	it	is	used	in	clinical	diagnostics,	for	organism	identification	and	as	the	
technology	 gets	 smaller	 the	 devices	 can	 be	 even	 used	 in	 remote	 locations	 (Wetterstrand	
2013)	(Gargis	et	al.	2012).	
The	first	one	of	its	kind	was	available	in	the	2000s	and	since	then	this	type	of	technology	was	
called	NGS.	By	now	there	are	different	types	of	NGS	technologies,	differing	in	read	length	and	
sequencing	biochemistry.	
I	will	briefly	describe	the	technologies	I	used	in	this	study	to	sequence	whole	IPNV	genomes:	
The	Illumina	MiSeq	and	the	Oxford	Nanopore	Technologies	MinION	system,	as	well	as	the	two	
RNA	processing	protocols,	Goettingen	(GOEP)	and	Glasgow	(GLAP)	protocol.	
	
1.2.2 IPNV	RNA	processing	
In	this	study,	IPNV	RNA	was	sequenced	with	two	different	protocols.	The	Goettingen	(GOEP)	
protocol,	 that	was	 initially	 developed	 for	 454	Pyrosequencing	of	 RNA	 viruses	 at	Goettingen	
University,	 Germany	 (Dilcher	 et	 al.	 2012).	 This	 protocol	 was	 transferred	 to	 whole	 genome	
sequencing	 (WGS)	 using	 next	 generation	 Illumina	 sequencing	 technology	 (NGS).	 During	 the	
study	 it	was	 assessed	 in	 comparison	 to	 a	 simplified	 protocol,	 the	Glasgow	protocol	 (GLAP),	
from	a	 team	at	MRC	Virology	Glasgow	University,	UK	 (Thomson	et	al.	2016)	 that	developed	
this	protocol	in	order	to	sequence	HCV	directly	from	whole	blood	samples.	
Compared	 to	GOEP,	GLAP	 requires	a	quantitative	RT-qPCR	prior	 sample	processing	as	GLAP	
has	no	template-amplifying	step	(PCR)	prior	to	library	preparation.	The	RT-qPCR	is	necessary	
as	 the	 Illumina	MiSeq	 system	 has	 a	 detection	 limit	 of	 1	 x	 104	 genome	 copies/mL	 (1	 x	 101	
copies/µl)	 (Frey	 et	 al.	 2014).	 When	 sequencing	 viral	 genomes,	 it	 is	 of	 advantage	 to	 use	 a	
minimum	of	amplification	steps	to	avoid	introduction	of	mutations	by	the	polymerase.	Using	
the	GOEP	includes	performing	two	amplification	steps:	one	during	the	ds-cDNA	synthesis	and	
another	during	the	library	preparation.	Using	GLAP	results	only	in	one	amplification	during	the	
library	preparation	step	itself.	Besides	that,	the	GLAP	has	a	shorter	DNase	step	of	5	minutes	at	
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37	 °C	 compared	 to	 the	 GOEP	 of	 30	 minutes	 at	 37	 °C.	 Assuming	 RNase	 activity	 through	
contamination,	the	short	DNase	step	ensures	a	maximum	preservation	of	viral	RNA.	
In	summary,	both	protocols	convert	viral	dsRNA	into	ds-cDNA	in	their	specific	manner.	The	ds-
cDNA	 is	 further	 used	 for	 library	 preparation	 using	 the	 Illumina	 Nextera	 XT	 DNA	 Library	
Preparation	Kit.	
	
1.2.3 MiSeq	
1.2.3.1 MiSeq	sequencing	technology	
The	 Illumina	 MiSeq	 system	 is	 a	 short-read	 Sequencing	 by	 Synthesis	 (SBS)	 system,	 which	
sequences	by	using	cyclic	 reversible	termination.	 In	 this	case	the	nucleotides	that	 terminate	
the	 sequencing	 reaction	 have	 labelled	 protected	 3’-OH	 groups,	 terminating	 elongation	 and	
allowing	for	further	fluorescence	detection.	
There	is	a	variety	of	library	preparation	systems	depending	on	the	input	sample.	The	Illumina	
Nextera	 XT	 DNA	 system	 uses	 transposons	 for	 fragmentation	 of	 DNA	 into	 pieces	 of	
approximately	300	bp	and	for	adding	adapters	in	the	same	step	(Figure	6).	This	is	followed	by	
a	PCR	with	a	low	number	of	cycles	which	adds	indices	and	allows	unique	labelling	of	up	to	384	
samples.	Ampure	XP	magnetic	bead	purification	then	selects	for	a	certain	amplificate	size	by	
adjusting	the	sample	to	beads	ratio.	This	is	important,	as	library	size	affects	the	choice	of	the	
sequencing	biochemistry	that	 is	used.	Normalisation	of	 libraries	 is	achieved	by	adjusting	the	
molarity	of	each	sample.	
	
	
Figure	7.	Template	with	different	termini	sites	required	for	Illumina	sequencing	(Illumina,	adapted).	
	
Single	stranded	library	fragments	generated	by	denaturation	are	pooled	and	loaded	into	the	
flow	 cell	 were	 they	 hybridise	 to	 oligonucleotides	 immobilised	 on	 the	 flow	 cell	 surface	
complementary	to	the	adapters	of	the	fragments.	A	polymerase	now	initiates	amplification	of	
the	first	strand	(forward	strand)	and	generates	many	copies	of	the	initial	template	(Figure	7)	
which	is	flushed	away	after	the	amplification.	The	amplified	strands	fold	over	to	hybridise	with	
a	 second	 complementary	 immobilised	 oligonucleotides	 on	 the	 flow	 cell	 surface	 to	 initiate	
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bridge	 amplification,	 generating	 clusters	 of	 fragments.	 After	 the	 bridge	 amplification	 the	
reverse	strands	are	washed	off.	
	
	
Figure	 8.	 Template	 amplification	 technology	 of	 Illumina	NGS	 devices	 (Goodwin,	McPherson,	 and	McCombie	
2016).	
	
The	sequencing	of	 the	 forward	strand	begins,	which	 is	defined	as	 read	1.	During	 this	 step	a	
mix	 of	 terminating	 3’-end	 blocked	 and	 labelled	 dNTPs	 is	 added.	When	 such	 a	 terminating	
dNTP	 binds,	 the	 reaction	 is	 flushed	 and	 an	 image	 is	 taken,	 followed	 by	 the	 removal	 of	 the	
blocking	group	and	the	fluorophore	and	a	new	cycle	begins.	As	only	one	terminating	dNTP	is	
added	 per	 cycle,	 it	 assures	 that	 repeating	 nucleotides	 of	 a	 sequence	 (i.e.	 TTTTT)	 are	 still	
accurately	sequenced.	The	number	of	cycles	determines	the	length	of	the	read.	Therefore,	the	
sequence	accuracy	decreases	with	 increasing	read	 length,	which	makes	this	 technology	only	
accurate	 for	 short	 reads.	 The	 detection	 system	 is	 optical	 (fluorescence)	 so	 the	 base	 call	 is	
defined	 by	 the	 emission	 wavelength	 and	 the	 signal	 density.	 After	 the	 forward	 strand	 was	
sequenced,	the	index	read	is	generated	by	sequencing	the	index.	After	that	a	polymerase	uses	
the	 template	 to	generate	a	 reverse	strand,	which	now	can	be	sequenced.	This	 is	defined	as	
read	2.	This	paired-end	sequencing	gives	a	high	coverage	per	site,	which	makes	the	data	more	
accurate.	
After	sequencing	the	Illumina	software	separates	the	samples	through	their	individual	indices.	
The	 raw	 reads	 with	 similar	 base	 calls	 are	 clustered	 together	 and	 can	 be	 used	 for	 genome	
assembly.	As	forward	and	reversed	reads	are	paired,	which	is	helpful	when	alignments	are	not	
clear,	 this	 system	 makes	 it	 possible	 to	 create	 accurate	 genome	 alignments	 based	 on	 a	
reference	 sequence	and	 is	perfectly	 capable	of	de	novo	 assembly	 (Metzker	2010,	Goodwin,	
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McPherson,	 and	 McCombie	 2016,	 Liu	 et	 al.	 2012,	 Glenn	 2011,	 Ambardar	 et	 al.	 2016,	
Rodríguez-Ezpeleta,	Hackenberg,	and	Aransay	2011).	
Data	processing	 is	divided	 into	 several	 steps,	which	 involve	 several	processing	 tools.	As	 the	
MiSeq	demultiplexes	the	data	and	clips	adaptors	there	is	no	necessity	for	a	tool,	although	it	
sometimes	 happens	 that	 due	 to	 mutations	 in	 the	 adaptors	 and	 indices	 MiSeq	 fails	 to	 clip	
properly.	 This	 is	 where	 the	 tools	 PRINSEQ	 (Schmieder	 and	 Edwards	 2011b)	 and	
TRIMMOMATIC	 (Bolger,	 Lohse,	 and	 Usadel	 2014)	 can	 be	 used.	 They	 identify	 not	 removed	
adaptors	 and	 perform	 additional	 quality	 trimming	 or	 eventually	 full	 removal	 of	 bad	 quality	
reads.	Prior	to	these	steps	FASTQC	(Andrews	2010)	 is	used	to	check	the	quality	of	the	reads	
and	 assess	 the	 quality	 of	 the	 sequencing	 output.	 DECONSEQ	 is	 used	 to	 eliminate	
contaminating	 reads	 not	 belonging	 to	 the	 genome	 of	 interest	 (Schmieder	 and	 Edwards	
2011a).	The	reads	are	then	ready	for	a	de	novo	or	a	reference-based	assembly.	In	this	study	
SPADES	(Nurk	et	al.	2013)	was	used	for	de	novo	and	TANOTI	(TANOTI:	a	rapid	BLAST-guided	
read	mapper	for	small,	divergent	genomes	(manuscript	communicated))	and	STAMPY	(Lunter	
and	Goodson	2011)	were	used	for	reference-based	assembly.	
The	 Illumina	MiSeq	 system	 creates	 very	 low	 non-random	errors	 (0.1	%),	which	 are	 hard	 to	
exclude	even	through	high	coverage	at	a	site.	The	error	rate	of	one	read	is	very	low,	but	as	the	
error	is	non-random	errors	will	persist	at	any	one	site	even	with	very	high	coverages	(Metzker	
2010,	Goodwin,	McPherson,	and	McCombie	2016,	Liu	et	al.	2012,	Glenn	2011,	Ambardar	et	al.	
2016,	Rodríguez-Ezpeleta,	Hackenberg,	and	Aransay	2011).	
Sequencing	features	of	the	Illumina	MiSeq	system	are	further	listed	in	Table	4.	
	
1.2.3.2 SPADES	for	de	novo	genome	assembly	
SPADES	 is	a	de	novo	genome	assembler,	which	uses	different	sizes	of	k-mers	 to	analyse	the	
reads.	 A	 k-mer	 is	 a	 nucleotide	 sequence	 with	 all	 possible	 sequences	 of	 a	 certain	 defined	
length.	Reads	are	chopped	 into	 the	k-mer	size	and	assembled	 (Nurk	et	al.	2013).	The	k-mer	
length	 that	yields	 the	best	assembly	outcome	 is	determined.	Subsequently	 the	evaluated	k-
mer	 length	 is	 then	 selected	 to	 puzzle	 the	 reads	 into	 a	 full	 genome.	 The	 k-mer	 analysis	 of	
SPADES	 is	automated	 in	 terms	of	k-mers-modulation,	while	ABYSS,	another	commonly	used	
de	novo	assembling	software,	requires	manual	setting	of	k-mers	(Simpson	et	al.	2009).	
After	assembling	a	sequence,	it	is	then	fully	aligned	to	the	reference	genome	to	check	for	any	
problems.	 If	 the	 sequence	 is	 fine,	 no	 changes	 are	 needed.	 If	 the	 assembly	 is	 unsatisfactory	
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(gaps,	 low	 coverage),	 the	 pipeline-protocol	 has	 to	 be	 optimised	 i.e.	 improved	 checks	 for	
contaminations,	 trim	 adaptors/indices,	 decrease	 coverage	 of	 the	 reads.	 Decontamination	 is	
very	 important	and	crucial	as	cleaner	 reads	give	better	assembly	 results.	The	 termini	of	 the	
assembled	 viral	 genome	 have	 eventually	 to	 be	 optimised	manually	 by	 assembling	 first/last	
300-400	bp	using	the	reference-based	approach.	
	
1.2.3.3 TANOTI	for	reference-based	genome	assembly	
TANOTI	assembles	short	reads	of	highly	variable	sequencing	data	by	mapping	the	reads	to	a	
reference	genome	(TANOTI:	a	rapid	BLAST-guided	read	mapper	for	small,	divergent	genomes	
(manuscript	 communicated))	 and	 was	 developed	 to	 detect	 resistance	 mutations	 in	 HCV	
(Hepatitis	 C	Virus).	 In	 contrast	 to	 SPADES	 it	 is	 a	 reference-based	genome	assembly	method	
created	 specifically	 for	 short	 viral	 genomes	with	high	 variability.	 The	 results	 are	mapped	as	
read-mountains	or	“stacks”	that	further	need	to	be	calculated	into	a	consensus	sequence.	The	
consensus	 sequence	 is	 then	 aligned	 to	 the	 reference	 genome	 to	 see	 if	 the	 assembly	 was	
successful.	 If	 it	 is	 not	 the	 case,	 especially	 when	 the	 genome	 varies,	 it	 has	 to	 be	 edited	
manually.	
Furthermore,	 using	 a	 reference-based	 genome	 assembly	 does	 not	 show	 genome	
rearrangements	and	other	changes	so	important	genomic	information	can	get	lost.	Therefore,	
it	is	better	to	use	a	de	novo	approach	as	it	takes	any	change	in	the	genome	into	account.	
	
1.2.3.4 STAMPY	for	reference-based	genome	assembly	
STAMPY	 is	 a	 reference-based	 genome	 assembler	 that	 was	 specifically	 developed	 for	 short	
Illumina	 generated	 reads	 and	 is	 very	 user	 friendly.	 Its	 distinctive	 feature	 is	 that	 it	 can	map	
reads	 to	 reference	 genome	 faster	 and	 more	 sensitive	 than	 other	 software.	 Even	 if	 reads	
contain	variations	and	mutations	such	as	insertions	or	deletions	making	it	a	great	tool	with	the	
ability	 for	 construction	 of	 the	 whole	 genome,	 including	 termini,	 but	 considering	 sequence	
variations	(Lunter	and	Goodson	2011).	
	
1.2.4 MinION	sequencing	technology	
Oxford	Nanopore	Technologies	created	a	long	read	single-molecule	sequencing	set	up	which	
uses	 a	 membrane	 made	 of	 a	 synthetic	 polymer.	 The	 membrane	 has	 a	 very	 high	 electrical	
resistance	and	protein	nanopores	are	inserted	into	it.	By	applying	an	electrochemical	solution,	
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a	potential	across	the	membrane	is	created.	This	results	in	an	ionic	current	through	the	pores.	
When	a	molecule	 (RNA,	DNA,	proteins)	 enters	 the	pore,	 it	 creates	 characteristic	 changes	 in	
the	current.	These	current	changes	are	also	specific	for	a	chain-group	of	nucleotides,	such	as	
k-mers	(Figure	8).	Briefly,	each	possible	k-mer	can	be	identified	as	an	individual	signal,	which	
results	in	more	than	1000	different	signals	rather	than	4.	
	
	
Figure	9.	Overview	of	the	MinION	sequencing	technology	(Oxford	Nanopore	Technologies,	adapted).	
	
During	 the	 library	 preparation	 the	DNA	 is	 physically	 sheared	 into	 a	 range	 of	 6	 to	 20	 kb	 by	
forcing	 the	 nucleic	 acid	 through	 an	 orifice	 by	 centrifugation.	 First	 the	 fragment	 ends	 are	
repaired	adding	an	A-tail.	This	is	followed	by	the	addition	of	a	leader	sequence	with	a	motor	
protein	and	a	tether,	as	well	as	a	hairpin	structure	(Figure	9).	The	purified	library	is	loaded	into	
the	flow	cell,	the	leader	sequence	interacts	with	the	pore	and	the	motor	protein	attaches	to	
the	pore.	The	attachment	causes	structural	changes	in	the	motor	protein	and	it	starts	to	unzip	
the	 leader	 sequence	of	 the	double	 stranded	 template,	which	 then	passes	 through	 the	pore	
nucleotide	per	nucleotide	until	the	first	strand	is	sequenced	and	reaches	the	hairpin	structure,	
which	allows	a	subsequent	sequencing	of	the	second	strand	without	any	interruption.	
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Figure	 10.	 Template	 for	MinION	 sequencing	 containing	 a	 leader	 and	 a	 hairpin	 structure	 (Oxford	 Nanopore	
Technologies,	adapted).	
	
This	 technology	 is	 quite	 interesting	 in	 terms	 of	 template	 termini.	 As	 the	 template	 can	 be	
sequenced	fully	it	allows	the	detection	of	terminal	nucleotides.	
The	MinION	flowcell	has	512	channels,	so	512	molecules	can	be	sequenced/identified	at	the	
same	 time,	 which	 are	 connected	 to	 4	 wells,	 providing	 data	 from	 one	 well	 at	 a	 time	 (Lu,	
Giordano,	 and	 Ning	 2016).	 5-mer	 or	 6-mer	 define	 base	 calling	 for	 each	 nucleotide	 (ATCG)	
which	 gives	 45	 or	 46	 possible	 combinations.	 The	MinION	has	 a	 throughput	of	 ca.	 70	bp	per	
second	and	can	process	templates	of	up	to	100	kb.	
Compared	 to	 the	 low	but	non-random	error	 rate	of	 the	 Illumina	MiSeq	 the	MinION	 system	
creates	 high	 levels	 of	 random	 errors	 of	 10	 %,	 but	 as	 error	 sites	 are	 distributed	 across	 the	
genome	in	a	random	manner,	with	increasing	coverage	per	site	the	overall	error	rate	is	much	
reduced	in	comparison	to	Illumina	reads.	
	
Table	4.	Comparing	Illumina	MiSeq	and	Oxford	Nanopore	Technologies	MinION	sequencing	systems	(Goodwin,	
McPherson,	and	McCombie	2016).	
Sequencing	
Technology	
Read	length	 Throughput	 Generated	reads	 Costs	per	Gb	
MiSeq	 2x	75	
paired	end	
3.3-3.8	Gb	 44-50	M	 250	USD	
	
MinION	 >	8	kb	 up	to	1.5	Gb	 >	100000	 750	USD	
	
The	MinION	can	generate	10-20	Gb	of	DNA	data	with	read	lengths	of	up	to	100	kb.	The	output	
files	 that	 are	 produced	 in	 the	 sequencing	 run	 are	 FAST5	 files	 and	 have	 to	 be	 processed	 in	
METRICHOR	 (Oxford	Nanopore	 Technologies),	 a	 real	 time	 base-calling	 software	 for	MinION	
sequencing.	Data	that	pass	this	step	are	stored	 in	a	new	FAST5	file.	NANOOK	(Leggett	et	al.	
2015)	uses	this	file	system	to	create	a	run	report	with	basic	information	about	the	run	such	as	
coverage	plots,	 lengths	of	sequenced	fragments,	pore	occupation	etc.	The	FAST5	file	can	be	
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converted	 into	FastA	or	FastQ	 files	using	PORETOOLS	 (Loman	and	Quinlan	2014)	 for	 further	
workflow	and	analysis	such	as	quality	control,	adaptor	trimming	and	reference-based	genome	
assembly	using	BWA	(Li	2013).	PORECHOP	(Wick	et	al.	2017)	can	be	used	to	solve	concatemer	
issues.	
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1.3 Sequence	Analysis	
1.3.1 Overview	
There	are	many	possibilities	to	analyse	a	sequenced	genome.	A	variety	of	algorithms,	scripts	
and	softwares	can	calculate	a	value	of	 interest	 to	describe	a	particular	 feature	of	a	site	 in	a	
genome,	 or	 the	 genome	 itself	 and	 genome	 evolution.	 These	 analysis	 techniques	 can	
contribute	to	understanding	the	character,	the	evolution	and	spread	of	virus	genomes.	Here	I	
will	briefly	introduce	the	models	used	in	this	study	to	analyse	IPNV	genomes.	
	
1.3.2 Calculating	Phylogenies	using	BEAST	
To	look	at	the	phylogeny	of	sequences	bioinformaticians	and	mathematicians	have	developed	
several	tools,	that	differ	in	models	and	therefore	in	computing	time.	This	work	only	uses	the	
methodology	for	the	purpose	of	phylogenetic	analysis	so	I	will	only	briefly	explain	the	subject	
matter.	 It	 was	 shown	 that	 tools	 which	 are	 based	 on	 Bayesian	 Markov	 Chain	 Monte	 Carlo	
analysis	 perform	 stable	 and	 accurate	 analysis	 of	 molecular	 sequences	 taking	 less	 time	 to	
perform	the	analysis	compared	to	heuristic	optimization	based	on	maximum	likelihood	(ML)	
(Huelsenbeck	and	Ronquist	2001,	Huelsenbeck	et	al.	2001).	MCMC	does	not	require	marginal	
likelihood	 calculation	 (Peter	 G.	 Foster,	 2009).	 By	 using	 random	 sampling	MCMC	 generates	
equitable	 samples	 out	 from	 a	 distribution	 of	 samples,	 therefore	 it	 can	 be	 used	 to	 analyse	
posterior	 distributions	 in	 Bayesian	 inference.	 It	 handles	 complex	 models	 and	 parameters	
(Peter	G.	Foster,	2009).	MCMC	perturbs	 stochastically	 the	current	 tree	and	proposes	a	new	
tree.	The	new	tree	is	accepted	or	rejected.	The	new	tree	is	then	used	for	further	perturbation	
(Huelsenbeck	 et	 al.,	 2001).	 The	 BEAST	 (Bayesian	 Evolutionary	 Analysis	 by	 Sampling	 Trees)	
package	 offers	 such	 an	 approach	 to	 analyse	 sequences	 to	 create	 evolutionary	 models	
(Drummond	 et	 al.	 2012).	 Comparing	 to	 ML	 the	 Bayesian	 approach	 describes	 the	 branch	
stability	 not	 via	 bootstrap	 values	 but	 rather	 through	 posterior	 probabilities,	 which	 is	 a	
combination	 of	 a	 phylogeny’s	 prior	 probability	 and	 tree	 likelihood,	 calculated	 using	MCMC	
(Huelsenbeck	 and	 Ronquist	 2001,	 Huelsenbeck	 et	 al.	 2001).	 The	 tree	 with	 the	 highest	
probability	 is	 considered	 as	 the	 best	 estimated	 phylogeny.	 Comparing	 to	 the	ML	 approach,	
where	the	tree	with	the	highest	likelihood	is	considered	as	the	best	(Rannala	and	Yang	1996).	
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1.3.3 Calculating	phylogenies	using	RAXML	
To	perform	phylogenetic	analysis	using	a	maximum	likelihood	algorithm,	RAXML	(Randomised	
axelerated	maximum	likelihood)	provides	a	great	graphic	user	interface.	Its	particular	benefit	
is	the	fast-maximum	likelihood	calculating	performance	from	a	nucleotide	substitution	model,	
which	describes	 the	process	of	genetic	variation,	 returning	 trees	with	high	 likelihood	scores	
with	the	opportunity	for	bootstrap	analysis.	
Nucleotide	 substitution	 models	 calculate	 evolutionary	 distances	 (divergence)	 between	
sequences	 that	 originated	 from	 a	 common	 ancestor	 by	measuring	 the	 number	 of	 changes	
between	 sequences.	 The	 calculated	 genetic	 distance	number	 is	 inverse	proportional	 to	 the,	
genetic	difference	of	the	respective	sequences.	
A	bootstrap	analysis	shows	the	robustness	of	a	tree	by	providing	a	statistical	error,	even	if	the	
sampling	distribution	is	unknown.	This	is	done	by	generating	new	alignments	from	the	original	
data	but	with	replacements	in	the	chosen	columns.	This	new	set	of	sequences	is	then	used	to	
generate	 trees.	 By	 calculating	 the	 proportion	 of	 each	 clade	 among	 the	 replicates	 it	 gives	 a	
statistical	 confidence	 to	 support	 the	 calculated	 tree.	 (Silvestro	 and	 Michalak	 2012,	 Lemey	
2009,	Stamatakis	2014,	2006,	Stamatakis,	Ludwig,	and	Meier	2004,	Kaehler	et	al.	2014).	
	
1.3.4 CAI	
The	 codon	 adaptation	 index	 measures	 synonymous	 codon	 usage	 biases	 given	 a	 genome	
reference.	CAI	 can	describe	 synonymous	 changes	of	 virus	 genomes	 towards	a	host	 genome	
over	 time	showing	how	the	codon	preference	of	 the	virus	adapts	or	evolves	 towards	codon	
usage	of	the	host.	Through	selection	pressure	and	drifts	a	virus	can	conserve	mutations	and	
this	way	optimise	replication	efficiency	and	increase	the	transmission	rate.	For	example,	 if	a	
virus	codes	for	tRNACUC	(Leucine)	but	the	hosts	translational	system	offers	more	tRNACUU	for	
Leucine	 instead,	 there	 is	 a	 selective	 pressure	 on	 the	 virus	 that	 could	 drive	 the	 evolution	
towards	 a	 mutation	 for	 coding	 tRNACUU	 in	 order	 to	 optimise	 the	 virus’	 replication	 and	
translation.	 In	 some	 persistent	 viruses	 we	 even	 see	 a	 codon	 usage	 pattern	 that	 reduces	
protein	expression	in	order	to	avoid	activation	of	the	immune	system.	Calculating	the	CAI	of	a	
virus	to	 its	host	can	help	to	gain	 insight	 in	viral	evolution	and	virulence	of	a	virus	as	viruses	
optimise	their	survival	by	not	killing	the	host	immediately	but	rather	try	to	be	shed	as	long	as	
possible	and	for	long	distances.	
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The	CAI	or	normalized	CAI	 (nCAI)	 for	each	coding	protein	 is	 calculated	as	 followed:	!"#$ =&"#$/("#$.	This	can	be	performed	on	an	online	platform	http://genomes.urv.es/CAIcal	and	
http://genomes.urv.es/CAIcal/E-CAI.	 The	 tool	 CAICAL	 is	 used	 to	 calculate	 raw	 CAI	 (rCAI).	
Expected	CAI	(eCAI)	is	generated	by	creating	multiple	random	sequences	similar	to	those	that	
are	used	for	calculation.	The	output	is	understood	as	greater	or	lower	than	1.	If	the	values	are	
higher	 than	 1	 it	 indicates	 that	 the	 virus	 is	 adapting	 its	 codon	usage	 to	 the	 one	 of	 the	 host	
(Sharp,	Tuohy,	and	Mosurski	1986,	Puigbo,	Bravo,	and	Garcia-Vallve	2008b,	a)	 (Di	Paola,	de	
Melo	Freire,	and	de	Andrade	Zanotto	2018).	
	
1.3.5 Selection	analysis	using	HYPHY	
Selection	analysis	 gives	 the	opportunity	 to	 see	which	 sites	 in	a	genome	or	a	protein	 coding	
region	are	under	positive	selection	pressure.	There	are	a	lot	of	different	established	models.	
For	this	study	I	decided	to	use	the	HYPHY	package	(Pond,	Frost,	and	Muse	2005),	with	variety	
of	models	which	work	based	on	an	optimised	and	extended	version	of	the	codon	based	MG94	
model	which	 describes	 protein	 coding	 sequence	 evolution	 by	modelling	 codon	 substitution	
using	a	Markov	process	(Muse	and	Gaut	1994,	Goldman	and	Yang	1994).	
One	possibility	 to	 calculate	 selection	 is	 by	 using	 SLAC	 (Single	 Likelihood	Ancestor	 Counting)	
(Kosakovsky	 Pond	 and	 Frost	 2005,	 Pond	 and	 Frost	 2005).	 This	 method	 is	 able	 to	 model	
variations	in	synonymous	and	non-synonymous	rates	under	the	MG94xREV	codon	model.	
Another	model	 is	MEME	 (Mixed	Effects	Model	of	Evolution)	 (Murrell	 et	 al.	 2012)	which	also	
works	 under	 the	MG94xREV	 codon	model.	 MEME	 hypothesise	 that	 sites	 have	 been	 under	
episodic	positive	or	diversifying	selection	under	a	proportion	of	branches.	
	
1.3.6 Dinucleotide	composition	
Dinucleotides	occur	in	16	variants,	AA,	AC,	AG,	AT,	CA,	CC,	CG,	CT,	GA,	GC,	GG,	GT,	TA,	TC,	TG,	
TT.	Especially	the	motif	CG	or	CpG	is	of	big	 interest	as	 it	 is	a	methylation	cite	 in	vertebrates	
and	 besides,	 suppressed	 throughout	 the	 DNA	 (Karlin,	 Doerfler,	 and	 Cardon	 1994),	 due	 to	
cytosine	methylation.	According	to	a	study	by	Cheng	et	al.	there	is	no	under-representation	of	
CpG	 observed	 for	 dsRNA	 viruses	 infecting	 vertebrate	 hosts	 as	 their	 mean	 CpGO/E	 of	 0.88	
defines	 as	 not	 under-represented	 in	 that	 study	 (Cheng	 et	 al.	 2013),	 There	 are	 several	
explanations	 for	 under-representation	 of	 CpG	motifs	 beside	methylation,	 especially	 not	 for	
RNA	viruses	without	DNA	 intermediates	during	replication	(Cheng	et	al.	2013).	One	possible	
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explanation	could	be	the	higher	energy	of	CpG	in	DNA,	although	the	CpG	energy	in	RNA	is	not	
specifically	higher	than	for	other	dinucleotides	(Breslauer	et	al.	1986,	Serra	and	Turner	1995).	
Another	idea	is	immune	escape	mechanism	of	a	virus.	This	is	quite	possible	as	non-methylated	
CpG	have	 an	 immune	 stimulating	 effect	 (Goldberg,	Urnovitz,	 and	 Stricker	 2000,	 Chen	 et	 al.	
2001,	Cheng	et	al.	2013),	as	it	was	shown	for	the	Toll-like	receptor	9,	which	initiated	an	innate	
immune	response	after	binding	of	CpG	motifs	 (Tyagi,	Kumar,	and	Singh	2017).	On	the	other	
hand,	it	was	shown	that	systems	that	recognise	dsRNA,	like	the	Toll-like	receptor	3,	the	RIG-I-
like	RNA	helicase	and	 the	dsRNA	binding	protein,	do	not	have	a	CpG	preference,	 indicating	
that	 there	 might	 be	 no	 pressure	 on	 the	 CpG	 content	 from	 the	 host.	 Either	 way,	 the	
representation	of	CpG	plays	an	important	role	in	terms	of	viral	evolution	with	the	host,	as	the	
mean	CpGO/E	in	vertebrates	is	0.47	(Cheng	et	al.	2013).	
To	estimate	the	dinucleotide	composition,	a	ratio	between	observed	CpG	and	estimated	CpG	
is	 calculated	 (CpGO/E).	 A	 CpG	 abundance	 is	 considered	 low	when	 CpGO/E	 ≤1	 and	 high	when	
CpGO/E	≥1	(Cheng	et	al.	2013,	Tyagi,	Kumar,	and	Singh	2017).	There	are	different	possibilities	
to	 achieve	 that.	 In	 this	 study	 EMBOSS	 COMPSEQ	 was	 used	 on	 an	 online	 platform	
[http://emboss.bioinformatics.nl/cgi-bin/emboss/compseq]	 to	 perform	 the	 calculation	 (Rice,	
Longden,	and	Bleasby	2000).	
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Objectives	
This	 project	 aimed	 at	 studying	 the	molecular	 epidemiology	 and	 virus	 to	 host	 adaptation	 of	
IPNV	 in	 Scotland	 by	whole	 genome	 sequence	 analysis	 of	 IPNV	 isolates	 spanning	 3	 decades	
from	1982	 to	2014,	as	well	as	at	optimising	a	protocol	avoiding	 specific	 terminal	primers	 in	
order	to	have	a	WGS	protocol	that	can	be	used	for	any	possible	virus.	
	
Specific	objectives	were:	
- To	select	and	culture	IPNV	from	diagnostic	TCID50	supernatants.	
- To	process	viral	RNA	of	IPNV	culture	supernatants	for	next	generation	sequencing.	
- To	 optimise	whole	 genome	 next	 generation	 sequencing	 for	 IPNV	 by	 comparing	 two	
RNA	processing	protocols,	the	Goettingen	(GOEP)	(Dilcher	et	al.	2012)	and	the	Glasgow	
(GLAP)	(Thomson	et	al.	2016)	protocol,	as	well	as	two	sequencing	platforms,	Illumina	
MiSeq	and	Oxford	Nanopore	Technologies	MinION.	
- To	optimise	IPNV	genome	assembly	
- To	assess	IPNV	genome	evolution	using	several	bioinformatics	assessment	tools.	
- To	investigate	a	possible	virus-to-host	adaptation.	
- To	see	if	IPNV	is	under	a	selective	pressure	and	what	could	possibly	drive	it.	
- To	detect	possible	reassortant	isolates.	
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2 Methods	
2.1 Whole	genome	sequencing	of	diagnostic	TCID	50	Isolates	
2.1.1 Bulking	up	diagnostic	TCID50	IPNV	isolates	in	cell	culture	
2.1.1.1 Maintenance	of	cell	lines	used	for	IPNV	growth	
2.1.1.1.1 General	description	
For	 this	work,	Chinook	 salmon	embryonic	 cells	 (CHSE-214)	 (Fryer,	 Yusha,	 and	Pilcher	1965),	
which	 derived	 from	 a	 Chinook	 salmon	 (Oncorhynchus	 tshawytscha)	 embryo	 and	 TO	 cells,	
which	derived	from	head	kidney	 leucocytes	of	the	Atlantic	salmon	(Salmo	salar)	 (Wergeland	
and	Jakobsen	2001),	were	used.	The	CHSE-214	and	TO	cell	lines	were	grown	at	22	°C	and	ca.	4	
%	CO2	 in	Eagle’s	Minimum	Essential	Medium	(EMEM;	Gibco)	with	10	%	Foetal	Bovine	Serum	
(FBS;	 Gibco),	 1x	 non-essential	 amino	 acids	 (NEAA;	 Gibco)	 and	 2µM	 L-glutamine	 (Gibco).	 In	
order	to	maintain	a	healthy	and	even	monolayer	cells	had	to	be	passaged	regularly.	
	
2.1.1.1.2 	Splitting	CHSE-214	or	TO	cells	with	a	1:3	split	ratio	
CHSE-214	 or	 TO	 cells	 were	 examined	 visually	 every	 day	 under	 a	 microscope	 at	 4x	 optical	
magnification.	 When	 the	 cell	 monolayer	 showed	 100	 %	 density	 and	 the	 cells	 appeared	
healthy,	 old	media	was	 decanted	 and	 the	 cell	monolayer	was	washed	 twice	with	 5mL	 PBS	
(Gibco).	Then	1	mL	trypsin-EDTA	(0.05	%;	Gibco)	was	added	to	detach	the	cells	from	the	flask	
surface.	After	ca.	1min	some	of	the	trypsin-EDTA	was	poured	off,	while	the	cells	were	still	100	
%	 attached	 to	 the	 flask	 surface,	 leaving	 approximately	 0.5	 mL	 in	 the	 flask.	 The	 enzymatic	
reaction	 of	 the	 trypsin	 was	 observed	 under	 the	microscope	 to	 determine	 the	 point	 of	 cell	
detachment.	When	the	cells	rounded	up	and	no	cell-to-cell	contact	was	visible,	the	flask	was	
shaken	 slightly	 to	 detach	 the	 cells	 from	 the	 surface.	 The	 cells	 were	 then	 re-suspended	 in	
EMEM+10	%	FBS	to	stop	the	enzymatic	activity	of	trypsin	and	aspirated	by	pipetting	up	and	
down	 several	 times	 to	 create	 a	 single	 cell	 suspension.	 The	 content	was	 equally	 transferred	
into	one	to	three	new	tissue	culture	flasks	(TC;	Sarstedt)	of	the	same	size	as	the	parent	flask,	
containing	5	mL	EMEM+10	%	FBS.	The	content	of	each	flask	was	mixed	by	pipetting	up	and	
down	several	times	and	the	cells	were	incubated	at	22	°C	and	4	%	CO2	with	a	1/4th	opened	lid	
for	gas	exchange.	
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2.1.1.1.3 	Sub-culturing	CHSE-214	and	TO	cells	of	a	25	cm2	TC	into	a	75	cm2	TC	with	a	1:3	split	
ratio	
Cells	of	a	25	cm2	TC	were	processed	in	the	same	manner	as	described	in	2.1.1.1.2.	The	cells	
were	then	re-suspended	in	EMEM+10	%	FBS	and	aspirated	by	pipetting	up	and	down	several	
times	to	create	a	single	cell	suspension.	The	cell	suspension	was	transferred	into	a	75	cm2	TC	
containing	17	mL	EMEM+10	%	FBS.	The	content	was	mixed	by	pipetting	up	and	down	several	
times	 and	 the	 cells	 were	 incubated	 at	 22°C	 and	 4%	 CO2	 with	 a	 1/4th	 opened	 lid	 for	 gas	
exchange.	
	
2.1.1.1.4 Sub-culturing	CHSE-214	and	TO	cells	of	a	75	cm2	TC	into	a	175	cm2	TC	with	a	1:3	split	
ratio	
Cells	of	a	75	cm2	TC	were	processed	in	the	same	manner	as	described	in	2.1.1.1.2.	The	cells	
were	 then	 re-suspended	 in	 EMEM+10	 %	 FBS	 (adjusted	 to	 a	 total	 volume	 of	 9	 mL)	 and	
aspirated	by	pipetting	up	and	down	several	times	to	create	a	single	cell	suspension.	Seven	mL	
of	the	cell	suspension	was	transferred	 into	a	175	cm2	TC	containing	36	mL	EMEM+10	%	FBS	
and	2x	1	mL	was	transferred	into	two	25	cm2	TCs	containing	5	mL	EMEM+10	%	FBS	each.	The	
content	of	each	flask	was	mixed	by	pipetting	up	and	down	several	 times	and	the	cells	were	
incubated	at	22	°C	and	4	%	CO2	with	a	1/4th	opened	lid	for	gas	exchange.	
	
2.1.1.1.5 Seeding	a	24	well	plate	(WP)	of	CHSE-214	and	TO	cells	for	inoculation	via	adsorption	
The	cell	monolayer	of	a	tissue	culture	flask	containing	CHSE-214	or	TO	cells	that	are	not	older	
than	7	days,	with	a	cell	density	of	ca.	95	%	and	are	 in	 the	 replicative	mode	were	examined	
visually	under	 the	microscope	 to	ensure	 the	cells	 fulfilled	 the	 requirements.	Old	media	was	
decanted	off	 and	 the	 cell	monolayer	was	washed	 twice	with	 5	mL	PBS.	 Then	1	mL	 trypsin-
EDTA	(0.05	%)	was	added	to	detach	the	cells	from	the	flask	surface.	After	ca.	1	min	some	of	
the	trypsin-EDTA	was	poured	off,	while	the	cells	were	still	100	%	attached	to	the	flask	surface,	
leaving	 approximately	 0.5-1	 mL	 in	 the	 flask.	 The	 enzymatic	 reaction	 of	 the	 trypsin	 was	
observed	 under	 the	 microscope	 to	 determine	 the	 point	 of	 cell	 detachment.	 When	 cells	
rounded	up	and	no	cell-to-cell	contact	was	visible,	the	flask	was	shaken	slightly	to	detach	the	
cells	from	the	surface.	The	cells	were	then	re-suspended	in	EMEM+10	%	FBS	and	aspirated	by	
pipetting	 up	 and	 down	 several	 times	 to	 create	 a	 single	 cell	 suspension.	 Adjusting	 the	
resuspension	media	to	3	or	6	mL	was	performed	if	further	subcultering	with	a	1:3	split	ratio	
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was	required.	The	cell	suspension	was	aspirated	by	pipetting	up	and	down.	Cells	were	counted	
and	seeded	at	a	density	of	1.5	x	105	cells	per	well	(see	2.1.1.1.5.1).	The	plate	was	incubated	at	
22	°C	and	4	%	CO2.	The	next	day	the	plate	was	examined	visually	to	ensure	that	each	well	had	
approximately	 the	 same	cell	density	and	 the	 cells	 looked	healthy.	 If	 the	 requirements	were	
fulfilled,	the	well	plate	was	used	for	inoculation	with	IPNV	samples.	
	
2.1.1.1.5.1 Determination	of	cell	numbers	in	a	haemocytometer	
A	mix	of	0.1	mL	cell	suspension	in	0.1	mL	Trypan	Blue	(0.5	%;	Sigma	Aldrich)	was	prepared	in	a	
polystyrene	container	(dilution	factor:	2).	A	cover	glass	was	placed	on	the	haemocytometer	so	
that	Newton’s	rings	were	visible.	One	of	the	two	counting	chambers	was	filled	with	the	cell-	
Trypan	Blue	mix	and	the	haemocytometer	was	placed	under	the	microscope.	The	focus	was	
set	on	10x	optical	magnification	without	orange	filter.	It	was	first	ensured	that	the	cell	density	
was	approximately	the	same	in	each	of	the	9	squares	of	the	haemocytometer.	Count	of	living	
cells	 (not	 stained	 blue)	 in	 3	 of	 the	 9	 squares	 at	 least	 was	 performed	 and	 the	 average	 cell	
amount	was	calculated.	The	depth	of	the	haemocytometer	is	0.1	mm.	The	volume	of	1	mm2	is	
1	x	1	x	0.1=0.1	mm3	=	0.0001	cm3	=	10-4	cm3.	When	1	cm3	=	1mL	the	cell	concentration/mL	is:	
average	cell	count	per	1	mm2	x	dilution	factor	(2)	x	104.	The	total	cell	amount	was	calculated	
by	multiplying	 the	cell	amount/mL	with	 the	volume	of	 the	cell	 suspension.	The	cell	number	
per	well	needed	for	CHSE-214	and	TO	cells	was	1.5	x	105	cells.	For	24	wells	+	2	wells	extra	(26	
wells)	a	cell	number	of	1.5	x	105	x	26=	3.9	x	106	cells	were	required.	The	following	calculation	
was	performed	to	estimate	the	volume	of	the	cell	suspension	containing	3.9	x	106	cells:	(3.9	x	
106	 /	 total	 cell	 number)	 x	 total	 volume	 of	 cell	 suspension.	 This	 volume	 was	 adjusted	 with	
EMEM+10	%	FBS	up	to	26	mL	and	1	mL	of	the	dilution	was	pipetted	into	each	well.	
	
2.1.1.1.6 	Seeding	a	24WP	of	CHSE-214	and	TO	cells	for	simultaneous	inoculation	
Cells	were	processed	in	the	same	manner	as	in	2.1.1.1.5.	Cells	were	counted	and	seeded	at	a	
density	of	1.75	x	105	cells	per	well	(see	2.1.1.1.5.1).	The	24WP	(Sarstedt)	was	incubated	at	22	
°C	and	4	%	CO2	for	maximum	30	min	so	cells	do	not	attach	to	the	well	bottom	and	used	for	
IPNV	inoculation	the	same	day.	
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2.1.1.2 Growing	IPNV	in	CHSE-214	and	TO	cells	
2.1.1.2.1 General	description	
CHSE-214	and	TO	 cells	were	 inoculated	with	diagnostic	 TCID50	 IPNV	 isolates	 via	 adsorption	
and	via	simultaneous	inoculation	and	processed	the	same	way.	HBSS+2	%	FBS	was	used	as	a	
diluent	and	as	a	negative	control.	Wells	with	a	certain	 isolate	 in	either	CHSE-214	or	TO	cells	
that	 showed	 a	 CPE	 were	 collected	 and	 passaged	 into	 a	 25	 cm2	 TC	 containing	 the	
corresponding	 cell	 line.	 When	 a	 full	 CPE	 was	 visible	 in	 the	 25	 cm2	 TC	 the	 content	 was	
harvested	and	passaged	into	a	175	cm2	TC	with	the	corresponding	cell	line	to	bulk	up	the	viral	
particles.	 Bulking	 up	 viral	 particles	 in	 a	 175	 cm2	 TC	 was	 only	 required	 for	 the	 Goettingen	
protocol.	Furthermore,	4x	0.5	mL	of	the	harvested	supernatant	of	a	25	cm2	TC	were	stored	at	-
70	°C	as	viable	IPNV	stocks.	
Negative	wells	were	passaged	up	to	2	times	 into	a	new	24WP	containing	the	corresponding	
cell	 line.	 The	 chosen	 passage	 method	 was	 a	 freeze	 (-70	 °C)/thaw	 passage	 via	 adsorption	
according	to	the	OIE	guidelines	for	IPNV	diagnostics.	
EMEM+10	%	FBS	was	used	as	growth	media	 for	 inoculation	after	 the	adsorption	period.	To	
prevent	 bacterial	 contamination	 a	 1x	 kanamycin/penicillin/streptomycin	 antibiotics	mix	was	
added	 into	EMEM+10	%	FBS.	One	 flask	of	 the	 same	 size	was	 treated	exactly	 the	 same,	but	
without	inoculation,	was	used	as	an	internal	control.	
In	order	to	perform	the	Goettingen	protocol	for	whole	genome	sequencing,	supernatant	of	a	
175	cm2	TC	was	used.	For	the	Glasgow	protocol	the	supernatant	of	a	25	cm2	TC	was	used.	
	
2.1.1.2.2 Inoculation	via	adsorption	
IPNV	 isolates	 of	 interest	 were	 defrosted	 and	 kept	 on	 ice.	 A	 1:10	 and	 1:50	 dilutions	 was	
prepared.	Media	of	a	24WP	prepared	on	the	previous	day	was	pipetted	off	and	150	µL	of	the	
neat	 sample,	 the	1:10	and	 the	1:50	dilutions	were	pipetted	 in	 a	 column	 in	 following	order:	
neat,	 1:10,	 1:50,	 negative	 control	 (NC).	 The	 plate	was	 sealed	with	 plastic	 paraffin	 film	 and	
incubated	at	15	°C	and	1	%	CO2	for	3	h.	The	plate	was	rocked	every	hour	to	ensure	that	the	
cells	were	equally	 covered	with	 the	 inoculum.	Then	1.5	mL	of	EMEM-10	%	FBS	media	were	
added	to	each	well	and	the	plate	was	incubated	at	15	°C	and	1	%	CO2.	Every	day	the	plate	was	
examined	for	a	cytopathic	effect	(CPE).	
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2.1.1.2.3 Simultaneous	inoculation	
IPNV	 isolates	 of	 interest	 were	 defrosted	 and	 kept	 on	 ice.	 A	 1:10	 and	 1:50	 dilutions	 was	
prepared.	Into	each	well	of	a	freshly	prepared	24WP	100	µL	of	the	neat	sample,	the	1:10	and	
the	1:50	dilutions	were	pipetted	in	a	column	in	following	order:	neat,	1:10,	1:50,	NC.	The	plate	
was	incubated	at	15	°C	and	1	%	CO2.	Every	day	the	plate	was	examined	for	a	CPE.	
	
2.1.1.2.4 Passage	of	positive	well(s)	into	a	25	cm2	TC	
When	a	full	CPE	was	visible	in	a	well,	or	in	several	wells	of	the	same	isolate,	the	supernatant	of	
the	 specific	 well	 was	 collected	 or	 multiple	 wells	 were	 pooled	 into	 a	 centrifuge	 tube	 and	
centrifuged	at	2500x	g	and	4	°C	for	15	min.	The	supernatant	was	decanted	 in	a	polystyrene	
container.	 A	 dilution	 of	 10-2	 up	 to	 10-4	 (depending	 on	 the	 virulence	 of	 the	 isolate)	 was	
prepared	 on	 ice.	 Old	 media	 of	 a	 25	 cm2	 TC	 was	 decanted	 off	 and	 1mL	 of	 the	 diluted	
supernatant	was	added	into	the	flask.	For	a	NC,	another	25	cm2	TC	was	incubated	with	1mL	of	
the	 diluent.	 The	 flasks	were	 incubated	 for	 1	 h	 at	 15	 °C	 and	 1	%	 CO2.	 After	 incubation,	 the	
inoculum	 was	 discarded	 and	 5mL	 EMEM+10	 %	 FBS	 media	 were	 added.	 The	 flasks	 were	
incubated	at	15	°C	and	1	%	CO2	and	examined	every	day	for	a	CPE.	
When	 a	 full	 CPE	 was	 visible	 in	 the	 25	 cm2	 TC,	 the	 supernatant	 was	 collected	 into	 a	 15mL		
centrifuge	tube	and	centrifuged	at	2500x	g	and	4	°C	for	15	min.	The	supernatant	was	further	
filtered	through	a	0,2	µm	sterile	filter	(Sartorius).	The	supernatant	was	stored	at	-70	°C	or	 it	
was	used	 immediately	 for	 inoculation	of	 a	 175	 cm2	 TC	 for	 the	Goettingen	protocol	 or	 used	
immediately	for	the	Glasgow	protocol.	
	
2.1.1.2.5 Passage	of	positive	25	cm2	TC	into	a	175	cm2	TC	
The	supernatant	from	a	25	cm2	TC	was	used	for	inoculation	of	a	175	cm2	TC.	A	dilution	of	10-3	
up	to	10-5	(depending	on	the	virulence	of	the	isolate)	was	prepared	on	ice	as	followed:	100	µL	
of	the	harvested	supernatant	+	900	µL	of	the	diluent	=	1	mL	of	a	10-1	dilution,	diluting	it	down	
to	10-4;	1	mL	of	the	10-4	dilution	+	9	mL	of	the	diluent	=	10	mL	of	a	10-5	dilution.	Old	media	of	a	
175	cm2	TC	was	decanted	off	and	7	mL	of	the	dilution	was	added	into	the	flask.	For	a	NC,	a	25	
cm2	TC,	that	was	prepared	from	the	same	parent	flask	as	the	175	cm2	TC,	was	incubated	with	
1mL	of	the	diluent.	The	flasks	were	incubated	for	1h	at	15	°C	and	1	%	CO2.	After	incubation,	
the	 inoculum	was	discarded	and	30	mL	of	EMEM+10	%	FBS	were	added	 to	 the	175	cm2	TC	
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(5mL	to	the	NC).	The	flasks	were	incubated	at	15	°C	and	1	%	CO2	and	examined	every	day	for	a	
CPE.	
	
2.1.1.2.6 Harvest	IPNV	supernatant	of	a	175	cm2	TC	for	RNA	extraction	
The	 culture	 medium	 of	 infected	 cells	 was	 harvested	 when	 the	 cells	 showed	 80-90	 %	 CPE.	
Medium	of	a	175	cm2	TC	was	transferred	into	a	50	mL	centrifuge	tube	(Sarstedt)	and	clarified	
by	centrifugation	for	10	min	at	2000	rpm	(700x	g).	The	new	supernatant	was	centrifuged	again	
for	5min	at	4000	rpm	(2800x	g).	After	that,	the	supernatant	was	filtered	into	a	new	centrifuge	
tube	 through	a	0.2	µm	sterile	 filter.	The	purified	supernatant	was	stored	at	 -70	 °C	before	 it	
was	processed	further	in	the	Goettingen	protocol.	
	
2.1.2 IPNV	RNA	processing	and	sequencing	
	
	
Figure	11	Overview	of	the	main	steps	of	GOEP	and	the	GLAP.	
	
Cell	 culture	 supernatants	 containing	 IPN	 virus	 were	 used	 for	 RNA	 extraction,	 ds-cDNA	
conversion	and	library	preparation	(Figure	10).	First	27	IPNV	samples	were	processed	with	the	
GOEP
(20	ml supernatant)
RNA	extraction
no	RT-qPCR
ds-cDNA	synthesis
amplification
library	preparation	
(Illumina	Nextera	XT)
GLAP
(400	µl	supernatant)
RNA	extraction
RT-qPCR
ds-cDNA	synthesis
no	amplification
library	preparation	
(Illumina	Nextera	XT)
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Goettingen	(GOEP)	protocol	and	30	IPNV	samples	were	processed	with	the	Glasgow	protocol	
(GLAP).	
	
2.1.2.1 RNA	extraction	and	processing	
2.1.2.1.1 	Goettingen	protocol	
This	 protocol	 was	 developed	 by	 Dr.	 Meik	 Dilcher,	 Department	 of	 Virology,	 University	
Goettingen,	Germany	and	was	used	for	whole	genome	sequencing	of	diagnostic	TCID50	IPNV	
isolates.	The	 initial	protocol	 (GOEP)	was	designed	for	use	of	Titanium	Shotgun	Rapid	Library	
Preparation	and	Pyrosequencing	system	by	Roche.	In	this	study,	for	both,	the	GOEP	and	GLAP,	
the	Nextera	XT	DNA	Library	Preparation	Kit	(Illumina)	was	used	instead.	
	
2.1.2.1.1.1 	Solutions	and	Buffers	
2.1.2.1.1.1.1 1	M	Tris,	pH6,5	(10	0mL)	
Tris	(12.11	g;	Sigma	Aldrich)	was	dissolved	in	80mL	distilled	water	(Sigma	Aldrich).	The	pH	was	
formulated	with	HCl	(VWR	Chemicals).	Then	the	solution	was	adjusted	to	100mL	with	distilled	
water,	autoclaved	and	stored	at	room	temperature.	
	
2.1.2.1.1.1.2 0.5	M	EDTA,	pH8,0	(100	mL)	
EDTA	(18.62	g;	Sigma	Aldrich)	was	dissolved	in	80mL	distilled	water.	The	pH	was	formulated	
with	 10	 N	 NaOH	 (Sigma	 Aldrich).	 Then	 the	 solution	 was	 adjusted	 to	 100	mL	 with	 distilled	
water,	autoclaved	and	stored	at	room	temperature.	
	
2.1.2.1.1.1.3 5	M	NaCl	(500	mL)	
NaCl	(146.1	g;	Sigma	Aldrich)	was	dissolved	in	500	mL	distilled	water,	autoclaved	and	stored	at	
room	temperature.	
	
2.1.2.1.1.1.4 10x	NTE	(200	mL)	
Twenty	mL	of	 1	M	Tris	 (pH6.5),	 4	mL	of	 0.5	M	EDTA	 (pH8.0)	 and	40	mL	of	 5	M	NaCl	were	
mixed.	The	volume	was	adjusted	to	200	mL	with	distilled	water	and	the	pH	was	checked	(pH	
ca.	7.0).	The	solution	was	then	autoclaved	and	stored	at	room	temperature.	
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2.1.2.1.1.1.5 30	%	PEG	in	NTE	(500	mL)	
PEG8000	(150	g;	Sigma	Aldrich)	were	dissolved	in	50	mL	10x	NTE.	The	volume	was	adjusted	to	
500	mL	with	distilled	water.	The	solution	was	autoclaved	and	stored	at	room	temperature.	
	
2.1.2.1.1.2 	Extraction	and	processing	of	IPNV	RNA	
2.1.2.1.1.2.1 IPNV	RNA	extraction	
Supernatant	from	2.1.1.2.6	was	defrosted.	To	20	mL	supernatant	1.48	mL	sterile	5	M	NaCl	and	
10.80	mL	sterile	30	%	(w/v)	PEG8000	in	NTE	(10	mM	Tris,	pH6.5;	1	mM	EDTA;	100	mM	NaCl)	
were	added.	The	mix	was	incubated	for	30min	on	a	rocker	at	4	°C	and	then	centrifuged	for	1.5	
h	 at	 3877x	 g	 and	 4	 °C.	 The	 pellet	 was	 re-suspended	 in	 250	 µL	 PBS	 (Gibco).	 To	 exclude	
contaminating	 nucleic	 acids	 an	 RNase-digestion	 of	 intact	 virus	 particles	 was	 performed	 by	
adding	12.5	µL	of	RNase	A	(20	mg/mL;	final	concentration:	1	mg/mL;	PeqLab)	to	the	sample.	
The	reaction	was	incubated	at	37	°C	for	30	min.	After	that	the	volume	was	adjusted	to	500	µL	
with	PBS.	The	sample	was	further	processed	by	adding	1.5	mL	Trifast	(PeqLab)	per	sample	and	
incubated	at	 room	 temperature	 for	 5	min.	 The	 sample	was	 then	 split	 into	 two	2	mL	 tubes.	
After	 that	 200	 µL	 chloroform	 (Sigma	 Aldrich)	 per	 1	 mL/sample	 were	 added	 followed	 by	
incubation	for	10	min	at	room	temperature.	Next	the	samples	were	centrifuged	for	5	min	at	
12.000x	g	and	room	temperature.	The	clear	supernatant	was	transferred	to	a	new	tube	and	2	
µL	glycogen	 (35	ng/µL;	PeqLab)	was	added.	Then	500	µL	100	%	 isopropanol	 (Sigma	Aldrich)	
was	added.	The	samples	were	incubated	at	-20	°C	over	night.	The	samples	were	centrifuged	
on	 the	 next	 day	 for	 15	min	 at	 12.000x	g	 and	 4	 °C	 and	washed	 twice	with	 1	mL	 cold	 75	%	
ethanol	 (Sigma	 Aldrich).	 The	 pellets	 were	 dried	 for	 20-30	min	 at	 room	 temperature	 in	 the	
open	 tube	 and	 re-suspended	 in	 25	 µL	 molecular	 grade	 water	 each.	 The	 eluted	 RNA	 was	
incubated	for	5	min	at	57	°C	in	a	heating	block	and	the	duplicates	were	combined	in	one	tube.	
The	RNA	was	stored	at	-70	°C	or	processed	further	immediately.	The	RNA	concentration	was	
measured	spectrophotometrically	via	NanoDrop	2.1.2.2.1.1.	
	
2.1.2.1.1.2.2 DNase	treatment	
To	exclude	contamination	DNA	0.1x	volume	of	10x	Turbo	DNase	buffer	and	1	µL	Turbo	DNA	
(Life	 Technologies)	 were	 added	 and	 incubated	 for	 5min	 at	 37	 °C	 in	 a	 heating	 block.	 To	
inactivate	 the	 DNase	 0.1x	 volume	 of	 well	 re-suspended	 DNase	 Inactivation	 Reagent	 (Life	
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Technologies)	 were	 added.	 The	 sample	 was	 incubated	 for	 5min	 at	 room	 temperature	 and	
centrifuged	for	1.5	min	at	10000x	g.	The	clear	supernatant	was	transferred	to	a	new	tube.	
	
2.1.2.1.1.2.3 Pellet	Paint	Precipitation	
To	 further	 purify	 viral	 RNA	 a	 Pellet-Paint-Precipitation	was	 performed.	 Pellet	 Paint®	NF	 Co-
Precipitant	 (PPP;	Merck	Millipore))	 and	 3	M	Na-Acetate	 (pH5,2;	 part	 of	 the	 PPP	 kit,	Merck	
Millipore)	were	equilibrated	 to	 room	 temperature.	 Two	µL	of	 PPP,	 0.1x	 volume	of	 3	M	Na-
Acetate	and	2x	volume	100	%	ethanol	were	added.	The	mixture	was	 incubated	for	2	min	at	
room	temperature	and	centrifuged	for	5	min	at	maximum	speed.	Afterwards	the	pellet	was	
washed	twice	with	1	mL	70	%	ethanol	and	one	time	with	1	mL	100	%	ethanol.	The	pellet	was	
then	 dried	 for	 20-30	 min	 at	 room	 temperature	 in	 the	 open	 tube,	 re-suspended	 in	 25	 µL	
molecular	 grade	 water	 and	 incubated	 for	 5	 min	 at	 57	 °C	 in	 the	 heating	 block.	 The	 RNA	
concentration	 was	 measured	 spectrophotometrically	 via	 NanoDrop.	 To	 estimate	 the	 exact	
RNA	 concentration	 an	 additional	 reading	was	performed	at	 lambda=600	mn	 to	 exclude	 the	
PPP.	 The	 RNA	 concentration	was	 then	 calculated	 as	 followed:	 RNA	 concentration	 (ng/µL)	 =	
(readingA260-(readingA600	 x	 0.84	 /PPP	 constant/))	 x	 40	 /RNA	 factor/.	 Additionally,	 2x	 1	 µL	 of	
RNA	was	used	for	an	in-house	IPNV	RT-qPCR,	developed	by	Dr.	Tharangani	Herath,	Institute	of	
Aquaculture,	 University	 of	 Stirling,	 Stirling,	 UK.	 The	 RNA	 was	 then	 stored	 at	 -70	 °C	 or	
processed	further	immediately.	
	
2.1.2.1.1.2.4 Ligation	of	a	3’	iSP9	adapter	
For	a	better	termini	coverage,	a	3’-end	iSP9	adaptor	(MW=10902.14	g/mol;	Synthesis:	1.0OD	=	
30.3	 µg	 or	 2.7	 nmol;	 HPLC-grade)	 was	 ligated	 to	 the	 viral	 RNA	 according	 to	 the	 modified	
protocol	of	(Maan	et	al.	2007).	The	reaction	was	set	up	as	shown	in	Table	5	using	components	
from	the	T4	Ligase	1	Kit	(NEB):	
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Table	5.	Ligation	reaction-set	up.	
Reagent	 per	sample	
RNA	(500–1000	ng)	 max.	12	µL	
3’	iSP9	adaptor	(500-1000	ng)	 2.0	µL	
10x	T4	RNA	Ligase	1	Buffer	 2.0	µL	
10	mM	ATP	 2.0	µL	
T4	RNA	Ligase	1	(10000	Units/mL)	 1.0	µL	
Protector	RNase-Inhibitor	(40	Units/µL;	Roche)	 1.0	µL	
Molecular	grade	water	 adjust	to	20	µL	
Σ	Volume:	 20	µL	
	
The	 reaction	 was	 incubated	 over	 night	 at	 4	 °C	 and	 purified	 the	 next	 day	 with	 the	 Qiagen	
RNeasy-MinElute	 Cleanup	 Kit	 according	 to	 the	 manufacturer’s	 protocol.	 Since	 the	 adaptor	
sequence	could	not	be	found	in	the	sequenced	samples,	it	was	decided	to	leave	this	step	out	
in	order	to	avoid	RNA	losses	during	this	procedure.	
	
2.1.2.1.1.2.5 Transplex	Whole	Transcriptome	Amplification	
The	 Transplex	 Whole	 Transcriptome	 Amplification	 Kit	 (WTA2)	 by	 Sigma-Aldrich	 (modified	
protocol)	was	used	to	generate	fragmented	ds-cDNA	of	the	viral	RNA.	
	
The	first	part	synthesis	reaction	was	prepared	as	listed	in	Table	6:	
	
Table	6.	Synthesis	reaction,	part	I/	II-	set	up.	
Reagent	 NC	 Per	sample	
60	ng	RNA	 ∅	 max.	8.46	µL	
Library	Synthesis	Solution	 1.5	µL	 1.5	µL	
Nuclease-free	water	 8.46	µL	 adjust	to	9.96	µL	
Σ	Volume:	 9.96	µL	 9.96	µL	
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The	mix	was	incubated	for	5	min	at	95	°C,	then	directly	transferred	on	ice	and	incubated	on	
ice	for	2	min.	Following	components	were	then	added	to	9.96	µL	of	cooled-primed	RNA	(Table	
7)	and	cycled	as	followed	(Table	8):	
	
Table	7.	Synthesis	reaction,	part	II/	II-	set	up.	
Library	Synthesis	Buffer	 1.5	µL	
Molecular	grade	water	 2.34	µL	
Library	Synthesis	Enzyme	 1.2	µL	
Σ	Volume:	 15	µL	
	
Table	 8.	 Synthesis	 reaction-	
cycling	conditions.	
18	°C	 11	min	
25	°C	 10	min	
37	°C	 30	min	
42	°C	 10	min	
70	°C	 20	min	
12	°C	 Hold	
	
Samples	were	 stored	 at	 -20	 °C	 or	 processed	with	 the	Amplification	 reaction	 step.	 This	 step	
includes	 a	 nucleotide	 stain,	 EvaGreen	 (Jena	 Bioscience),	 which	 helps	 to	 estimate	 the	
amplification	 plateau,	 so	 amplification	 of	 “unspecific”	 genomes	 or	 primer-dimer	 formations	
can	be	avoided.	The	reaction	was	set	up	in	a	96	well	plate	(WP)	and	cycled	as	followed	(Table	
9,	Table	10)	in	the	Light	Cycler	480	(Roche):	
	
Table	9.	Amplification	with	EvaGreen-	set	up.	
Molecular	grade	water	 59.7	µL	
Amplification	Mix	 7.5	µL	
WTA2	dNTPs	 1.5	µL	
Amplification	Enzyme	 0.75	µL	
EvaGreen	(50x)	 0.75	µL	
Library	Synthesis	Reaction	 4.8	µL	
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Table	10.	Amplification	with	EvaGreen-	cycling	conditions	in	the	LC480II.	
Denaturation	 94	°C	 2	min	 	
Amplification	 94	°C	 30	sec	 25	
cycles	70	°C	 5	min	
Cooling	 40	°C	 5	min	 	
	
When	 the	 amplification	 curves	 fulfilled	 the	 requirements	 and	 it	 was	 clear	 when	 the	
amplification	reaches	its	plateau,	samples	without	EvaGreen	were	prepared	in	duplicates	and	
cycled	as	followed	in	a	thermal	cycler	(Table	11,	Table	12):	
	
Table	11.	Amplification	without	EvaGreen-	set	up.	
Molecular	grade	water	 60.45	µL	
Amplification	Mix	 7.5	µL	
WTA2	dNTPs	 1.5	µL	
Amplification	Enzyme	 0.75	µL	
Library	Synthesis	Reaction	 4.8	µL	
	
Table	12.	Amplification	without	EvaGreen-	cycling	conditions	in	a	thermocycler.	
Denaturation	 94°C	 2min	 	
Amplification	 94°C	 30sec	 X	cycle(s)	
+	2-3	cycles	70°C	 5min	
Cooling	 40°C	 5min	 	
	
The	samples	were	stored	at	 -20	 °C	or	purified	directly	via	 the	QiaQuick	PCR-Purification-Kit.	
The	 DNA	 concentration	 was	 measured	 via	 NanoDrop.	 The	 values	 were	 used	 to	 dilute	 the	
sample	 to	 50	 ng/µL	 in	 100	 µL	 (in	 molecular	 grade	 water)	 for	 a	 following	 Ampure	 Bead	
purification	 to	 exclude	DNA	 fragments	 smaller	 than	 300	 bp.	 The	 diluted	 sample	was	mixed	
with	70	µL	of	well	 re-suspended	beads	 (0.9x)	and	 incubated	 for	10	min	on	a	mixer	at	 room	
temperature.	 The	 sample	 was	 placed	 in	 a	 tube	 magnet	 (Life	 Technologies)	 to	 discard	 the	
supernatant.	 After	 three	 washing	 steps	 (30	 sec	 each)	 with	 500	 µL	 freshly	 prepared	 70	 %	
ethanol	while	 keeping	 the	 sample	 in	 the	magnet,	 the	pellet	was	dried	 in	 the	magnet	 for	 at	
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least	3	min	at	 room	temperature.	The	DNA	was	eluted	 in	18	µL	molecular	grade	water	and	
transferred	 into	 a	 new	 tube.	 The	 DNA	 concentration	 was	 measured	 via	 NanoDrop.	
Additionally,	1	µL	of	the	sample,	diluted	to	25	ng/µL	with	molecular	grade	water,	based	on	the	
NanoDrop	 results,	was	used	 for	a	 fragment	analysis	on	a	Bioanalyzer	 (Agilent	Technologies)	
(see	2.1.2.2.2.3).	The	DNA	was	used	immediately	for	library	preparation	via	Illumina	Nextera	
XT	DNA	Library	Preparation	Kit	or	stored	at	-20	°C.	
	
2.1.2.1.2 	Glasgow	protocol	
This	protocol	was	developed	by	Dr.	Emma	Thomson,	MRC-University	of	Glasgow,	Centre	 for	
Virus	Research,	Glasgow,	UK	and	was	used	for	whole	genome	sequencing	of	diagnostic	TCID50	
IPNV	 isolates.	 This	 protocol	 requires	 less	 input	 material,	 has	 one	 PCR	 step	 less	 that	 the	
Goettingen	 protocol,	 is	 cheaper	 and	 faster.	 The	 initial	 protocol	 used	 the	NEB	Next®	Ultra™	
Directional	RNA	Library	Prep	Kit	for	Illumina	(New	England	Biolabs)	for	library	preparation	and	
the	KAPA	SYBR®	FAST	qPCR	Kit	(Kapa	Biosystems)	for	library	normalisation.	In	this	study,	the	
Nextera	XT	DNA	Library	Preparation	Kit	(Illumina)	was	used	instead.	
	
2.1.2.1.2.1 IPNV	RNA	extraction	
IPNV	RNA	was	extracted	via	Agencourt	RNAdvance	Blood	Kit	according	to	Part	C	–	Agencourt	
RNAdvance	Blood	2mL	Tube	Protocol	(Beckman	Coulter)	with	following	changes:	
Filtered	 cell	 culture	 supernatant	 from	2.1.1.2.4	 (400	 µL)	was	 treated	with	 a	 Protease	 K	 (50	
mg/mL)-lysis	buffer	mix	for	15	min	at	55	°C.	After	an	incubation	of	2	min	at	room	temperature	
410	µL	of	Bind	1/isopropanol	solution,	containing	10	µL	Bind	1	and	400	µL	100	%	isopropanol,	
were	added.	The	mix	was	 incubated	 for	5	min	at	 room	temperature	before	 the	 tubes	were	
placed	 into	a	magnetic	rack.	The	clear	supernatant	was	discarded.	The	tubes	were	removed	
from	the	magnetic	rack	and	washed	with	400	µL	of	the	wash	buffer.	The	tubes	were	placed	
into	the	magnet	to	remove	the	wash	buffer.	The	second	wash	was	performed	by	adding	800	
µL	of	70	%	ethanol	into	the	tubes,	which	remained	in	the	magnet.	After	1	min	the	ethanol	was	
removed	and	the	beads	were	air-dried.	The	tubes	were	removed	from	the	magnet	and	100	µL	
of	the	DNase	solution,	containing	85	µL	water,	10	µL	10x	DNase	buffer	and	5	µL	DNase	I	(Life	
Technologies),	was	added	to	each	tube	prior	to	incubating	at	37	°C	for	5	min.	Then	200	µL	of	
the	 Bind	 2	 buffer	 was	 added	 and	 the	mix	 was	 incubated	 at	 room	 temperature	 before	 the	
tubes	were	placed	 in	 the	magnet	and	the	clear	supernatant	was	discarded.	The	beads	were	
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washed	twice	by	adding	800	µL	of	70	%	ethanol,	incubating	for	1	min	in	the	magnetic	rack	and	
discarding	 the	 ethanol.	 The	 beads	 were	 air-dried	 in	 the	magnet	 for	 10	min.	 The	 RNA	 was	
eluted	by	re-suspending	the	beads	in	20µL	molecular	grade	water	and	incubating	the	mix	for	2	
min	at	room	temperature.	The	tubes	were	placed	into	the	magnet	and	the	clear	RNA	solution	
was	transferred	into	a	fresh	tube.	An	aliquot	was	prepared	for	concentration	analysis	and	in-
house	IPNV	RT-qPCR	and	the	stock	was	stored	at	-70	°C	until	further	processing.	
	
2.1.2.1.2.2 ds-cDNA	synthesis	
2.1.2.1.2.2.1 Synthesis	of	the	first	cDNA	strand	
The	RNA	was	converted	into	cDNA	by	mixing	11	µL	of	RNA	(maximum	1	µg	total	RNA)	with	10	
µL	of	the	following	master	mix	using	components	from	Life	Technologies	(Table	13):	
	
Table	13.	cDNA	synthesis-	master	mix.	
5x	Reverse	Transcriptase	Buffer	 4	µL	
Super	Script	III	RT	 2	µL	
RNaseOUT	Recombinant	Ribonuclease	Inhibitor	 1	µL	
Random	Hexamers	(50µM)	 1	µL	
dNTP’s	(2.5mM)	 1	µL	
DTT	 1	µL	
Σ	Volume	 10	µL	
	
The	cDNA	reaction	was	incubated	in	a	thermocycler	as	followed	(Table	14):	
	
Table	 14.	 cDNA	 synthesis-	
cycling	conditions.	
25	°C	 10	min	
55	°C	 60	min	
70	°C	 15	min	
4	°C	 hold	
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2.1.2.1.2.2.2 Synthesis	of	the	second	cDNA	strand	
Using	the	NEB	Next	mRNA	Second	Strand	Synthesis	Module	Kit	the	ds-cDNA	was	prepared	by	
adding	 20	 µL	 of	 the	 previously	 produced	 single	 stranded	 cDNA	 (ss-cDNA)	 to	 60	 µL	 of	 the	
following	 master	 mix	 (Table	 15,	 Table	 16)	 using	 components	 from	 the	 NEBNext®	 mRNA	
Second	Strand	Synthesis	Module	(NEB):	
	
Table	15.	cDNA	second	strand	synthesis	reaction-	master	mix.	
10x	Second	Strand	Synthesis	Reaction	Buffer	 8	µL	
Second	Strand	Synthesis	Enzyme	 4	µL	
Molecular	Grade	Water	 48	µL	
Σ	Volume	 60	µL	
	
The	ds-cDNA	reaction	was	incubated	in	a	thermocycler	as	followed:	
	
Table	 16.	 cDNA	 second	
strand	 synthesis-	 cycling	
conditions.	
25	°C	 2	min	30	sec	
4	°C	 hold	
	
2.1.2.1.2.2.3 Clean-up	of	the	ds-cDNA	
After	this	step,	the	product	was	either	stored	at	-20	°C	or	processed	directly.	The	product	was	
cleaned	 up	 by	 adding	 80	 µL	 of	 Ampure	 XP	 beads	 (Beckman	 Coulter)	 per	 sample	 (1x)	 and	
incubation	for	5	min	at	room	temperature.	The	sample	was	placed	into	a	magnet	rack	so	the	
clear	supernatant	could	be	discarded.	The	magnetic	beads	pellet	was	washed	twice	with	200	
µL	of	freshly	prepared	70	%	ethanol,	while	keeping	the	tube	 in	the	magnet	and	dried	 in	the	
magnet	for	5	min	at	room	temperature	to	remove	all	ethanol	traces.	The	pellet	was	eluted	in	
25	 µL	 molecular	 grade	 water	 and	 transferred	 into	 a	 new	 Eppendorf®	 DNA	 LoBind	
microcentrifuge	 1.5	 mL	 tube	 (Eppendorf).	 The	 DNA	 was	 stored	 at	 -20	 °C	 or	 used	 for	
concentration	 measurement	 and	 library	 preparation	 via	 Illumina	 Nextera	 XT	 DNA	 Library	
Preparation	Kit.	
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2.1.2.1.3 	Comparison	of	the	Glasgow	and	the	Goettingen	protocols	regarding	whole	genome	
sequencing	
For	the	purpose	of	saving	time	and	funding	the	Glasgow	protocol,	which	is	cheaper	and	faster,	
and	the	Goettingen	protocols	were	compared	using	samples	 IoA024	and	 IoA030	 in	terms	of	
virus	sequence	completeness.	The	samples	were	bulked	up	as	listed	in	Table	17:	
	
Table	17.	IPNV	samples	used	to	compare	the	Goettingen	and	the	Glasgow	protocol.	
Sample	 Cell	line	 Flask	size	 Passage	in	cell	culture	 Protocol	
IoA024	 TO	 25	cm2	 P3	 Glasgow	
IoA024	 TO	 175	cm2	 P4	 Goettingen	
IoA030	 TO	 25	cm2	 P1	 Glasgow	
IoA030	 TO	 175	cm2	 P2	 Goettingen	
	
The	 samples	 were	 processed	 with	 either	 the	 Glasgow	 or	 the	 Goettingen	 protocol.	 The	 ds-
cDNA	was	prepared	as	 in	2.1.2.1.1	or	2.1.2.1.2	and	 libraries	were	prepared.	The	 library	was	
prepared	and	run	as	in	2.1.2.3.	
	
2.1.2.2 	Nucleic	acid	analysis	
2.1.2.2.1 RNA	analysis	
2.1.2.2.1.1 Measure	RNA	concentration	via	Nano	Drop	
The	 sample	 panel	 of	 the	Nano	Drop	 (Thermo	 Fisher	 Scientific)	was	 cleaned	with	molecular	
grade	 water	 before	 the	 first	 use.	 The	 instrument	 was	 adjusted	 with	 2	 µL	 molecular	 grade	
water.	The	setting	was	changed	to	RNA.	The	measurement	was	carried	out	with	2	µL	of	the	
sample.	
	
2.1.2.2.1.2 	IPNV	RT-qPCR	
In	order	to	estimate	the	threshold	of	concentration	of	IPNV	genome	equivalents	higher	than	
104	copies/mL,	which	are	needed	for	a	successful	whole	genome	sequencing,	an	in-house	RT-
qPCR	 for	 IPNV	 was	 used.	 It	 was	 developed	 by	 Dr.	 Tharangani	 Herath	 in	 the	 Institute	 of	
Aquaculture,	 Stirling,	 UK	 and	 includes	 a	 cloned	 IPNV	 standard	 (Ct=16;	 108	 copies/µl).	 The	
working	 dilution	 (Ct=19-20;	 107	 copies/µl)	 was	 diluted	 with	 molecular	 grade	 water	 in	 1:10	
steps	down	to	101	copies/µl.	Samples,	all	standards	and	the	NC	(molecular	grade	water)	ran	in	
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duplicate	 in	a	Light	Cycler	480	(Roche).	The	master	mix	was	set	up	as	 followed	according	to	
the	LightCycler	480	RNA	Master	Hydrolysis	Probes	Kit	by	Roche	(Table	18):	
	
Table	18.	IPNV	RT-qPCR-	set	up.	
1.	2.7x	Buffer	mix	 7.5	µL	(1x)	
2.	Activator	(MnCl2)	50	mM	 1.3	µL	(3.25	mM)	
Forward	primer	10	µM	(10	pmol)	 1.0	µL	(500	nM)	
Reverse	primer	10	µM	(10	pmol)	 1.0	µL	(500	nM)	
Probe	10	µM	(10	pmol)	 0.4	µL	(200	nM)	
3.	PCR	grade	water	 7.8	µL	
Σ	Volume	 19	µL	
	
The	master	mix	was	added	to	1	µL	standard,	NC	or	sample	RNA	in	a	96WP,	mixed,	pelleted	at	
approximately	2000	rpm	and	cycled	in	the	Light	Cycler	480II	(Roche)	as	followed	(Table	19):	
	
Table	19.	IPNV	RT-qPCR-	cycling	conditions.	
Reverse	transcription	 63	°C	 3	min	 	
Activation	 95	°C	 30	sec	 	
Amplification	 95	°C	
60	°C	
5	sec	
15	sec	
45	
cycles	
Cooling	 40	°C	 40	sec	 	
	
For	 data	 analysis	 the	 Abs	 Quant/Fit	 Points	 algorithm	 (Roche)	 was	 used	 to	 estimate	 the	 Ct	
value	and	the	copy	number.	
	
2.1.2.2.2 DNA	analysis	
2.1.2.2.2.1 	Measure	DNA	concentration	via	Nano	Drop	
The	 sample	 panel	 was	 cleaned	 with	 molecular	 grade	 water	 before	 the	 first	 use.	 The	
instrument	was	adjusted	with	2	µL	molecular	grade	water.	The	setting	was	changed	to	DNA.	
The	measurement	was	carried	out	with	2	µL	of	the	sample.	
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2.1.2.2.2.2 	Gel	electrophoresis	
Gel	 electrophoresis	 was	 used	 as	 a	 PCR	 control.	 A	 1	 %	 Agarose	 gel	 (Bioline),	 which	 was	
considered	as	 appropriate	 for	 the	 size	of	 the	PCR	product	 (Table	20),	 containing	0.5	µg/mL	
(final	 concentration)	 ethidium	 bromide	 (Thermo	 Fisher	 Scientific)	 was	 loaded	 with	 1	 µL	
sample,	 which	 was	 prior	 diluted	 in	 5	 µL	 6x	 Loading	 Dye	 (Thermo	 Fisher	 Scientific).	 A	 DNA	
Ladder	 (Thermo	 Fisher	 Scientific)	 was	 also	 loaded	 as	 a	 size	 control	 according	 to	
manufacturer’s	protocol.	The	gel	was	run	for	40	min	at	75	V.	
	
Table	 20.	 Correlation	 between	 Agarose	 gel	 %-age	 and	 DNA	 size	 distribution	 (Ref.:	
http://www.promega.co.uk/resources/pubhub/enotes/what-percentage-agarose-is-
needed-to-sufficiently-resolve-my-dna-sample/?activeTab=0).	
%	Gel	and	DNA-size	distribution	(Promega)	 Agarose	 0.5x	TAE	
1	%	Gel	(500–10000	bp)	 0.3	g	 30	mL	
1.5	%	Gel	(200-3000	bp)	 0.45	g	 30	mL	
2	%	Gel	(50-2000	bp)	 0.7	g	 35	mL	
	
2.1.2.2.2.3 	Bioanalyzer	analysis	
To	 verify	 the	 size	 distribution	 and	 quality	 of	 fragmented	 DNA	 after	 the	 fragmentation	 and	
purification	step	in	the	Goettingen	protocol	or	after	the	PCR-purification	step	of	the	Nextera	
XT	 DNA	 Library	 Preparation	 Kit	 the	 Agilent	 High	 Sensitivity	 DNA	 Kit	 was	 used	 according	 to	
manufacturer’s	protocol	(Agilent	Technologies).	
The	gel	matrix	was	prepared	by	adding	15	µL	of	the	dye	 into	the	gel.	The	mix	was	vortexed	
and	loaded	on	a	filter	membrane	to	centrifuge	at	2250x	g	for	10	minutes.	
The	DNA	chip	was	prepared	in	the	priming	station	by	loading	9	µL	of	the	gel-dye	mix	into	the	
distribution	well.	Further	9	µL	of	the	gel-dye	mix	were	added	to	other	gel	wells.	After	that	5	µL	
DNA	marker	were	added	in	every	sample	well	as	well	as	the	DNA	ladder	well.	One	µL	of	the	
ladder	was	loaded	into	the	ladder	well.	After	pipetting	1	µL	of	sample	into	sample	wells,	the	
chip	was	vortexed	at	2500	rpm	for	1	min	and	ran	in	the	Bioanalyzer.	Results	were	processed	
using	the	corresponding	software.	
	
2.1.2.2.2.4 	Qubit	analysis	
A	 Qubit	 dsDNA	 HS	 Assay	 Kit	 (Life	 Technologies)	 was	 used	 for	 an	 exact	 concentration	
measurement	 of	 ds-cDNA	 on	 a	 Qubit	 2.0	 Fluorometer	 (Life	 Technologies).	 The	 DNA	
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concentration	was	first	measured	via	NanoDrop	and	the	results	were	used	to	check	if	the	DNA	
concentration	was	within	the	accurate	working	ratio	from	10	pg/µL	to	100	ng/µL	of	the	used	
assay.	 The	 Qubit	 working	 solution	 and	 the	 standards	 were	 prepared	 according	 to	 the	
manufacturer’s	protocol.	The	samples	were	prepared	by	mixing	1	µL	of	the	DNA	with	199	µL	
of	the	Qubit	working	solution.	The	reading	in	ng/mL	was	calculated	with	the	following	formula	
to	 get	 the	 exact	 concentration:	 concentration	 of	 the	 sample	 in	 ng/µL	 =	 (concentration	 in	
ng/mL	 x	 200/	 X	 µL	 of	 sample	 input)/1000	 mL.	 The	 concentration	 provided	 by	 the	 Qubit	
analysis	 was	 used	 to	 dilute	 samples	 more	 precisely	 for	 the	 Nextera	 XT	 DNA	 Library	
preparation,	 since	 the	 exact	 DNA	 input	 is	 very	 crucial	 to	 the	 outcome	 of	 the	 library	
preparation.	
	
2.1.2.3 Library	preparation	
For	 whole	 genome	 sequencing	 of	 IPNV	 samples	 processed	 with	 Goettingen	 or	 Glasgow	
protocol	NGS	libraries	were	prepared	according	to	the	Nextera	XT	DNA	Library	Preparation	Kit	
(Illumina).	
	
2.1.2.3.1 Tagmentation	
For	 the	 tagmentation	2.5	µL	DNA	 (0.5	ng	of	 total	DNA)	were	mixed	with	5	µL	TD	 (Tagment	
DNA	 Buffer)	 and	 2.5	 µL	 AMT	 (Amplicon	 Tagment	Mix)	 in	 a	 0.2	mL	 PCR	 tube.	 The	mix	was	
centrifuged	at	280x	g	and	20	°C	for	1	min	and	incubated	for	5	min	at	55	°C	in	a	thermocycler.	
The	mix	was	cooled	down	to	10	°C	and	the	tagmentation	reaction	was	neutralized	by	pipetting	
2.5	µL	of	NT	(Neutralize	Tagment	Buffer)	into	the	sample	mix.	The	mix	was	centrifuged	at	280x	
g	and	20	°C	for	1	min	and	incubated	for	5	min	at	room	temperature.	
	
2.1.2.3.2 PCR	amplification	
The	PCR	mix	was	set	up	by	pipetting	7.5	µL	NPM	(Nextera	PCR	Mastermix)	and	2.5	µL	of	index	
primer	 1	 and	 2	 of	 the	 Nextera	 XT	 Index	 Kit	 (for	 24	 libraries)	 to	 the	 sample	 mix	 from	 the	
tagmentation	 step.	 The	mix	 was	 centrifuged	 at	 280x	 g	 and	 20	 °C	 for	 1	 min	 and	 cycled	 as	
followed	(Table	21):	
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Table	21.	PCR	amplification	cycling	conditions.	
72	°C	 3	min	 	
95	°C	 30	sec	 	
95	°C	
55	°C	
72	°C	
10	sec	
30	sec	
30	sec	
	
12	cycles	
72	°C	 5	min	 	
10	°C	 hold	 	
	
The	PRC	reaction	was	processed	immediately	or	stored	at	4-8	°C	for	up	to	2	days.	
	
2.1.2.3.3 PCR	Clean-Up	
The	PCR	 tubes	were	pelleted	at	approximately	2000	 rpm	and	 the	 samples	were	 transferred	
into	a	1.5	mL	 tube.	Forty-five	µL	of	AMPure	XP	beads	were	added	 to	each	sample	 (1.8x)	 to	
select	for	300-500	bp	long	sample	fragments	and	incubated	for	5	min	at	room	temperature.	
The	 tubes	 were	 placed	 into	 a	 magnetic	 rack	 and	 incubated	 for	 minimum	 2	 min	 until	 the	
supernatant	had	cleared.	The	supernatant	was	discarded.	The	samples	 (still	 in	 the	magnetic	
rack)	were	washed	twice	with	freshly	prepared	80	%	ethanol	for	30	sec.	The	samples	were	left	
on	 the	magnetic	 rack	 for	 15	 min	 to	 air-dry	 the	 beads.	 The	 tubes	 were	 removed	 from	 the	
magnetic	rack	to	elute	the	libraries	 in	26	µL	RSB	(Resuspension	Buffer).	The	elution	mix	was	
incubated	 for	2	min	at	 room	temperature	and	the	 tubes	were	placed	back	on	the	magnetic	
rack	to	separate	the	beads	from	the	eluted	libraries.	After	the	supernatant	has	cleared,	23	µL	
of	 the	 supernatant	were	 transferred	 into	 a	 new	 1.5	mL	 tube.	 The	 samples	were	 processed	
immediately	or	stored	at	-15-25	°C	for	up	to	a	week.	
	
2.1.2.3.4 Library	Normalisation	
To	normalise	the	quantity	of	each	library	45.8	µL/sample	of	LNA1	and	8.3	µL/sample	of	LNB1	
were	 mixed	 together	 and	 45	 µL	 of	 the	 LNA1/LNB1	 mix	 were	 added	 to	 each	 sample	 and	
incubated	for	30	min	on	a	mixer	at	99	rpm.	The	samples	were	placed	into	a	magnetic	rack	and	
incubated	until	the	supernatant	has	cleared.	The	supernatant	was	removed	and	the	samples	
were	washed	with	45	µL	LNW1	by	incubating	the	tubes	at	99	rpm	for	5	min	on	a	mixer.	Then	
the	tubes	were	placed	back	in	the	magnetic	rack.	The	clear	supernatant	was	removed	and	the	
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samples	 were	 washed	 as	 described	 one	 more	 time.	 The	 tubes	 were	 removed	 from	 the	
magnetic	 rack	 and	30	µL	 of	 freshly	 prepared	0.1	N	NaOH	were	 added	 to	 each	 sample.	 The	
elution	mix	was	incubated	for	5	min	at	99	rpm	on	a	mixer.	During	the	incubation	step	30	µL	of	
LNS1	were	pipetted	into	a	fresh	1.5	mL	tube.	The	samples	were	placed	in	the	magnetic	rack	
after	the	incubation	and	30	µL	of	the	clear	supernatant	were	transferred	to	the	1.5	mL	tube,	
which	contains	30	µL	LNS1.	The	eluted	 library	was	pelleted	at	approximately	2000	 rpm	and	
processed	immediately	or	stored	at	-15-25	°C.	
	
2.1.2.3.5 Library	Pooling	and	loading	
Each	 library	was	mixed	 and	 pelleted	 at	 approximately	 2000	 rpm.	 Then	 5	 µL	 of	 each	 library	
were	pooled	into	a	1.5	mL	tube.	Another	1.5	mL	tube	was	used	to	mix	570	µL	of	HT1	and	12	µL	
of	 PhiX	 Control	 v3.	 Eighteen	 µL	 of	 the	 pooled	 library	were	 added	 to	 this	mix.	 Right	 before	
loading	the	mix	into	the	MiSeq	reagent	cartridge	of	the	MiSeq	Reagent	Kit	v3	(150	cycles)	the	
mix	was	pelleted	at	approximately	2000	rpm	and	incubated	at	96	°C	for	2	min	in	a	heat	block.	
Then	 the	 library	mix	was	cooled	 for	5	min	 in	an	 ice-ethanol	mix	and	 loaded	 into	 the	MiSeq	
reagent	cartridge,	which	was	previously	thawed	at	room	temperature.	The	rest	of	the	pooled	
library	mix	was	stored	at	-15-25	°C	for	up	to	a	week.	The	MiSeq	reagent	cartridge	was	placed	
into	the	previously	maintained	MiSeq	sequencer	(Illumina)	and	a	paired	end	sequencing	run	
was	performed	according	to	the	manufacturer’s	protocol.	
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2.2 Improving	the	Glasgow	protocol	
2.2.1 Improving	the	ds-cDNA	synthesis	
2.2.1.1 Introduction	
In	order	to	improve	the	coverage	of	the	3’-end	of	IPNV	segment	A	and	B	some	changes	were	
introduced	to	the	Glasgow	protocol	using	the	sample	IoA039:	
	
Table	22.	Changes	in	the	GLAP	compared	to	standard	GLAP.	
IoA039	
Sample	
variation	
GP32	protein	
	
3’	primer	 RNase	
treatment	
Elute	
RNA	in	
dNTPs	
and	
random	
hexamers	
Incubate	
RNA	at	
75	°C	for	
5	min	
Normal	
Glasgow	
protocol	
1	 	 	 	 	 	 	 	 	
2	 	 	 	 	 	 	 	 	
3	 	 	 	 	 	 	 	 	
4	 	 	 	 	 	 	 	 	
5	 	 	 	 	 	 	 	 	
6	 	 	 	 	 	 	 	 	
7	 	 	 	 	 	 	 	 	
8	 	 	 	 	 	 	 	 	
9	 	 	 	 	 	 	 	 	
10	 	 	 	 	 	 	 	 	
	
GP32	 is	 a	 ssDNA	binding	 protein	 and	 it	was	 used	 to	 improve	 the	 yield	 and	 efficiency	 of	 RT	
during	RT-PCR	 (Shamoo	et	al.	1995).	 In	 this	experiment	1	µg/25µL	reaction	volume	of	GP32	
(Roche)	were	used	to	improve	amplification.	For	that,	GB32	was	included	in	the	ss-cDNA	step	
(Table	22	1)	or	the	ds-cDNA	step	(Table	22	2)	or	in	both	steps	(Table	22	3).	
To	 improve	 termini	 coverage	 a	 primer	was	 created	 that	 is	 as	 long	 as	 the	 random	primers/	
oligos	 from	 the	 respective	 kits,	 within	 30-100	 bp	 of	 the	 3’-end.	 The	 primer	 was	 used	
additionally	 to	 the	 random	 primers/oligos	 from	 the	 respective	 kit	 in	 the	 first	 cDNA	 strand	
	 65	
synthesis	(Table	22	4)	or	second	cDNA	strand	synthesis	(Table	22	5)	or	in	both	reactions	(Table	
22	6).	
The	5’-3’	 sequence	of	 the	primer	 is	complementary	 to	 the	3’-end	of	 the	3’-5’	 sequence	and	
will	 initiate	 a	 transcription	 to	 the	 end.	 The	 primers	 for	 segment	 A	 and	 B	 were	 created	 by	
creating	a	contig	sequence	of	multiple	IPNV	sequences	available	(Table	23).	
	
Table	23.	Primer	for	IPNV	segment	A	and	B.	
	 5’	–	3’	sequence	 Tm	 Position	
IPNV	A	 CGACGACCCCG	 45	°C	 2933-2943	
IPNV	B	 GCTCCR(A	or	G)CGCC	 46	°C	 2694-2703	
	
In	this	optimisation	an	RNase	treatment	after	the	first	strand	synthesis	was	performed	for	20	
min	at	37	°C	(Table	22	7).	
Another	 optimisation	 step	was	 to	 elute	 the	 extracted	 IPNV	RNA	 in	 a	mix	 of	water,	 random	
hexamers	and	dNTPs	(Table	22	8).	
Further	the	IPNV	RNA	was	incubated	at	75	°C	for	5	min	prior	to	the	first	strand	cDNA	synthesis	
instead	 of	 65	 °C	 as	 in	 the	 original	 protocol	 (Table	 22	 9)	 as	 higher	 incubation	 temperature	
allows	a	better	unfolding	of	potential	complex	secondary	structures	at	the	genomic	ends.	
	
2.2.1.2 Setting	up	the	experiment	
2.2.1.2.1 GP32	
IPNV	RNA	was	extracted	from	400	µL	cell	supernatant	as	in	Glasgow	protocol	step	2.1.2.1.2.1	
(RNAdvance	Blood	Kit)	and	eluted	in	20	µL	water.	The	RNA	was	stored	at	-70	°C	if	necessary	or	
processed	immediately.	IPNV	RNA	concentration	was	measured	using	the	NanoDrop	and	the	
in-house	IPNV	RT-qPCR.	
Three	different	reactions	were	performed	by	adding	GP32	(final	concentration:	0.28	mg/mL)	
only	in	the	ss-cDNA	synthesis,	only	in	the	ds-cDNA	synthesis	and	in	both	steps.	The	ds-cDNA	
synthesis	was	performed	according	to	the	Glasgow	protocol.	
The	reactions	were	cleaned	up	as	described	in	step	2.1.2.1.2.2.3	and	stored	at	-20	°C	until	next	
procedure.	Ds-cDNA	was	analysed	on	a	High-Sensitivity	DNA	Bioanalyzer	Chip	(concentration,	
fragment	 size,	 molarity)	 and	 compared	 with	 others.	 Sequencing	 libraries	 were	 prepared	
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according	to	the	Illumina	Nextera	XT	DNA	Library	Preparation	Kit	and	sequenced	according	to	
the	MiSeq	Reagent	Kit	(v3;	150	cycles).	
	
2.2.1.2.2 Specific	3’	-	Primer	
IPNV	RNA	was	extracted	from	400	µL	cell	supernatant	as	in	Glasgow	protocol	step	2.1.2.1.2.1	
(RNAdvance	Blood	Kit)	and	eluted	in	20	µL	water.	The	RNA	was	stored	at	-70	°C	if	necessary	or	
processed	immediately.	IPNV	RNA	concentration	was	measured	using	the	NanoDrop	and	the	
in-house	IPNV	RT-qPCR.	
Three	 different	 reactions	were	 performed	 by	 adding	 specific	 3’-primer	 only	 in	 the	 ss-cDNA	
synthesis,	only	 in	the	ds-cDNA	synthesis	and	in	both	steps.	The	additional	primer	had	a	final	
concentration	in	the	master	mix	of	2.38	µM	(same	as	the	random	hexamers	in	the	first	cDNA	
strand	 synthesis	 step).	 The	 ds-cDNA	 synthesis	 was	 performed	 according	 to	 the	 Glasgow	
protocol.	
The	reactions	were	cleaned	up	as	described	in	step	2.1.2.1.2.2.3	and	stored	at	-20	°C	until	next	
procedure.	Ds-cDNA	was	analysed	on	a	High-Sensitivity	DNA	Bioanalyzer	Chip	(concentration,	
fragment	 size,	 molarity)	 and	 compared	 with	 others.	 Sequencing	 libraries	 were	 prepared	
according	to	the	Illumina	Nextera	XT	DNA	Library	Preparation	Kit	and	sequenced	according	to	
the	MiSeq	Reagent	Kit	(v3;	150	cycles).	
	
2.2.1.2.3 changes	in	RNA	incubation	
IPNV	RNA	was	extracted	from	400	µL	cell	supernatant	as	in	Glasgow	protocol	step	2.1.2.1.2.1	
(RNAdvance	Blood	Kit)	and	eluted	in	20	µL	water.	The	RNA	was	stored	at	-70	°C	if	necessary	or	
processed	immediately.	IPNV	RNA	concentration	was	measured	using	the	NanoDrop	and	the	
in-house	 IPNV	RT-qPCR.	Following	the	Glasgow	protocol	as	usual,	 the	RNA	was	 incubated	at	
75	°C	for	5	min	instead	of	65	°C.	
The	reactions	were	cleaned	up	as	described	in	step	2.1.2.1.2.2.3	and	stored	at	-20	°C	until	next	
procedure.	Ds-cDNA	was	analysed	on	a	High-Sensitivity	DNA	Bioanalyzer	Chip	(concentration,	
fragment	 size,	 molarity)	 and	 compared	 with	 others.	 Sequencing	 libraries	 were	 prepared	
according	to	the	Illumina	Nextera	XT	DNA	Library	Preparation	Kit	and	sequenced	according	to	
the	MiSeq	Reagent	Kit	(v3;	150	cycles).	
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2.2.1.2.4 Eluting	RNA	in	a	‘premix’	
IPNV	RNA	was	extracted	from	400	µL	cell	supernatant	as	in	Glasgow	protocol	step	2.1.2.1.2.1	
(RNAdvance	Blood	Kit)	and	eluted	in	13	µL	Premix	(11	µL	water	+	1	µL	dNTPs	+	1	µL	random	
hexamers)	The	RNA	was	stored	at	-70	°C	if	necessary	or	processed	immediately	according	to	
the	Glasgow	protocol.	
The	reactions	were	cleaned	up	as	described	in	step	2.1.2.1.2.2.3	and	stored	at	-20	°C	until	next	
procedure.	Ds-cDNA	was	analysed	on	a	High-Sensitivity	DNA	Bioanalyzer	Chip	(concentration,	
fragment	 size,	 molarity)	 and	 compared	 with	 others.	 Sequencing	 libraries	 were	 prepared	
according	to	the	Illumina	Nextera	XT	DNA	Library	Preparation	Kit	and	sequenced	according	to	
the	MiSeq	Reagent	Kit	(v3;	150	cycles).	
	
2.2.1.2.5 RNase	treatment	
IPNV	RNA	was	extracted	from	400	µL	cell	supernatant	as	in	Glasgow	protocol	step	2.1.2.1.2.1	
(RNAdvance	Blood	Kit)	and	eluted	in	20	µL	water.	The	RNA	was	stored	at	-70	°C	if	necessary	or	
processed	immediately.	IPNV	RNA	concentration	was	measured	using	the	NanoDrop	and	the	
in-house	 IPNV	RT-qPCR.	After	 the	 ss-cDNA	 synthesis	 step	 the	RNA	was	 removed	 incubating	
the	mix	with	E.	coli	RNaseH	(Life	Technologies)	for	20	min	at	37	°C.	The	rest	was	performed	
according	to	the	standard	Glasgow	protocol.	
The	reactions	were	cleaned	up	as	described	in	step	2.1.2.1.2.2.3	and	stored	at	-20°C		until	next	
procedure.	Ds-cDNA	was	checked	on	a	High-Sensitivity	DNA	Bioanalyzer	Chip	and	compared	
with	 others.	 Sequencing	 libraries	were	 prepared	 according	 to	 the	 Illumina	Nextera	 XT	DNA	
Library	Preparation	Kit	and	sequenced	according	to	the	MiSeq	Reagent	Kit	(v3;	150	cycles).	
	
2.2.2 Improving	RNA	procedure	
In	 order	 to	 further	 improve	 the	 termini	 coverage	 if	 the	 IPNV	 genome	 samples	 IoA035	 and	
IoA111	 were	 randomly	 selected	 to	 perform	 changes	 in	 the	 RNA	 incubation	 step	 of	 the	
Glasgow	protocol.	
IPNV	RNA	was	extracted	from	400	µL	cell	supernatant	as	in	Glasgow	protocol	step	2.1.2.1.2.1	
(RNAdvance	Blood	Kit)	and	eluted	in	20	µL	water.	The	RNA	was	stored	at	-70	°C	if	necessary	or	
processed	immediately.	IPNV	RNA	concentration	was	measured	using	the	NanoDrop	and	the	
in-house	IPNV	RT-qPCR.	
	 68	
Prior	ss-cDNA	synthesis	step	RNA	of	each	sample	was	incubated	5min	at	95	°C	and	at	65	°C	as	
in	 the	 standard	Glasgow	protocol.	 Further	 steps	were	performed	according	 to	 the	protocol.	
The	reactions	were	cleaned	up	as	described	in	step	2.1.2.1.2.2.3	and	stored	at	-20	°C	until	next	
procedure.	Ds-cDNA	was	analysed	on	a	High-Sensitivity	DNA	Bioanalyzer	Chip	(concentration,	
fragment	 size,	 molarity)	 and	 compared	 with	 others.	 Sequencing	 libraries	 were	 prepared	
according	to	the	Illumina	Nextera	XT	DNA	Library	Preparation	Kit	and	sequenced	according	to	
the	MiSeq	Reagent	Kit	(v3;	150	cycles).	
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2.3 Persistency	experiment	
2.3.1 Introduction	
The	whole	genome	sequencing	analysis	of	several	 IPNV	samples	revealed	a	 large	amount	of	
persistent	 strains,	 which	 have	 the	 amino	 acid	 Proline	 at	 position	 217	 and	 a	 Threonine	 at	
position	221	in	the	VP2	protein.	
It	 is	 known	 that	 cell	 culture	 adaptations	 lead	 to	 attenuation	 of	 the	 virus	 to	 replicate	more	
efficiently	 in	the	cell	 line	(Santi,	Vakharia,	and	Evensen	2004b,	Song	et	al.	2005).	 In	order	to	
estimate	whether	the	persistence	pattern	observed	in	the	analysed	IPNV	strains	was	natural	
or	due	to	cell	culture	adaptation,	IPNV	isolates	IoA068,	039,	090,	076	and	035	known	to	have	
the	persistence	pattern	were	passaged	at	 least	3	times	 in	CHSE-214	and	RTG-2	cells	 (Officer	
1964),	since	it	was	shown	that	even	after	10	passages	in	RTG-2	cells,	there	are	no	changes	in	
the	amino	acid	(AA)	sequence	of	the	VP2	protein	which	makes	RTG-2	cells	a	useful	cell	line	for	
virulence/persistence	analysis	of	IPNV	(Song	et	al.	2005).	
	
2.3.2 Methods	
2.3.2.1 RTG-2	cell	line	maintenance	
Cells	were	processed	in	the	same	manner	as	described	in	2.1.1.1	but	with	several	changes:	
- L-15	(Leibovitz’s	L-15	medium;	Gibco)+10	%	FBS	media	instead	
- split	ratio	was	1:2	
- cells	were	incubated	at	22	°C	and	no	CO2	with	a	fully	closed	lid.	
	
2.3.2.2 Seeding	density	estimation	of	RTG-2	cells	for	a	24	well	plate	(WP)	
In	order	to	have	an	optimal	cell	density	in	each	well	of	a	24WP,	several	seeding	densities	were	
tested.	For	that	cells	were	processed	as	in	2.1.1.1.5	but	with	L-15+10	%	FBS.	A	cell	calculation	
was	performed	for	several	densities:	5	x	104,	7.5	x	104,	1.0	x	105,	1.5	x	105,	1.75	x	105,	and	2.0	x	
105	cells/well.	One	mL	of	each	calculated	cell	dilution	was	pipette	in	4	wells	of	each	of	the	6	
rows.	 The	 plate	was	 incubated	 at	 22	 °C	 and	 no	 CO2.	 The	 next	 day	 the	 plate	was	 examined	
visually	to	ensure	that	each	well	of	the	six	different	seeding	densities	had	approximately	the	
same	 cell	 density	 and	 the	 cells	 looked	 healthy.	 The	 cell	 density	 with	 the	 best	 suitable	
monolayer	was	marked	and	the	plate	was	incubated	over	night	at	15	°C	and	no	CO2	which	are	
the	incubation	requirements	for	IPNV	inoculation.	The	next	day	the	plate	was	again	examined	
visually,	 especially	 the	 marked	 row	 with	 the	 best	 suitable	 seeding	 density.	 If	 the	 seeding	
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density	of	interest	fulfilled	the	requirements,	it	was	used	for	initial	inoculation	with	IPNV	in	a	
24WP.	
	
2.3.2.3 Seeding	a	24WP	of	RGT-2	cells	for	inoculation	via	adsorption	
Cell	were	processed	as	described	in	2.3.2.1	and	2.1.1.1.5.	The	cell	number	per	well	that	was	
needed	for	RTG-2	cells	is	1.0	x	105	cells/well.	Cell	dilution	was	pipetted	in	each	well.	The	plate	
was	 incubated	at	22	°C	and	no	CO2.	The	next	day	the	plate	was	examined	visually	to	ensure	
that	 each	well	 had	approximately	 the	 same	 cell	 density	 and	 the	 cells	 looked	healthy.	 If	 the	
requirements	were	fulfilled,	the	well	plate	was	used	for	inoculation	with	IPNV	samples.	
	
2.3.2.4 Infecting	a	RTG-2	24WP	with	IPNV	
Isolates	(TCID50)	IoA068,	039,	090,	076	and	035	that	were	shown	to	belong	to	the	persistent	
strain	type	were	randomly	selected	for	inoculation	via	adsorption	of	RTG-2	cells	in	a	24WP.	
IPNV	 isolates	 of	 interest	 were	 defrosted	 and	 kept	 on	 ice.	 1:10	 and	 1:50	 dilutions	 were	
prepared	using	HBSS+2	%	FBS	media	as	diluent.	Media	of	a	24WP	that	was	prepared	on	the	
previous	day	was	pipetted	off	and	150	µL	of	the	neat	sample,	the	1:10	and	the	1:50	dilutions	
were	pipetted	in	a	column	in	following	order:	neat,	1:10,	1:50,	negative	control	(NC=	HBSS+2	
%	FBS).	The	plate	was	sealed	with	plastic	paraffin	film	and	incubated	at	15	°C	w/o	CO2	for	3	h.	
The	 plate	 was	 rocked	 every	 hour	 to	 ensure	 that	 the	 cells	 were	 equally	 covered	 with	 the	
inoculum.	Then	1.5	mL	of	 L15+10	%	FBS	media	were	added	 to	each	well	 and	 the	plate	was	
incubated	at	15	°C	w/o	CO2.	Every	day	the	plate	was	examined	for	a	cytopathic	effect	(CPE).	
	
2.3.2.5 Passage	of	positive	well(s)	into	a	25	cm2	TC	
When	a	full	CPE	was	visible	in	a	well,	or	in	several	wells	of	the	same	isolate,	the	supernatant	of	
the	 specific	 well	 was	 collected	 or	 multiple	 wells	 were	 pooled	 into	 a	 centrifuge	 tube	 and	
centrifuged	at	2500x	g	and	4	°C	for	15	min.	The	supernatant	was	decanted	 in	a	polystyrene	
container	and	filtered	through	a	0.2	µm	filter	into	a	new	polystyrene	container.	A	dilution	of	
10-2	 up	 to	 10-4	 (depending	 on	 the	 virulence	 of	 the	 isolate)	 was	 prepared	 on	 ice	 by	 using	
HBSS+2	%	FBS	media.	Old	media	of	 a	 25	 cm2	TC	was	decanted	off	 and	1	mL	of	 the	diluted	
supernatant	was	added	into	the	flask.	For	a	NC,	another	25	cm2	TC	was	incubated	with	1mL	of	
the	 diluent	 (HBSS+2	 %	 FBS).	 The	 flasks	 were	 incubated	 for	 1h	 at	 15	 °C	 w/o	 CO2.	 After	
incubation,	 the	 inoculum	was	 discarded	 and	 5mL	 L15+10	%	 FBS	media	 were	 added	 to	 the	
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sample	and	the	NC	flask.	The	flasks	were	incubated	at	15	°C	w/o	CO2	and	examined	every	day	
for	a	CPE.	
	
2.3.2.6 Harvest	IPNV	supernatant	of	a	25	cm2	TC	for	RNA	extraction	
The	culture	medium	of	 infected	cells	was	harvested	when	 the	cells	 showed	80-90	%	CPE	as	
previously	described	in	2.1.1.2.4	(second	paragraph).	
	
2.3.2.7 Processing	IPNV	RNA,	ds-cDNA	synthesis	and	sequencing	
The	RNA	was	processed	 via	 the	Glasgow	protocol	 and	 sequenced	 according	 to	 the	 Illumina	
Nextera	XT	DNA	Library	Preparation	Kit	(see	2.1.2.1.2	and	2.1.2.3).	
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2.4 MinION	sequencing	
2.4.1 Introduction	
In	 order	 to	 improve	 termini	 coverage	 of	 the	 IPNV	 samples	 beside	 changes	 in	 the	 ds-cDNA	
protocol,	 it	was	decided	 to	 try	 to	 sequence	on	 the	MinION	device	as	 it	has	a	different	NGS	
technology,	which	could	yield	in	better	termini	coverage	as	 it	was	previously	seen	for	whole	
genome	sequencing	of	Influenza	A	(H3N2)	virus	by	(Wang	et	al.	2015).	
	
2.4.2 Methodology	
2.4.2.1 DNA	input	
The	 ds-cDNA	 of	 one	 randomly	 selected	 IPNV	 sample	 IoA039	 was	 used	 as	 for	 the	 MiSeq	
sequencing.	The	MinION	2D	cDNA	R9	version	protocol	using	the	SQK-NSK007	R9	version	(v.R9;	
Oxford	 Nanopore	 Technologies)	 sequencing	 Kit	 required	 1	 µg	 cDNA	 as	 input.	 As	 viral	 RNA	
recovered	from	cell	culture	supernatant	could	not	reach	such	yields,	the	maximum	volume	of	
ds-cDNA	was	used	as	input.	
	
2.4.2.2 End-prep	
Forty-five	µL	of	ds-cDNA	were	mixed	with	15µL	of	 the	 following	master	mix	and	pelleted	at	
approximately	2000	rpm	(Table	24):	
	
Table	 24.	 End-prep	 set-up	 .	 All	 reagents	 are	
included	in	the	NEBNext	Ultra	II	End-Prep	kit.	
Reagent	 Volume	
Ultra	II	End-prep	buffer	 7	µL	
Ultra	II	End-prep	enzyme	mix	 3	µL	
Water	 5	µL	
	
The	mix	was	incubated	at	20	°C	for	5	min	and	65	°C	for	5	min	in	a	thermal	cycler	and	cleaned	
up	 using	 60	 µL	 of	 AMPure	 XP	 beads	 (1x).	 After	 adding	 the	 beads	 to	 the	 reaction,	 it	 was	
incubated	on	a	mixer	at	70	rpm	on	the	UU	setting	and	pelleted	at	approximately	2000	rpm	
before	placed	 into	a	magnetic	 rack.	The	beads	were	washed	while	 remaining	 in	 the	magnet	
twice	with	200	µL	70	%	ethanol.	To	pipette	off	any	 residual	ethanol	 the	 tube	was	 removed	
from	the	magnet	to	spin	the	content	down.	The	beads	were	briefly	dried	and	the	end-prepped	
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DNA	was	eluted	in	16	µL	water	outside	the	magnet.	The	mix	was	incubated	for	2	min	at	room	
temperature.	The	tube	was	placed	back	into	the	magnet	and	the	clear	supernatant	with	the	
DNA	was	transferred	into	a	fresh	tube.	
	
2.4.2.3 Ligation	of	PCR	adapters	and	amplification	
The	mix	was	set	up	as	followed	(Table	25):	
	
Table	25.	Adaptor	ligation	set-up.	All	reagents	are	included	in	the	NEB	Blunt/TA	kit	or	the	SQK-NSK007	(v.R9)	
kit.	
Reagent	 Volume	
dA-tailed	DNA	 15	µL	
PCR	adapters	 5	µL	
Blunt/TA	Ligase	Master	Mix	 20	µL	
	
The	reaction	was	mixed	and	incubated	for	15	min	at	room	temperature	and	cleaned	up	using	
28	 µL	 of	 AMPure	 XP	 beads.	 After	 adding	 the	 beads	 to	 the	 reaction,	 it	 was	 incubated	 on	 a	
mixer	at	70	rpm	on	the	UU	setting	and	pelleted	at	approximately	2000	rpm	before	placed	into	
a	magnetic	rack.	The	beads	were	washed	while	remaining	in	the	magnet	twice	with	200	µL	70	
%	ethanol.	To	pipette	off	any	residual	ethanol	the	tube	was	removed	from	the	magnet	to	spin	
the	content	down.	The	beads	were	briefly	dried	and	the	end-prepped	DNA	was	eluted	in	25	µL	
water	outside	the	magnet.	The	mix	was	incubated	for	2	min	at	room	temperature.	The	tube	
was	placed	back	into	the	magnet	and	the	clear	supernatant	with	the	DNA	was	transferred	into	
a	fresh	0.2	mL	PCR	tube	for	the	PCR,	which	was	set	up	as	followed	(Table	26):	
	
Table	 26.	 PCR	mix	 set-up	 of	 ligated	 sample.	 All	
reagents	are	included	in	the	LongAmp	Taq	2x	kit	
or	the	SQK-NSK007	(v.R9)	kit.	
Reagent	 Volume	
Adapter-ligated	library	 25	µL	
PRM	 2	µL	
LongAmp	Taq	2x	Master	mix	 50	µL	
Water	 23	µL	
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The	reaction	was	mixed	and	cycled	as	followed	(Table	27):	
	
Table	27.	PCR	cycling	conditions.	
Step	 Temperature	 Time	 Cycle	
Initial	denaturation	 95	°C	 3	min	 1	
Denaturation	
Annealing	
Extension	
95	°C	
62	°C	
72	°C	
15	sec	
15	sec	
3	min	
	
18	cycles	
Final	extension	 65	°C	 10	
min	
1	
Hold	 4	°C	 hold	 	
	
The	reaction	was	then	cleaned	up	using	1.8x	reaction	volume	in	a	1.5	mL	centrifuge	tube.	The	
beads	were	mixed	with	 the	PCR	reaction	and	 incubated	 for	5minutes	at	 room	temperature.	
The	mix	was	placed	in	a	tube	magnet	rack	and	incubated	for	2	minutes	until	the	supernatant	
was	 clear,	 which	 was	 then	 discarded.	 The	 beads	 were	 washed	 twice	 with	 200	 µL	 of	 70	 %	
ethanol	without	 disturbing	 the	beads.	 The	beads	were	 air	 dried	 and	 re-suspended	 in	 46	µL	
molecular	grade	water.	The	elution	 reaction	was	 incubated	2	minutes	at	 room	temperature	
outside	the	magnetic	rack.	After	this	the	tube	was	placed	back	in	the	magnetic	rack	and	the	
clear	supernatant	was	transferred	 into	a	new	centrifuge	tube.	One	µL	of	the	clean	DNA	was	
used	for	concentration	measurement	in	the	Qubit	fluorometer	(as	described	in	2.1.2.2.2.4).	
	
2.4.2.4 End-prep	of	post-PCR	DNA	
The	 post-PCR	 DNA	 was	 transferred	 into	 a	 fresh	 0.2	 mL	 PCR	 tube	 containing	 the	 following	
reaction	(Table	28):	
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Table	28.	End-prep	set-up	after	the	PCR.	All	reagents	are	included	in	the	NEBNext	End-Repair/dA-tailing	kit.	
Reagent	 Volume	
DNA	 45	µL	
Ultra	II	End-prep	reaction	buffer	 7	µL	
Ultra	II	End-prep	enzyme	mix	 3	µL	
Water	 5	µL	
Σ	Volume	 60	µL	
	
The	mix	was	incubated	at	20	°C	for	5	min	and	65	°C	for	5	min	in	a	thermal	cycler	and	cleaned	
up	using	60	µL	of	AMPure	XP	beads.	After	adding	the	beads	to	the	reaction,	it	was	incubated	
on	a	mixer	at	70	rpm	on	the	UU	setting	and	pelleted	at	approximately	2000	rpm	before	placed	
into	a	magnetic	rack.	The	beads	were	washed	while	remaining	in	the	magnet	twice	with	200	
µL	70	%	ethanol.	To	pipette	off	any	residual	ethanol	the	tube	was	removed	from	the	magnet	
to	spin	the	content	down.	The	beads	were	briefly	dried	and	the	end-prepped	DNA	was	eluted	
in	31	µL	water	outside	the	magnet.	The	mix	was	 incubated	 for	2	min	at	 room	temperature.	
The	 tube	 was	 placed	 back	 into	 the	 magnet	 and	 the	 clear	 supernatant	 with	 the	 DNA	 was	
transferred	 into	 a	 fresh	 tube.	 One	 µL	 of	 the	 clean	 DNA	 was	 used	 for	 concentration	
measurement	in	the	Qubit.	
	
2.4.2.5 Adapter	ligation	
The	DNA	was	diluted	to	500	ng	in	22.5	µL	for	the	reaction,	which	was	set	up	as	followed	(Table	
29):	
	
Table	29.	Ligation	set-up	of	the	hairpin	adapter.	All	reagents	are	included	in	the	NEB	Blunt/TA	Ligase	kit	or	the	
SQK-NSK007	(v.R9)	kit.	
Reagent	 Volume	
700	ng	of	DNA	 30	µL	
Water	 88	µL	
Adapter	Mix	 10	µL	
HP	adapter	 2	µL	
Blunt/TA	Ligase	master	mix	 50	µl	
Σ	Volume	 100µL	
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The	 reaction	 was	 mixed,	 pelleted	 at	 approximately	 2000rpm	 and	 incubated	 at	 room	
temperature	for	10	minutes.	After	that	1	µL	of	the	HP	Tether	was	added	to	the	mix,	mixed,	
pelleted	at	approximately	2000	rpm	and	incubated	at	room	temperature	for	10	minutes.	
	
2.4.2.6 Preparation	of	MyOne	C1	beads	
The	beads	(Life	Technologies)	were	mixed	and	50	µL	of	the	beads	were	transferred	into	a	new	
tube.	 The	 tube	 was	 placed	 into	 a	magnetic	 rack	 and	 the	 clear	 supernatant	 was	 discarded.	
Then	100	µL	of	the	bead	binding	buffer	was	added	to	the	beads.	The	beads	were	mixed	and	
placed	into	the	magnet.	The	clear	supernatant	was	discarded	and	the	wash	was	repeated.	In	
the	end,	the	beads	were	re-suspended	in	100	µL	of	the	bead	binding	buffer.	
	
2.4.2.7 Library	purification	and	elution	
One	hundred	µL	of	previously	prepared	MyOne	C1	beads	were	added	to	the	tethered	sample,	
mixed	and	 incubated	on	a	mixer	 for	5	minutes	at	50	 rpm.	The	 tube	was	 then	placed	 into	a	
magnetic	rack	and	the	clear	supernatant	was	discarded.	The	beads	were	washed	twice	by	re-
suspending	them	in	150	µL	Bead	Binding	Buffer	outside	the	magnetic	 rack,	placing	the	tube	
back	 into	the	rack	and	taking	the	clear	supernatant	off.	To	get	rid	of	any	residual	 liquid,	the	
tube	was	centrifuged,	placed	back	in	the	magnet	and	any	possible	 liquid	was	discarded.	The	
beads	were	then	re-suspended	in	25	µL	of	Elution	buffer,	mixed	and	incubated	at	37	°C	for	10	
minutes.	 The	 tube	was	 then	placed	 in	 a	magnet	 and	 the	 clear	 supernatant	was	 transferred	
into	a	new	tube.	One	µL	was	used	for	quantification	 in	a	Qubit	fluorometer	(as	described	 in	
2.1.2.2.2.4).	
	
2.4.2.8 Priming	the	Flow	Cell	and	loading	the	library	
Before	priming	the	flow	cell,	a	QC	had	to	be	performed.	For	that	the	flow	cell	FLO-MIN104	R9	
version	 was	 placed	 into	 the	 MinION	 sequencer	 and	 the	 QC	 option	
NC_Platform_QC_FLO_MIN104	was	selected	within	the	MinKNOW	software.	
To	prime	the	flow	cell,	the	sample	port	was	opened	and	the	flow	cell	was	checked	for	bubbles.	
To	remove	any	bubbles	a	small	amount	of	 liquid	was	aspirated	and	discarded.	The	 flow	cell	
priming	mix	was	prepared	as	followed	(Table	30):	
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Table	 30.	 Preparation	 of	
the	 priming	 mix.	 All	
reagents	 are	 included	 in	
the	 SQK-NSK007	 (v.R9)	
kit.	
Reagent	 Volume	
RBF1	 500	µL	
Water	 500	µL	
Total	 1000	µL	
	
First	 500	 µL	 of	 the	 mix	 were	 loaded	 into	 the	 flow	 cell	 through	 the	 sample	 port.	 After	 an	
incubation	of	5	minutes	procedure	was	repeated.	
The	library	loading	mix	was	set	up	as	followed	(Table	31):	
	
Table	 31.	 Preparation	 of	 the	 library	mix	 to	 load	
on	the	flow	cell.	All	 reagents	are	 included	 in	the	
SQK-NSK007	(v.R9)	kit.	
Reagent	 Volume	
RBF1	 75	µL	
Water	 63	µL	
Adapted	and	tethered	library	 12	µL	
Total	 150	µL	
	
The	library	mix	was	mixed	and	pelleted	at	approximately	2000	rpm	before	it	was	loaded	into	
the	 flow	 cell	 drop	 by	 drop.	 After	 loading	 the	 sample	 port	 was	 closed	 and	 the	 set	 up	
NC_48H_Seq_Run_FLO_MIN_104	was	run.	
	
2.4.2.9 Washing	the	flow	cell	for	immediate	reuse	
After	 24	 h	 the	 run	was	 stopped	 and	 the	 flow	 cell	 was	washed	 using	 the	Wash	 Kit	 (Oxford	
Nanopore	Technologies)	 to	be	 ready	 for	 loading	 the	 second	half	of	 the	 sample.	The	 sample	
port	 cover	was	opened	and	150	µL	of	 the	Solution	A	were	added	 through	 the	 sample	port.	
After	an	incubation	of	10	minutes	150	µL	of	Solution	B	were	added	through	the	sample	port	
and	 the	 library	 was	 added	 as	 described	 in	 previous	 steps.	 No	 platform	 QC	 and	 following	
priming	were	performed	when	running	another	library	immediately.	
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2.4.2.10 Washing	and	storage	of	the	flow	cell	
After	 24	 h	 the	 run	was	 stopped	 and	 the	 flow	 cell	was	washed	 to	 be	 ready	 for	 loading	 the	
second	half	of	the	sample.	The	sample	port	cover	was	opened	and	150	µL	of	the	Solution	A	
were	 added	 through	 the	 sample	port.	After	 an	 incubation	of	 10	minutes	 500	µL	of	 Storage	
buffer	were	added	through	the	sample	port.	The	sample	port	was	closed	and	all	buffer	was	
removed	from	the	waste	compartments	through	the	waste	port.	The	flow	cell	was	stored	at	4	
°C	 for	 up	 to	 72	 h.	 A	 platform	 QC	 and	 following	 priming	 were	 performed	 before	 running	
another	library	as	described	before.	
	
2.4.3 Improving	size	selection	for	MinION	sequencing	
As	 the	MinION	 is	 capable	 of	 sequencing	 very	 large	 fragments,	 it	was	 of	 interest	 to	 see	 if	 a	
change	in	the	sample	to	AmpureXP	beads	ratio	from	1x	to	0.6x	can	select	for	fragments	longer	
than	500	bp.	This	was	done	by	testing	it	on	one	randomly	selected	betanodavirus	(provided	by	
Dr.	 Benjamin	 Lopez-Jimena)	 ds-cDNA	 sample	 that	was	 processed	 according	 to	 the	 Glasgow	
protocol,	using	1x	AmpureXP	beads	to	sample	ratio	in	the	last	clean	up	step.	
Twenty	µL	of	betanodavirus	ds-cDNA	were	mixed	with	12	µL	AmpureXP	beads	and	processed	
as	in	the	post	ds-cDNA	synthesis	clean	up	step	in	the	Glasgow	protocol	0.	
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2.5 Bioinformatics	analysis	
2.5.1 Processing	the	raw	data	from	MiSeq	(Illumina)	
2.5.1.1 Overview	
A	successfully	assembled	genome	results	in	2	big	segments	(both	full)	and	some	little	ones.	If	
the	assembly	 resulted	 in	 several	 semi-big	 segments,	 they	have	 to	be	put	 together	manually	
using	the	reference	genome	for	orientation.	The	assembled	sequence	 is	 then	aligned	to	the	
reference	genome	to	check	for	any	problems.	If	the	sequence	is	fine,	no	changes	are	needed.	
If	the	sequence	turned	out	bad,	the	pipeline-protocol	has	to	be	optimised:	increased	check	for	
contaminations,	trim	adaptors/indices,	decrease	coverage	of	the	reads.	The	decontamination	
is	very	important	and	crucial	as	cleaner	reads	give	better	assembly	results.	The	ends	have	to	
be	 optimised	 manually	 by	 assembling	 first/last	 300-400	 bp	 using	 the	 reference-based	
approach.	
	
2.5.1.2 Workflow	for	Illumina	MiSeq	raw	data	processing	
The	workflow	for	processing	 the	 raw	data	 through	to	 the	assembled	genome	 in	a	FastA	 file	
was	 developed	 by	 Dr.	 Stefanie	 Wehner,	 containing	 multiple	 steps	 of	 data	 processing.	 The	
detailed	workflow	is	given	in	the	separate	additional	appendix	under	V.1.	
The	MiSeq	generates	per	cycle	base	call	(bcl)	files	as	primary	files.	The	files	are	combined	and	
converted	 into	 FASTQ	 by	 BCL2FASTQ	 (Illumina,	 Inc.)	 by	 the	MiSeq.	 This	 software	 is	 able	 to	
perform	 the	 file	 conversion	 and	 demultiplexing	 at	 the	 same	 time	 using	 the	 sample	 sheet	
information	providing	index	–	sample	information.	During	this	step	one	error	in	the	index	can	
be	detected	and	corrected.	
The	 quality	 of	 the	 raw	 reads	was	 then	 checked	 using	 FASTQC.	 The	 report	 outcome	was	 to	
ignore	as	this	tool	was	not	directly	used	for	filtering	but	it	provides	a	first	simple	overview	of	
the	data,	gives	information	about	the	sequence	quality	and	shows	overrepresented	sequences	
such	as	contaminations	or	adapter	sequences.	
After	that	the	reads	were	trimmed	and	clipped	using	PRINSEQ	and	TRIMMOMATIC	to	remove	
low	quality	reads	and	eventually	not	removed	adapter	sequences.	
To	remove	reads	belonging	to	the	host	organism	(fish),	contamination	(human,	bacteria)	and	
the	 Illumina	PhiX	control	genome,	DECONSEQ	was	used.	 In	 this	 step	 it	was	crucial	 to	watch	
out	for	possible	“hidden”	virus	sequences	such	as	those	that	are	embedded	into	a	cell	line	etc.	
which	should	then	also	be	removed.	
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In	case	of	short	genomes,	a	faster	and	better	assembly	can	be	achieved	by	down	sampling	the	
reads	with	 KHMER	 (Crusoe	 et	 al.	 2015).	 In	 this	 step	 redundant	 short	 reads	 are	 eliminated,	
while	the	individual	reads	are	not	modified.	
After	that	the	reads	were	used	for	a	de	novo	assembly	via	SPADES.	In	parallel,	reference-based	
assemblies	 were	 created	 using	 TANOTI	 and	 STAMPY	 with	 NC_001915.1	 (segment	 A)	 and	
NC_001916.1	 (segment	B)	as	 reference	 sequences.	The	 resulting	 sequences	were	compared	
with	 the	 reference	 sequence	 using	 BLAST	 (Altschul	 et	 al.	 1990)	 to	 find	 the	most	 complete	
genome.	 De	 novo	 assembled	 sequences	 were	 preferred	 in	 this	 approach	 as	 it	 takes	 into	
account	 potential	 insertions,	 deletions	 and	 rearrangement	 of	 the	 genome.	 The	 reference-
based	assembly	was	used	to	eventually	cover	the	de	novo	sequences	at	the	genome	termini.	
BOWTIE2	(Langmead	and	Salzberg	2012)	and	SAMTOOLS	(Li	et	al.	2009)	were	used	to	map	the	
MiSeq	reads	to	the	assembled	genome	to	get	the	number	of	mapped	reads	for	the	coverage	
plots.	 They	 show	 how	 many	 reads	 map	 per	 base	 of	 the	 genome.	 Mean	 coverage	 was	
calculated	 as	 well	 and	 refers	 to	 the	 mean	 coverage	 of	 all	 mean	 coverages.	 So	 the	 mean	
coverage	of	each	assembled	segment	was	calculated.	Based	on	these	values	an	overall	mean	
coverage	 was	 calculated.	 Whereas	 for	 minimum/maximum	 mean	 coverage,	 for	 every	
assembled	 segment	 the	minimal/maximal	 coverage	was	 taken	 and	 then	 again	 a	mean	was	
calculated	(based	on	the	minimum/maximum	values).	
For	single	protein	analysis	and	CAI	Dr.	Michaël	Bekaert	aligned	the	sequences	to	the	reference	
genome	 using	 CLUSTAL	 OMEGA	 (Goujon	 et	 al.	 2010,	 Sievers	 et	 al.	 2011),	 transferred	 the	
genome	annotation	from	the	reference	sequence	using	RATT	(Otto	et	al.	2011)	and	extracted	
the	sequences	 for	each	aligned	protein	 in	a	FastA	file.	The	detailed	workflow	 is	given	 in	the	
separate	additional	appendix	under	V.3.	
	
2.5.2 Processing	raw	data	from	MinION	(Oxford	Nanopore	Technologies)	
The	workflow	for	processing	the	raw	data	up	until	the	assembled	genome	in	a	FastA	file	was	
done	 by	 Dr.	 Stefanie	 Wehner.	 The	 detailed	 workflow	 is	 given	 in	 the	 separate	 additional	
appendix	under	V.2.	
The	 reads	 were	 first	 processed	 by	 the	 corresponding	 software	 METRICHOR.	 NANOOK	 was	
used	 to	 create	a	 run	 report	with	basic	 information	about	 the	 run.	 To	 convert	MinION	 filing	
system	 FAST5	 into	 FastA	 PORETOOLS	 was	 used.	 PORECHOP	 was	 used	 additionally	 to	
eventually	 trim	 adaptors	 and	 indices	 as	 there	 were	 sometimes	 issues	 observed	 such	 as	
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adaptor	 bleed	 over	 and	 concatemer	 formations.	 The	 reads	 were	 aligned	 with	 BWA	 to	
generate	a	reference-based	genome	assembly.	The	coverage	plots	for	the	MinION	runs	were	
generated	using	a	script	in	R,	which	based	on	the	NANOOK	script.	
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2.6 Phylogenetic	analysis	
2.6.1 General	handling	of	sequences	
CLUSTAL	Omega	was	used	on	an	online	platform	https://www.ebi.ac.uk/Tools/msa/clustalo/	
(Goujon	et	al.	2010,	Sievers	et	al.	2011)	to	align	IPNV	sequences.	
For	 conversion	 of	 sequence	 file	 formats,	
http://sequenceconversion.bugaco.com/converter/biology/sequences/index.html	was	used.	
	
2.6.2 MEGA	
MEGA	 v6.0.6	 (Molecular	 Evolutionary	 Genetics	 Analysis)	 (Tamura	 et	 al.	 2013)	was	 used	 for	
work	with	alignment	files	and	for	eventual	manual	editing.	 It	was	used	to	create	amino	acid	
alignments	overviews	of	the	IPNV	sequences	to	visually	estimate	differences.	
	
2.6.3 BEAST	package	
To	 calculate	 phylogenetic	 properties,	 sequences	 of	 segment	 A	 and	 segment	 B	 of	 57	 IPNV	
isolates	 were	 put	 together	 in	 one	 FastA	 file	 with	 additional	 reference	 genomes	 (Table	 32,	
Table	33).	BEAUTI	 v1.8.3	was	 then	used	 to	generate	an	 xml	 file	with	10,000,000	 chains	per	
cycle	with	every	1000th	chain	being	recorded,	using	the	HKY	substitution	model,	a	strict	clock	
and	a	coalescent	tree	according	to	(Kingman	1982a,	Kingman	1982b).	The	xml	file	was	loaded	
in	BEAST	v1.8.3	to	perform	the	calculation	of	the	tree	(Drummond	et	al.	2012).	The	trees	were	
viewed	and	edited	using	FIGTREE	v1.4.0	(Rambaut	2012).	
	
Table	32.	Reference	strains	used	for	phylogenetic	analysis	of	segment	A;	NA	means	not	assigned.	
Strain	 GenBank	 Geographical	
Origin	
Reference	
Ca3	 AF342734	 Canada	 (Blake	et	al.	2001)	
Connecticut1	 JF440810	 USA	 (Glenney	et	al.	2012)	
Ca2	 AF342733	 Canada	 (Blake	et	al.	2001)	
TABV2013	 KP268663.1	 Australia	 (Mohr	et	al.	2015)	
TABV1998	 NC_028252.1	 Australia	 (Mohr	et	al.	2015)	
1146	 AJ489222.1	 Spain	 (Cutrin	et	al.	2004)	
Sp	 KF279643	 Iran	 (Dadar	et	al.	2013)	
Gre	 NA	 Turkey	 Unpublished	
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SDF4	 NA	 Turkey	 Unpublished	
1054	 NA	 Turkey	 Unpublished	
Sp	 AF342728	 Denmark	 (Blake	et	al.	2001)	
Ireland	 HQ457197.1	 Ireland	 (Mutoloki	and	Evensen	2011)	
DPL	 AY026485.1	 Thailand	 (Blake	et	al.	2001)	
Fr21	 AY026483.1	 France	 (Blake	et	al.	2001)	
OV2	 AY026484.1	 England,	UK	 Blake	et	al.,	2001	(Blake	et	al.	2001)	
N1	 D00701	 Norway	 (Havarstein	et	al.	1990)	
Chile	 HQ457169	 Chile	 (Mutoloki	and	Evensen	2011)	
Norway	 HQ457199	 Norway	 (Mutoloki	and	Evensen	2011)	
Sp	vir.	 AY374435.1	 Norway	 (Santi,	Vakharia,	and	Evensen	2004a)	
Ab	 AF342729	 Denmark	 (Blake	et	al.	2001)	
2284	 AJ489223	 Spain	 (Cutrin	et	al.	2004)	
Ab	 L40580.1	 Denmark	 (Heppell	et	al.	1993)	
CVHB1	 AY026489.1	 Taiwan	 (Blake	et	al.	2001)	
	
	
	
	
	
	
S	 AY026487	 Taiwan	
V	 AY026486.1	 Japan	
PV	 AY026488.1	 Taiwan	
Ca1	 AF342732	 Canada	
ASV	 AY026490.1	 Canada	
Te2	 AF342731	 England,	UK	
AY98	 AY283785.1	 Japan	 (Zhang	and	Suzuki	2004)	
	YTAV_Y6	 AY283781	 Japan	
GC1	 AY064396.1	 Korea	 unpublished	
Ja	 AF342735.1	 Canada	 (Blake	et	al.	2001)	
	Reno	 AY026345	 USA	
Ja2310	 AJ489225	 Spain	 (Cutrin	et	al.	2004)	
HL1	 D26526.1	 Korea	 (Chung	et	al.	1994)	
Ja	 NC_001915.1	 Canada	 (Duncan	et	al.	1987)	
VR299	 AF343572	 USA	 (Blake	et	al.	2001)	
	
	
93	 AY026346.1	 USA	
11	 AY026347.1	 USA	
Mexico	 JX174178	 Mexico	 unpublished	
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114	 AY026348	 USA	 (Blake	et	al.	2001)	
	
	
	
	
	
91	 AF343570	 USA	
Buhl	 AF343573	 USA	
DryMills	 AF343571.1	 USA	
WB	 AF342727	 USA	
He	 AF342730	 Germany	
VTAB	 NC_030242.1	 Australia	 (Mohr	et	al.	2015)	
	
Table	33.	Reference	strains	used	for	phylogenetic	analysis	of	segment	B;	NA	means	not	assigned.	
Strain	 GenBank	 Geographical	
Origin	
Reference	
Mexico	 EU665685.1	 Mexico	 unpublished	
HL1	 D26527.1	 Korea	 (Lee,	Chung,	and	Lee	1994)	
2310	 AJ489241	 Spain	 (Cutrin	et	al.	2004)	
Ja	Duncan	 NC_001916	 Canada	 (Duncan	et	al.	1991)	
WB	 AF078669.1	 USA	 Yao	et	al.,	1998	(Yao	and	Vakharia	1998)	
YTAV-06	 AB281674	 Japan	 (Hirayama	et	al.	2007)	
POBV	 EU161286.1	 China	 (Zhao	et	al.	2008)	
YTAV-NC1	 AY129666	 Korea	 (Zhang	and	Suzuki	2003)	
Y-6	 AY129662	 Japan	 (Zhang	and	Suzuki	2003)	
AY-98	 AY123970	 Japan	 unpublished	
VTAB	 NC_030244.1	 Australia	 (Mohr	et	al.	2015)	
He	 JF734351.1	 Spain	 (Bandin	et	al.	2014)	
	
	
	
Ca2	 JF734354	 Canada	
Ca3	 JF734355	 Canada	
Ca1	 JF734353	 Canada	
Ab2	 JF734350.1	 NA	
Ab1	 AM114033.1	 NA	 (Cutrin	et	al.	2004)	
2284	 AJ489239.1	 Spain	 (Cutrin	et	al.	2004)	
Sp1	 AJ622823	 France	 (Galloux,	Chevalier,	Henry,	Huet,	Costa,	et	
al.	2004)	
IRIPNV	 KC900161.1	 Iran	 (Dadar	et	al.	2013)	
Gre	 NA	 Turkey	 Unpublished	
SDF4	 NA	 Turkey	 Unpublished	
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1054	 NA	 Turkey	 Unpublished	
Sp3	 AM889221	 Denmark	 (Dixon	et	al.	2008)	
Sp2	 M58757.1	 NA	 (Duncan	et	al.	1991)	
Sp122	 AY354524.1	 Norway	 (Shivappa	et	al.	2004)	
Chile	 KU609618	 Chile	 (Jorquera	et	al.	2016)	
Sp116	 AY354523	 Norway	 (Shivappa	et	al.	2004)	
	Sp103	 AY354522.1	 Norway	
TABV2013	 KP268678.1	 Australia	 (Mohr	et	al.	2015)	
	TABV1998	 NC_028253.1	 Australia	
Te	 AJ920336	 UK	 (Nobiron	et	al.	2008)	
	
2.6.4 RAXML	
To	 calculate	 phylogenetic	 properties,	 sequences	 of	 segment	 A	 and	 segment	 B	 of	 57	 IPNV	
isolates	were	put	together	 in	one	FastA	file	with	additional	reference	genomes.	RAXML	v1.5	
beta	was	then	used	to	generate	a	maximum	likelihood	tree	using	the	GTRGAMMA	nucleotide	
substitution	 model	 and	 supporting	 bootstrap	 calculation	 of	 1000	 replicates	 of	 random	
generated	 trees	 (Silvestro	 and	 Michalak	 2012).	 The	 trees	 were	 viewed	 and	 edited	 using	
FigTree	v1.4.0	(Rambaut	2012).	
	
2.6.5 CAI	calculation	
CAI	was	calculated	by	Nicholas	Di	Paola	according	 to	his	publication	using	 the	webserver	at	
http://genomes.urv.es/CAIcal	 and	 http://genomes.urv.es/CAIcal/E-CAI	 (Puigbo,	 Bravo,	 and	
Garcia-Vallve	2008b,	a)	using	the	protein	alignment	FastA	files	created	by	Dr.	Michaël	Bekaert.	
The	 script	 and	 the	 used	 Salmo	 salar	 and	 Onchorhynchus	 mykiss	 genomes	 used	 in	 the	
calculation	are	listen	in	the	separate	additional	appendix	under	V.4.	
	
2.6.6 HYPHY	package	
To	perform	positive	 selection	 calculation	on	HYPHY,	 FastA	 files	of	 each	 IPNV	protein	 (all	 57	
sequenced	 isolates	 aligned)	 with	 a	 corresponding	 tree	 file	 (created	 using	 BEAST	 package;	
newick	file	format)	were	used.	
SLAC	on	HYPHY	was	performed	using	the	following	set	up:	
1. Type	of	selection:	Positive	Selection	à	Quick	Selection	Detection	
2. Genetic	code:	Universal	Code	
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3. Model:	012345	
4. dN/dS	option:	estimate	dN/dS	only	
5. Ancestor	counting	option:	Single	Ancestor	counting	
6. SLAC	option:	Full	Tree	
7. Ancestral	state	reconstruction	and	counting:	Averaged	
8. Test	statistics:	Approximate	
9. Significance	level:	0.1	
10. Output	option:	Chart	
11. dN/dS	count:	Skip	
	
MEME	on	HYPHY	was	performed	using	the	following	set	up:	
1. Type	of	selection:	Positive	Selection	à	Quick	Selection	Detection	
2. Genetic	code:	Universal	Code	
3. Model:	012345	
4. dN/dS	option:	estimate	dN/dS	only	
5. Ancestor	counting	option:	MEME	
6. Significance	level:	0.1	
	
2.6.7 Dinucleotide	composition	
To	 estimate	 the	 abundance	 of	 dinucleotides	 in	 IPNV	 segment	 A	 and	 B	 sequences,	 EMBOSS	
COMPSEQ	 was	 used	 online	 (http://emboss.bioinformatics.nl/cgi-bin/emboss/compseq).	 The	
expected	frequencies	were	calculated	based	on	the	single	base	frequency	of	 input	sequence	
and	 not	 by	 assumption,	 that	 every	 dinucleotide	 has	 equal	 frequency.	 A	 CpG	 abundance	 is	
considered	low	when	CpGO/E	≤1	and	high	when	CpGO/E	≥1.	
	
2.6.8 SPLITSTREE	
SPLITSTREE	 v4.14.6	 (Huson	 and	Bryant	 2005)	was	 used	 to	 generate	Neighbour	Networks	 of	
the	 IPNV	 VP2	 and	 VP3	 proteins	 using	 nucleotide	 acid	 alignments	 provided	 by	 Dr.	 Michaël	
Bekaert.	 The	 sequence	 was	 converted	 in	 amino	 acid	 sequence	 using	 MEGA	 v6.0.6	 and	
homologue	amino	acids	were	removed	with	UGENE	v1.25.0	(Okonechnikov	et	al.	2012)	prior	
loading	in	SPLITSTREE.	
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2.6.9 Statistics	and	graphs	
The	graphic	and	statistical	analysis	was	performed	using	the	Mann-Whitney	test	in	GRAPHPAD	
PRISM	v.6.	
Graphical	finish	of	trees,	networks	and	figures	was	done	using	Adobe	Illustrator	CS5.	
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3 Results	
To	 analyse	 genomic	 changes	 in	 IPNV	 over	 the	 last	 three	 decades	 IPNV	 isolates	 from	 the	
diagnostic	 collection	 of	 the	 IoA	 were	 subjected	 to	 whole	 genome	 sequencing	 (WGS)	 using	
next	generation	sequencing	(NGS)	technology	on	the	Illumina	MiSeq	platform.	
	
3.1 WGS	protocol	development	and	improvement	
Initially	 a	 protocol	 for	 whole	 genome	 sequencing	 (WGS)	 using	 next	 generation	 sequencing	
technology	(NGS)	of	RNA	viruses	developed	at	Goettingen	University	(GOEP)	was	used	(Dilcher	
et	al.	2012).	This	protocol	was	assessed	in	comparison	to	a	simplified	protocol	from	a	team	at	
MRC	Virology	Glasgow	University	(GLAP)	(Thomson	et	al.	2016).	Altogether,	27	IPNV	isolates	
were	sequenced	with	the	GOEP	and	30	with	the	GLAP.	
Both	 protocols	 have	 a	 specific	 type	 of	 RNA	 extraction	 and	 ds-cDNA	 synthesis	 prior	 to	 the	
library	preparation	according	to	the	Illumina	protocol	2.1.2.3.	
To	 determine	 if	 the	 GLAP	was	 efficient	 for	 IPNV	WGS,	 three	 samples	 (IoA024,	 IoA030	 and	
IoA107)	 were	 randomly	 selected	 and	 processed	 with	 both	 the	 GOEP	 and	 the	 GLAP	 for	
comparison	of	yield	and	the	amount	of	terminal	nucleotides	determined	by	de	novo	assembly.	
All	RNA	samples	had	a	mean	concentration	of	 IPNV	genome	equivalents	of	higher	 than	104	
copies/mL	 which	 is	 the	 minimum	 requirement	 for	 Illumina	 NGS.	 There	 was	 no	 significant	
difference	 estimated	 using	 the	 Mann-Whitney	 test	 in	 the	 ds-cDNA	 concentration,	 as	
measured	on	Qubit	(see	2.1.2.2.2.4),	between	the	two	protocols	(p=0.1000)	as	seen	in	Figure	
34,	 Section	 I.	 The	 concentrations	 (p=0.1000),	 the	 molarity	 (p=0.1000)	 and	 the	 average	
fragment	 size	 (p=0.7000)	 of	 the	 library,	 estimated	 by	 Bioanalyzer	 (see	 2.1.2.2.2.3),	 did	 not	
differ	 significantly	 between	 the	protocols	 (see	 Table	 34	 Section	 I).	 The	GOEP	 resulted	 in	 an	
overall	higher	mean	coverage	throughout	the	whole	genome.	The	first	third	of	the	genome	in	
most	cases	had	a	higher	coverage	(see	Figure	12).	
The	mean	 coverage	was	higher	 in	 samples	 IoA024	and	 IoA030	using	 the	GLAP	but	 lower	 in	
sample	IoA107.	However,	there	was	no	significant	difference	between	the	two	protocols	used	
(p>0.9999	segment	A;	p=0.7000	segment	B)	(Table	35).	
An	analysis	of	the	terminal	nucleotides	for	each	segment	and	the	overall	mapping	rate	before	
manual	editing	yielded	no	significant	difference	between	the	two	protocols	(p=0.2000	missing	
terminal	 nucleotides;	 p>0.9999).	 Furthermore,	 both	 protocols	 did	 not	 yield	 sequences	
	 89	
sufficient	for	a	full	genome	assembly	with	a	de	novo	approach	as	seen	in	the	total	number	of	
missing	 terminal	 nucleotides	 (Table	 36).	
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Table	34.	Control	values	of	selected	 libraries	 in	Section	 I:	 randomly	selected	samples	processed	with	the	Goettingen	(GOEP)	and	the	Glasgow	(GLAP)	sequencing	protocol;	Section	 II:	 Improvement	
variants	for	GLAP;	Section	III:	temperature	variants	tested	for	GLAP;	Section	IV:	range	of	control	values	of	57	sequenced	IPNV	samples.	Conc.=concentration.	
																																																																																								RNA																																																															ds-cDNA																																																																								Library	
	 Sequence	ID	and	
variant	
RNA	
conc.	
NanoDrop	
Mean	conc.	
qPCR	
ds-cDNA	conc.	
NanoDrop	(ng/µL)	
ds-cDNA	conc.	Qubit	
(ng/µL)	
Average	
fragment	size	
(bp)	
Conc.	(pg/µL)	 Mol.	(pmol/l)	
Se
ct
io
n	
I	
IoA024	GOEP	 558.97	 3.93E8	 85.56	 34.20	 268	 1649.56	 9887.4	
IoA024	GLAP	 8.67	 8.69E10	 8.07	 0.57	 249	 983.33	 6301.6	
IoA030	GOEP	 330.83	 5.31E8	 76.69	 35.00	 277	 2733.47	 15937.0	
IoA030	GLAP	 17.39	 2.47E11	 10.75	 1.298	 253	 926.00	 5887.6	
IoA107	GOEP	 620.15	 5.24E11	 24.25	 8.68	 279	 1472.53	 8492.7	
IoA107	GLAP	 19.81	 1.94E9	 5.26	 0.369	 368	 24.64	 108.7	
Se
ct
io
n	
II	
Initial	sample	IoA039	 21.20	 4.77E7	 	 	 	 	 	
ss-cDNA-GP32	 	 	 19.46	 2.14	 281	 2090.31	 12160.0	
ds-cDNA-GP32	 	 	 12.11	 1.34	 280	 3306.55	 19334.5	
ss/ds-cDNA-GP32	 	 	 20.66	 1.58	 232	 565.39	 3947.7	
ss-cDNA-3'Primer	 	 	 17.85	 1.41	 274	 3975.92	 23764.9	
ds-cDNA-3'Primer	 	 	 12.63	 1.51	 281	 3755.30	 21969.5	
ss/ds-cDNA-3'Primer	 	 	 18.06	 1.17	 279	 2632.13	 15502.0	
RNaseH	treatment	 	 	 17.19	 1.72	 276	 3025.48	 18038.7	
dNTPs	and	rand.hex.	 	 	 11.26	 1.85	 282	 2671.15	 15559.0	
RNAincub.75°C/5min	 	 	 18.63	 1.25	 285	 1690.73	 9724.8	
GLAP	unchanged	 	 	 19.44	 1.50	 276	 2438.04	 14458.2	
Se
ct
io
n	
III
	 IoA035	GLAP	 26.82	 1.01E7	 12.39	 3.06	 332	 9983.41	 53481.7	
IoA035	GLAP	95°C	 26.82	 1.01E7	 13.25	 1.81	 437	 6687.40	 30316.7	
IoA111	GLAP	 49.43	 2.62E8	 9.03	 0.49	 246	 1746.83	 12334.0	
IoA111	GLAP	95°C	 49.43	 2.62E8	 7.29	 0.50	 278	 4159.70	 31451.3	
Se
ct
io
n	
IV
	
GLAP	lowest	value	 3.07	
135.77	
2.99E1	
8.48E8	
5.64	
17.85	
0.18	
2.80	
154	
473	
51.26	
8208.93	
544.2	
48193.5	GLAP	highest	value	
GOEP	lowest	value	 21	
1845.73	
1.56E1	
5.24E11	
1.79	
172.28	
0.72	
89.80	
260	
457	
813.00	
5085.71	
5785.1	
31114.9	GOEP	highest	value	
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Table	35.	Mean	coverage	(number	of	reads/reference	bases)	of	segment	A	and	B	for	the	samples	
processed	with	the	GLAP	and	the	GOEP.	
Sequence	ID	 Mean	coverage	segment	A	 Mean	coverage	segment	B	
IoA024	GOEP	 534.7	 1665.3	
IoA024	GLAP	 9784.3	 10731.3	
IoA030	GOEP	 15120.6	 41682.0	
IoA030	GLAP	 20066.3	 23085.9	
IoA107	GOEP	 6222.1	 19385.3	
IoA107	GLAP	 126.4	 167.6	
	
	
IoA024	GLAP	 	 	 	 	 					IoA024	GOEP	
Figure	12.	Coverage	(number	of	reads/reference	bases)	plots	of	one	of	the	three	randomly	selected	samples	
processed	with	the	GOEP	and	the	GLAP.	Plots	for	the	other	samples	see	Figure	28	in	the	Appendix.	Plots	were	
generated	using	BOWTIE	and	SAMTOOLS	(2.5.1.2).	
	
Table	 36.	 Comparison	 of	missing	 nucleotides	 and	 the	 overall	mapping	 rate	 in	 samples	 processed	with	 the	
GOEP	and	the	GLAP	after	de	novo	assembly.	
Sequence	ID	
variant	
segment	A	(bp)	 segment	B	(bp)	 Total	(bp)	 Mapping	rate	(%)	
5’	 3’	 5’	 3’	 	 	
IoA024	GOEP	 54	 31	 1	 0	 86	 2.20	
IoA024	GLAP	 30	 26	 89	 2	 147	 39.5	
IoA030	GOEP	 0	 19	 8	 39	 66	 69.2	
IoA030	GLAP	 36	 2	 7	 32	 77	 50.7	
IoA107	GOEP	 1	 17	 9	 1	 28	 41.7	
IoA107	GLAP	 36	 157	 36	 76	 305	 4.8	
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3.1.1 Improvements	to	the	double	strand	cDNA	synthesis	step	of	the	Glasgow	protocol	
In	 order	 to	 improve	 the	 termini	 coverage	 in	 the	 GLAP,	 an	 IPNV	 sample	 (IoA039)	 was	
randomly	chosen	and	several	changes	to	the	ds-cDNA	synthesis	step	were	introduced	to	the	
GLAP	(see	2.2.1):	
- the	 single	 strand	 binding	 protein	GP32	was	 added	 in	 the	 first,	 or	 the	 second	 or	 in	
both	steps	of	the	ds-cDNA	synthesis.	
- a	 3’	 primer	was	 added	 in	 the	 first,	 or	 the	 second	 or	 in	 both	 steps	 of	 the	 ds-cDNA	
synthesis.	
- ss-cDNA	was	treated	with	RNase	H	prior	the	second	strand	synthesis.	
- random	hexamers	and	dNTPs	were	added	to	the	RNA	prior	the	RNA	heat	incubation	
step.	
- the	RNA	was	incubated	at	75	°C	for	5	minutes.	
	
Table	37.	Mean	coverage	(number	of	reads/reference	bases)	of	segment	A	and	B	for	the	sample	processed	
with	different	changes	in	the	GLAP.	
Sequence	ID	 Mean	coverage	segment	A	 Mean	coverage	segment	B	
ss-cDNA-GP32	 1966.5	 2553.8	
ds-cDNA-GP32	 1968.6	 2759.1	
ss/ds-cDNA-GP32	 890.2	 1178.1	
ss-cDNA-3'Primer	 1550.1	 2255.1	
ds-cDNA-3'Primer	 1462.8	 2315.0	
ss/ds-cDNA-3'Primer	 1691.9	 2405.9	
RNaseH	treatment	 1017.7	 1461.5	
dNTPs	and	rand.hex.	 2109.5	 3296.6	
RNAincub.75	°C/5	min	 754.2	 1169.2	
GLAP	unchanged	 1238.6	 1732.7	
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ss-cDNA-GP32		 	 	 	 				ds-cDNA-GP32	
	
ss/ds-cDNA-GP32	
Figure	13.	Coverage	(number	of	reads/reference	bases)	plots	of	protocol	variants	with	added	GP32.	Plots	for	
the	other	variants	see	Figure	29	in	the	Appendix	section.	Plots	were	generated	using	BOWTIE	and	SAMTOOLS	
(2.5.1.2).	
	
Table	38.	Comparison	of	missing	nucleotides	and	the	overall	mapping	rate	of	one	randomly	selected	sample	
and	its	improvement	variants	after	de	novo	assembly.	
Sequence	ID	
variant	
segment	A	(bp)	 segment	B	(bp)	 Total	(bp)	 Mapping	rate	(%)	
5’	 3’	 5’	 3’	
ss-cDNA-GP32	 31	 2	 89	 2	 124	 4.12	
ds-cDNA-GP32	 5	 12	 23	 20	 60	 4.31	
ss/ds-cDNA-GP32	 6	 4	 41	 19	 70	 2.77	
ss-cDNA-3'Primer	 79	 6	 42	 2	 129	 2.76	
ds-cDNA-3'Primer	 22	 3	 89	 978	 1092	 2.20	
ss/ds-cDNA-
3'Primer	
8	 32	 23	 21	 84	 3.39	
RNaseH	treatment	 79	 18	 42	 19	 158	 2.27	
dNTPs	and	
rand.hex.	
	
37	 2	 24	 993	 1056	 3.86	
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RNAincub.75	°C/5	
min	
36	 6	 42	 15	 99	 2.27	
GLAP	unchanged	 8	 28	 42	 19	 97	 3.23	
	
The	 sequencing	 results	 of	 these	 variant	 protocols	were	 compared	 to	 the	 results	with	 the	
unchanged	GLAP	in	terms	of	the	genome	coverage	after	de	novo	assembly.	
Significant	improvements	between	variants	in	regard	to	the	ds-cDNA	concentration	and	the	
Bioanalyzer	results	were	not	observed	(see	Table	34	Section	II).	
RNaseH	treatment,	RNA	incubation	at	75	°C/5	min,	and	ss/ds-cDNA-GP32	resulted	in	a	lower	
mean	 coverage	 in	 both	 segments	 A	 and	 B	 compared	 to	 the	 unchanged	Glasgow	 protocol	
(Table	37).	
The	variations	in	the	protocol	had	no	significant	influence	on	the	coverage	plots	and	did	not	
improve	read	yields	for	full	termini	coverage	regarding	missing	nucleotides	after	a	de	novo	
genome	assembly	(Figure	13,	Table	38,	p=0.061772).	
	
3.1.2 Improvements	to	RNA	procedures	of	the	Glasgow	protocol	
Finally,	 it	 was	 investigated	 if	 specific	 changes	 in	 the	 RNA	 incubation	 before	 ds-cDNA	
synthesis	 have	 an	 impact	 on	 full	 genome	 de	 novo	 assembly.	 For	 this	 2	 samples	 were	
randomly	chosen	and	the	RNA	was	processed	at	a	standard	incubation	temperature	of	65°C	
and	in	comparison	at	95	°C,	as	it	is	known	that	RNA	unfolds	at	very	high	temperatures	(See	
Table	34	Section	III)	(Li,	Vieregg,	and	Tinoco	Jr	2008,	Tinoco	Jr	2004).	
Sample	 IoA111	 showed	 higher	 ds-cDNA	 concentration	 by	 Qubit	 measurement,	 larger	
average	fragment	size	and	higher	concentration	and	molarity	estimated	by	the	Bioanalyzer	
after	the	95°C	incubation.	However,	this	was	not	observed	for	sample	IoA035.	
The	obtained	coverage	plots	 show	that	 samples	 incubated	with	95	 °C	have	a	higher	mean	
coverage	 for	 segment	 A	 and	 B,	 except	 for	 segment	 A	 of	 IoA111	 95	 °C	 RNA	 where	 the	
unchanged	GLAP	results	in	a	higher	mean	coverage	(Figure	14).	The	coverage	(Table	39)	was	
not	significantly	better	for	both	segments	between	the	two	variants	(p=0.6667	segment	A;	
p=0.3333	segment	B).	
The	 total	number	of	missing	nucleotides	was	not	 significant	between	 samples	whose	RNA	
was	 incubated	 at	 95	 °C	 prior	 the	ds-cDNA	 synthesis	 step	 and	 samples	 processed	with	 the	
unchanged	Glasgow	protocol	 (p=	0.6667).	 The	overall	mapping	 rate	 showed	no	 significant	
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difference	(p=0.3333).	Full	genomes	could	not	be	assembled	using	de	novo	without	editing	
despite	the	changes	in	the	incubation	step	of	the	protocol	(Table	40).	
	
Table	39.	Mean	coverage	(number	of	reads/reference	bases)	of	segment	A	and	B	for	two	samples	processed	
with	RNA	incubation	changes	in	the	GLAP.	
Sequence	ID	 Mean	coverage	segment	A	 Mean	coverage	segment	B	
IoA035	GLAP	95	°C	 33761.8	 64944.6	
IoA035	GLAP	 27.3	 71.4	
IoA111	GLAP	95	°C	 767.0	 19879.1	
IoA111	GLAP	 1452.9	 2064.0	
	
	
IoA035	GLAP	95	°C	 	 	 	 							IoA035	GLAP	 	
	
IoA111	GLAP	95	°C	 	 	 	 						IoA111	GLAP	
Figure	14.	 Coverage	 (number	of	 reads/reference	bases)	plots	of	 two	 randomly	 selected	 samples	processed	
with	different	 incubation	 conditions	 for	RNA	prior	 ds-cDNA	 synthesis.	 Plots	were	generated	using	BOWTIE	
and	SAMTOOLS	(2.5.1.2).	
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Table	 40.	 Comparison	 of	missing	 nucleotides	 and	 the	 overall	 mapping	 of	 two	 randomly	 selected	 samples	
processed	with	different	incubation	conditions	for	RNA	prior	ds-	cDNA	synthesis	after	de	novo	assembly.	
Sample	
variant	
segment	A	(bp)	 segment	B	(bp)	 Total	(bp)	 Mapping	rate	(%)	
5’	 3’	 5’	 3’	 	
IoA035	GLAP	95	
°C	
31	 11	 41	 4	 87	 93.46	
IoA035	GLAP	 59	 156	 44	 29	 288	 0.12	
IoA111	GLAP	 40	 7	 41	 20	 108	 8.54	
IoA111	GLAP	95	
°C	
26	 31	 41	 15	 113	 43.22	
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3.2 Sequencing	Results	
3.2.1 Illumina	MiSeq	sequencing	
57	 IPNV	 samples	were	 randomly	 selected	 from	 the	 diagnostic	 collection	 and	 subjected	 to	
whole	 genome	 sequencing	 (WGS)	using	next	 generation	 technology	 (NGS)	on	 the	 Illumina	
MiSeq	platform.	The	selected	 isolates	were	collected	from	1982	–	2014.	Thirty-seven	were	
isolated	from	S.	salar	and	5	from	O.	mykiss	(Table	41).	
IPNV	samples	were	grown	in	the	corresponding	cell	 line	and	harvested	in	order	to	perform	
RNA	 extraction,	 which	was	 then	 used	 for	 ds-cDNA	 synthesis,	 according	 to	 the	 GOEP	 (see	
2.1.2.1.1)	and	later	to	the	GLAP	(see	2.1.2.1.2).	Library	preparation	was	performed	according	
to	the	Illumina	protocol	in	the	same	way	for	all	samples	(see	2.1.2.3).	
	
Table	41.	Sequenced	IPNV	samples	and	their	sampling	information	and	the	protocol	used;	NA=not	assigned.	
Sequence	ID	 Collection	
Year	
Cell	line	 Protocol	 Host	 Country	
of	origin	
Region	
IOA_IPNV006	 1982	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Argyll	
IOA_IPNV060	 1983	 CHSE-214	 Goettingen	 NA	 NA	 NA	
IOA_IPNV007	 1984	 CHSE-214	 Glasgow	 Oncorhynchus	mykiss	 UK	 Scotland,	
Borders	
IOA_IPNV008	 1984	 CHSE-214	 Glasgow	 Oncorhynchus	mykiss	 UK	 Scotland,	
Borders	
IOA_IPNV011	 1986	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Highlands	
IOA_IPNV061	 1986	 CHSE-214	 Goettingen	 Scophthalmus	
maximus	
NA	 NA	
IOA_IPNV019	 1987	 CHSE-214	 Glasgow	 Oncorhynchus	mykiss	 UK	 Scotland,	
Highlands	
IOA_IPNV021	 1987	 CHSE-214	 Glasgow	 Oncorhynchus	mykiss	 UK	 Scotland,	
Strathclyde	
IOA_IPNV062	 1987	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV063	 1987	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV064	 1987	 CHSE-214	 Goettingen	 NA	 UK	 Scotland,	
Highlands	
IOA_IPNV065	 1987	 CHSE-214	 Goettingen	 NA	 UK	 Scotland,	
Highlands	
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IOA_IPNV066	 1988	 CHSE-214	 Goettingen	 Salmo	salar	 UK	 Scotland,	
Highlands	
IOA_IPNV027	 1989	 CHSE-214	 Glasgow	 Oncorhynchus	mykiss	 UK	 Scotland,	
Borders	
IOA_IPNV032	 1989	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Shetland	
IOA_IPNV068	 1989	 CHSE-214	 Goettingen	 Salmo	salar	 UK	 Scotland,	
Highlands	
IOA_IPNV026	 1990	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Shetland	
IOA_IPNV069	 1992	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV070	 1992	 CHSE-214	 Goettingen	 NA	 Norway	 Norway	
IOA_IPNV071	 1992	 TO	 Goettingen	 NA	 UK	 Scotland,	
Argyll	
IOA_IPNV072	 1992	 CHSE-214	 Goettingen	 NA	 UK	 Scotland,	
Shetlands	
IOA_IPNV073	 1993	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV075	 1993	 TO	 Goettingen	 Salmo	salar	 Norway	 Norway	
IOA_IPNV076	 1994	 TO	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV081	 1994	 CHSE-214	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV082	 1996	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV083	 1997	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV084	 1997	 CHSE-214	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV087	 1997	 CHSE-214	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV088	 1997	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Shetlands	
IOA_IPNV090	 1998	 CHSE-214	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV107	 1999	 CHSE-214	 Goettingen	 Salmo	salar	 UK	 Scotland,	
Shetlands	
IOA_IPNV111	 1999	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Shetlands	
IOA_IPNV001	 2000	 TO	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV003	 2002	 TO	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV009	 2003	 CHSE-214	 Goettingen	 Salmo	salar	 UK	 Scotland,	
Argyll	
IOA_IPNV010	 2003	 TO	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV013	 2004	 TO	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Argyll	
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IOA_IPNV014	 2004	 CHSE-214	 Goettingen	 NA	 NA	 NA	
IOA_IPNV018	 2004	 TO	 Glasgow	 NA	 NA	 NA	
IOA_IPNV024	 2005	 TO	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV030	 2006	 TO	 Goettingen	 Salmo	salar	 NA	 NA	
IOA_IPNV031	 2006	 TO	 Glasgow	 Salmo	trutta	 UK	 Scotland,	
Shetlands	
IOA_IPNV035	 2007	 CHSE-214	 Glasgow	 Salmo	trutta	 UK	 Scotland,	
Shetlands	
IOA_IPNV039	 2008	 CHSE-214	 Glasgow	 Salmo	salar	 NA	 NA	
IOA_IPNV051	 2010	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Highlands	
IOA_IPNV052	 2011	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Highlands	
IOA_IPNV053	 2011	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Strathclyde	
IOA_IPNV054	 2011	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Shetland	
IOA_IPNV055	 2012	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Highlands	
IOA_IPNV056	 2012	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Orkney	
IOA_IPNV057	 2013	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Shetland	
IOA_IPNV047	 2014	 CHSE-214	 Goettingen	 NA	 NA	 NA	
IOA_IPNV048	 2014	 CHSE-214	 Goettingen	 NA	 NA	 NA	
IOA_IPNV049	 2014	 CHSE-214	 Goettingen	 NA	 NA	 NA	
IOA_IPNV050	 2014	 CHSE-214	 Goettingen	 NA	 NA	 NA	
IOA_IPNV058	 2014	 CHSE-214	 Glasgow	 Salmo	salar	 UK	 Scotland,	
Outer	
Hebrides	
	
During	sample	preparation,	measurements	were	performed	on	each	sample	to	control	 the	
amount	 of	 RNA,	 ds-cDNA	 and	 of	 the	 library.	 As	 a	 quality	measure	 for	 samples	 that	were	
processed	with	the	GLAP	the	quantity	of	target	RNA	molecules/mL	was	determined	using	RT-
qPCR	 (see	 2.1.2.2.1.2).	 All	 samples	 had	 a	 mean	 concentration	 over	 104	 copies	 of	 IPNV	
genome	equivalents/mL,	which	was	considered	as	a	minimum	threshold	for	successful	virus	
genome	sequencing	using	NGS.	
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The	 library	 fragment	 sizes	 ranged	 from	 154	 bp	 to	 473	 bp	 as	 determined	 with	 capillary	
electrophoresis.	 We	 observed	 a	 significant	 difference	 (p<0.0001)	 in	 the	 initial	 RNA	
concentration	 measured	 on	 the	 NanoDrop	 (see	 2.1.2.2.1.1)	 as	 well	 as	 in	 the	 ds-cDNA	
concentration	 measured	 on	 the	 Qubit	 (p<0.0001)	 between	 the	 GOEP	 and	 the	 GLAP	 with	
higher	 concentrations	 in	 samples	 processed	 with	 the	 GOEP	 (See	 Table	 34	 Section	 IV	 and	
Table	60).	
Before	sequence	reads	were	used	for	the	de	novo	genome	assembly,	they	were	checked	for	
quality	 and	 were	 decontaminated	 using	 a	 specific	 tool	 that	 deletes	 non-viral	 reads	 (see	
Methods	2.5.1).	A	significant	difference	(p=0.0032	forward	reads;	p=	0.0034	reverse	reads)	
between	 the	 RNA	 to	 ds-cDNA	 protocols	 was	 noted,	 with	 the	 GOEP	 resulting	 in	 higher	
number	 of	 reads	 remaining	 after	 read	 preparation	 steps	 that	 is	 later	 used	 for	 genome	
assembly	(Figure	14,	Table	61).	
	
	
Figure	 15.	 Forward	 and	 reverse	 reads	 recovered	 from	 IPNV	
samples	processed	with	the	GLAP	or	the	GOEP.	
	
Sequencing	 reads	were	 then	used	to	estimate	 the	genome	coverage	based	on	a	 reference	
genome	 for	 segment	 A	 and	 B	 (Figure	 15).	 There	was	 no	 difference	 in	 the	mean	 coverage	
between	 the	 two	protocols	 (p=0.5203	 segment	A;	 p=	0.0695	 segment	B)	 using	 the	Mann-
Whitney	test.	
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Figure	16.	Mean	coverage	(number	of	reads/reference	bases)	of	
segment	A	and	B	for	57	processed	IPNV	samples	with	the	GLAP	
or	GOEP.	
	
The	mean	maximum	coverage	for	segment	A	was	18004.51	and	for	segment	B	38575.39.	The	
mean	minimum	coverage	for	segment	A	was	0.88,	and	for	segment	B	5.26	(Table	62).	Some	
samples	 shared	a	 similar	 coverage	pattern	with	a	high	coverage	 towards	 the	5’-end	and	a	
lower	 coverage	 towards	 the	3’-end	of	 the	 sequence,	 as	well	 as	 the	position	of	 the	peaks.	
Some	 dips	 were	 observed	 in	 several	 IPNV	 samples	 in	 the	 second	 thirds	 of	 the	 genome	
(Figure	30).	
There	are	no	visible	 clear	differences	between	 the	 reads	obtained	 from	 the	GLAP	and	 the	
GOEP.	Coverage	at	the	termini	of	both	segments	 in	all	cases	was	very	 low,	 independent	of	
the	protocol	used.	For	segment	A	missing	nucleotides	ranged	from	1-92	bp	at	the	5’-end	and	
1-157	bp	at	the	3’-end,	and	for	segment	B	from	1-26	bp	at	the	5’-end	to	1-37	bp	at	the	3’-
end.	Segment	A	showed	a	higher	number	of	missing	nucleotides	than	segment	B	(Table	63).	
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Figure	 17.	Missing	 terminal	 nucleotides	 of	 both	 segments	 of	 IPNV	
samples	 processed	 with	 the	 GLAP	 or	 the	 GOEP	 after	 de	 novo	
assembly.	
	
An	important	part	of	post	de	novo	assembly	is	to	quantify	missing	terminal	nucleotides.	This	
allows	to	assess,	how	well	a	protocol	or	procedure	is	working	for	the	determination	of	the	
sequence	 of	 linear	 virus	 genomes.	 After	 assembling	 the	 IPNV	 genomes	 with	 the	 de	 novo	
approach,	nucleotides	at	the	termini	were	missing	in	most	samples	(Figure	16,	Table	63)	with	
a	 significant	 difference	 between	 the	 protocols	 (p=0.0143).	 The	 overall	 mapping	 rate	 was	
significantly	 different	 between	 the	 two	 protocols	 used	 (p=0.0210)	 resulting	 in	 higher	
mapping	rates	for	the	GOEP.	
Whole	genome	de	novo	assemblies	with	no	missing	nucleotides	at	the	termini	and	therefore	
without	manual	editing	were	achieved	only	 in	a	few	samples	with	both,	the	GOEP	and	the	
GLAP,	as	seen	in	samples	IoA60,	011,	019,	021,	062,	066,	071	and	081.	
	
3.2.2 MinION	
In	 order	 to	 further	 improve	 the	 termini	 coverage,	MinION	 sequencing	 technology	 (Oxford	
Nanopore	 Technology,	 UK)	 was	 tested,	 which	 sequences	 the	 DNA	 strand	 by	 threading	 it	
through	a	pore	protein	embedded	in	a	membrane	to	 identify	 individual	nucleotides	by	the	
unique	 change	 in	 the	 electrical	 conductivity	 as	 the	 DNA	 molecule	 passes	 through	 the	
nanopore	protein	(see	1.2.4).	
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One	 IPNV	sample	(IoA039)	was	randomly	selected	and	sequenced	on	the	MiSeq,	using	the	
GLAP	 for	 RNA	 extraction	 and	 ds-cDNA	 synthesis	 and	 the	 Illumina	 protocol	 for	 library	
preparation,	and	compared	it	to	the	sequences	obtained	from	MinION	sequencing,	using	the	
protocol	according	to	Oxford	Nanopore	sequencing	(see	2.4,	Table	42).	
MinION	sequencing	resulted	in	a	consistent	coverage	throughout	the	genome.	
The	 average	 fragment	 size	 of	 the	 library	 for	 MinION	 sequencing	 was	 higher	 but	 the	
concentration	and	molarity	was	lower	than	in	the	library	for	MiSeq	sequencing	(Table	43).	
The	coverage	plots	of	a	sample	sequenced	on	the	MiSeq	and	the	MinION	seen	in	Figure	18	
show	an	up	to	40	times	higher	mean	coverage	recovered	from	the	MiSeq	(Table	44).	Reads	
recovered	from	both	methods	cover	the	full	genome	only	with	manual	editing	after	the	de	
novo	assembly,	although	the	mapping	rates	are	higher	on	the	MiSeq	(Table	45).	
There	 is	 no	 significant	 difference	 in	 missing	 terminal	 nucleotides	 between	 the	 genomes	
recovered	from	sequencing	on	the	MiSeq	and	the	MinION	(p=0.3143).	
	
Table	42.	Control	values	of	one	randomly	selected	sample	processed	for	MinION	2D	sequencing.	
Sequence	
ID	
initial	conc.	
of	ds-cDNA	
Qubit	
(ng/µL)	
cDNA	amplification	 Library	preparation	
post	Ligation	
conc.	
(ng/µL)	
post	PCR	
amplification	
conc.	(ng/µL)	
post	EndPrep	
conc.	(ng/µL)	
post	Elution	
conc.	(ng/µL)	
IoA039	 1.50	 0.52	 2.26	 4.16	 0.95	
	
Table	43.	Bioanalyzer	 results	of	 the	 library	of	one	randomly	selected	sample	processed	 for	MinION	2D	and	
MiSeq	sequencing.	
Sequence	ID	 Library	preparation	
Average	fragment	size	(bp)	 Conc.	(pg/µL)	 Mol.	(pmol/l)	
IoA039	MinION	 1110	 1501.18	 3199.5	
IoA039	MiSeq	 274	 3975.92	 23764.9	
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Table	44.	Mean	coverage	(number	of	reads/reference	bases)	of	segment	A	and	B	for	one	samples	sequenced	
on	the	MiSeq	and	the	MinION.	
Sequence	ID	 Mean	coverage	segment	A	 Mean	coverage	segment	B	
IoA039	MinION	 41.7	 61.1	
IoA039	MiSeq	 1534.4	 2228.7	
	
	
	
Figure	18.	Comparing	the	coverage	(number	of	reads/reference	bases)	plots	of	one	randomly	selected	sample	
(upper:	segment	A,	 lower:	segment	B)	sequenced	on	the	MinION	(blue,	 left	coordinates)	and	on	the	MiSeq	
(green,	right	coordinates).	Plots	were	generated	using	BOWTIE	and	SAMTOOLS	(2.5.1.2).	
	
Table	45.	Missing	nucleotides	and	the	overall	mapping	rate	of	one	randomly	selected	sample	sequenced	on	
the	MinION	and	the	MiSeq	in	comparison	after	de	novo	assembly.	
Sequence	ID	 Segment	A	(bp)	 Segment	B	(bp)	 Total	(bp)	 Mapping	rate	(%)	
5’	 3’	 5’	 3’	 	
IoA039	MinION	 10	 12	 0	 14	 36	 0.85	
IoA039	MiSeq	 1	 5	 2	 2	 10	 2.78	
	
3.2.2.1.1 Improvement	of	MinION	sequencing	
In	order	to	check	if	the	fragment	length	for	MinION	sequencing	can	be	in	general	increased,	
it	was	decided	to	change	the	sample	to	AmpureXP	beads	ratio	by	testing	it	on	one	randomly	
selected	betanodavirus	ds-cDNA.	For	this	the	beads	to	sample	ratio	was	changed	from	1x	to	
0.6x	 (see	 2.4.3).	 Using	 this	 approach,	 the	 fragments	 size	 eluted	 yielded	 a	 much	 more	
pronounced	peak	at	600-1000	bp	as	seen	in	Figure	18.	
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Figure	 19.	 Bioanalyzer	 results	 of	 one	 randomly	 selected	 betanodavirus	 sample	 used	 for	 improvement	 of	
fragment	 length	 for	MinION	 sequencing;	 upper	 shows	 the	 fragment	 range	with	 1x	 beads	 to	 sample	 ratio,	
lower	shows	the	fragment	range	with	0.6x	beads	to	sample	ratio.	
	
Table	46.	Bioanalyzer	results	of	two	randomly	selected	samples	used	for	improvement	of	fragment	length	for	
MinION	sequencing.	
Sequence	ID	 Average	fragment	size	
(bp)	
Conc.	
(pg/µL)	
Mol.	
(pmol/l)	
Noda	
Pt/08/Sba	
before	size	selection	 642	 3163.08	 10387.5	
after	size	selection	 770	 983.43	 2325.2	
	
Table	46	shows	that	after	the	change	to	0.6x	beads	to	sample	ratio,	 the	average	fragment	
size	increased	although	the	concentration	and	molarity	decreased.	
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3.3 Sequencing	Analysis	
3.3.1 Phylogenetic	analysis	
In	order	to	obtain	an	insight	into	the	phylogenetic	relationship	of	the	57	IPNV	isolates	a	tree	
was	calculated	using	the	BEAST	(MCMC	method)	software	package	(2.6.3)	and	RAXML	(2.6.4;	
results	 not	 shown	 as	 trees	 showed	 the	 same	 result)	 in	 reference	 to	 published	 sequences	
available	from	GenBank	(Table	32	and	Table	33).	
Fifty	seven	IPNV	sequences	determined	from	isolates	in	Scotland	spread	across	genogroups	I	
(Jaster),	III	(Tellina/Canada1)	and	V	(Sparajub)	in	case	of	segment	A	and	across	genogroups	I,	
II	(Abild),	III	and	V	in	case	of	segment	B	(Figure	20	and	Figure	21,	Table	64).	
Samples	IoA	060,	061	and	081	group	in	genogroup	I	both	in	segment	A	and	B.	Segment	A	of	
samples	IoA	006,	011,	019,	063,	064,	065,	066,	068	and	069	cluster	in	genogroup	III	(Figure	
20)	whereas	for	segment	B	only	samples	IoA	006,	011,	019	and	069	belong	to	genogroup	III	
(Figure	21)	while	 IoA063,	064,	065,	066	and	068	cluster	 in	genogroup	 II.	All	other	samples	
cluster	within	genogroup	V	for	both	segments.	
In	 segment	B	we	observe	 that	 genogroup	 III	 seems	 to	be	 split	 up	as	 the	Tellina	 reference	
isolate	is	grouping	separately	and	not	as	 in	segment	A	within	the	genogroup	III.	This	might	
be	due	to	serotyping/genotyping	issue.	 In	serotyping	the	neutralizing	antibodies	to	specific	
epitopes,	with	in	IPNV	are	within	the	VP2	protein,	which	is	coded	in	segment	A.	Sequencing	
and	 genotyping	 the	 segment	 B	 therefore	 might	 result	 in	 a	 different	 grouping	 of	 the	
previously	serotyped	and	defined	(by	segment	A)	isolates.	
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Figure	20.	Phylogenetic	classification	of	57	IPNV	isolates	based	on	segment	A	sequences	using	reference	sequences	(Table	32).	The	unrooted	tree	was	calculated	using	BEAST	with	10,000,000	
chains	per	cycle	with	every	1000th	chain	being	recorded.	Posterior	probability	values	are	shown	at	corresponding	nodes	in	percent.	The	scale	represents	0.02	substitutions	per	nucleotide	site.	
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Figure	 21.	 Phylogenetic	 classification	 of	 57	 IPNV	 isolates	 based	 on	 segment	 B	 sequences	 using	 reference	
sequences	 (Table	 33).	 The	unrooted	 tree	was	 calculated	using	BEAST	with	 10,000,000	 chains	 per	 cycle	with	
every	1000th	chain	being	recorded.	Posterior	probability	values	are	shown	at	corresponding	nodes	in	percent.	
The	scale	represents	0.06	substitutions	per	nucleotide	site.	Te	serotype	clusters	separately	but	is	still	defined	
as	genogroup	III	(see	Table	2).	
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Table	47.	Genogroup	distribution	of	the	sequenced	IPNV	isolates.	
Genogroup	
V	 I	 	 II	 III	
45	(78.95	%)	 3	(5.26	%)	 segment	A	 0	 9	(15.79	%)	
	 	 segment	B	 5	(8.77	%)	 4	(7.02	%)	
	
An	 analysis	 of	 the	 distribution	 of	 genogroups	 revealed	 that	 78.95	 %	 of	 the	 57	 IPNV	
sequences	belong	to	genogroup	V	and	only	5.26	%	to	genogroup	I.	Of	the	remaining	isolates	
15.79	 %	 of	 segment	 A	 sequences	 cluster	 within	 genogroup	 III	 and	 8.77	 %	 of	 segment	 B	
sequences	cluster	within	genogroup	II	and	7.02	%	within	the	genogroup	III	(Table	47)	
	
3.3.2 Analysis	of	amino	acid	sequence	features	of	IPNV	proteins	
When	 comparing	 the	 amino	 acid	 composition	 of	 the	 57	 sequenced	 IPNV	 isolates	 (IoA32	
excluded	for	segment	A	and	its	encoded	proteins)	several	genogroup-specific	differences	in	
all	 IPNV	proteins	genes	were	observed.	Some	amino	acids	are	specific	for	two	of	the	three	
genogroups	 throughout	 the	 genomes.	Within	 the	 genogroup	 II/III	 we	 observe	 amino	 acid	
differences	between	samples	that	cluster	within	genogroup	III	in	both,	segment	A	and	B	and	
samples	 that	 cluster	within	 genogroup	 III	 in	 segment	 B.	 In	 the	 following	 the	 comparative	
analysis	of	the	individual	protein	sequences	highlights	the	main	observed	features.	
	
3.3.2.1 Analysis	of	features	of	VP2	
Previous	work	on	IPNV	has	indicated	the	importance	of	amino	acid	sites	217,	221,	247,	252,	
281,	282	and	319	in	VP2	for	the	pathogenicity	of	IPNV,	with	a	focus	on	the	positions	217	and	
221.	 To	 analyse	 and	 compare	 the	 VP2	 protein	 sequence	 of	 56	 IPNV	 isolates	 (excluding	
IoA032,	as	it	was	showing	gaps	in	the	region	of	interest)	the	segment	A	protein	sequences	of	
all	 56	 isolates	were	 aligned	 in	 reference	 to	 the	 virulent	 Sp	 strain	NVI-001	documented	by	
Santi	et	al.	in	2004.	
All	genogroup	III	strains	share	the	same	amino	acid	residue	pattern	(Table	48).	
Two	genogroup	 I	 isolates,	 IoA060	from	1983	and	 IoA061	(ex	Scophthalmus	maximus)	 from	
1986	 share	 the	 same	 residue	 pattern	 whereas	 IoA081	 from	 1994	 (ex	 Salmo	 salar)	 has	
different	amino	acids	in	positions	217,	247	and	282.	
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Within	the	genogroup	V	strains	a	range	of	amino	acid	variations	in	all	decades	and	hosts	can	
be	seen.	
	
Table	 48.	 VP2	 residue	 characteristics	 pattern	 of	 sequenced	 IPNV	 isolates	 compared	 to	 the	 virulent	
reference	 strain	 excluding	 IoA032.	Amino	acid	positions	 identified	 in	previous	 studies	as	 important	 in	
terms	of	viral	virulence	are	listed,	with	a	focus	on	the	positions	217	and	221	(underlined).	
Cluster	 Sequence	ID	 Collection	
Year	
Genogroup		 Amino	acid	position	
217							221								247							252					281									282							319	
1	 IOA_IPNV	
06,11,19,	63,	
64,	65,	66,	68,	
69	
1982,	1986,	
1987,	1988,	
1989,	1992	
III	 P	 T	 		P	 A	 T	 A	 A	 	
2	 IOA_IPNV	
7,	8,	21,	62,	
26,	70,	71,	73,	
75,	76,	81,	83,	
84,	107,	1,	3,	
39	
1984,	1987,	
1990,	1992,	
1993,	1994,	
1997,	1999,	
2000,	2002,	
2008	
I	or	V	 P	 T	 		A	 N	 T	 N	 A	 	
3	 IOA_IPNV	
27	
1989	 V	 P	 T	 		A	 N	 T	 N	 V	 	
4	 IOA_IPNV	
24,	31,	57,	47,	
48,	50	
2005,	2006,	
2013,	2014	
V	 P	 T	 		A	 V	 T	 N	 A	 	
5	 IOA_IPNV	
72	
1992	 V	 P	 A	 		A	 T	 T	 N	 A	 	
6	 IOA_IPNV	
87,	88,	90,	111	
1997,	1998,	
1999	
V	 P	 A	 		A	 I	 T	 N	 A	 	
7	 IOA_IPNV	
9,	10,	13,	18,	
30,	35,	51,	52,	
54,	55,	56,	49,	
58	
2003,	2004,	
2006,	2007,	
2010,	2011,	
2012,	2014	
V	 P	 A	 		A	 V	 T	 N	 A	 	
8	 IOA_IPNV	
60,	61,	82	
1983,	1986,	
1996	
I	or	V	 A	 T	 		E	 N	 T	 A	 A	 	
9	 IOA_IPNV	
14	
2004	 V	 P	 S	 		A	 V	 T	 N	 A	 	
10	 IOA_IPNV	
53	
2011	 V	 T	 A	 		A	 V	 T	 N	 A	 	
	 Santi	et	al.,	
2004	
	
2000	
V	 T	 A	 		T	 V	 T	 N	 A	 	
	
Apart	 from	 the	 configuration	 for	 virulence	 in	 VP2	 (T217,	 A221),	 Santi	 also	 described	 low	
virulent	 (P217,	 A221),	 avirulent	 (T217,	 T221)	 or	 persistent	 (P217,	 T221)	 configurations	
respectively.	
Of	the	56	IPNV	isolates	analysed	here,	more	than	half	belong	to	the	persistent	type,	followed	
by	 low	 virulent	 strains.	 Only	 one	 sequence	 shows	 a	 virulent	 amino	 acid	 characteristic,	 as	
defined	by	previous	research.	No	avirulent	isolates	were	found.	One	isolate	shows	an	P217,	
S221	amino	acid	characteristic	and	3	 isolates	show	a	A217,	T221	amino	acid	characteristic.	
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One	 isolate	 could	 not	 be	 characterised	due	 to	 non-assigned	nucleotides	 in	 the	 alignment.	
The	 virulence	 characteristic	 distribution	 shows	 that	 persistent	 type	 is	 dominating	 in	 this	
study	(see	Table	49	and	Table	65).	
The	persistent	types	were	from	samples	from	all	three	decades	and	ex	S.	salar	as	well	as	ex	
O.	mykiss.	Low	virulent	types	were	exclusively	ex	S.	salar	starting	in	the	1990’s.	
	
Table	49.	Distribution	of	variants	of	56	sequenced	 IPNV	strains;	NA=not	
assigned.	
	 Amino	acid	position	 	
N	
	
%		 217	 221	
Virulent	 T	 A	 1	 1.79	
Low	virulent	 P	 A	 18	 32.14	
Avirulent	 T	 T	 0	 0	
Persistent	 P	 T	 33	 58.93	
NA	 P	 S	 1	 1.79	
NA	 A	 T	 3	 5.36	
	
To	 gain	 a	 deeper	 insight	 into	 the	 VP2	 protein,	 which	 is	 the	 major	 capsid	 protein	 that	 is	
recognised	by	the	immune	system	and	contains	the	sites	that	determine	the	virulence	of	the	
virus,	 a	 Neighbour	 Network	was	 calculated	 using	 only	 non-homologues	 amino	 acids	 from	
genogroup	V	IPNV	isolates.	The	results	show	that	the	main	cluster	is	composed	of	persistent	
(PT)	 and	 low	 virulent	 type	 (PA)	 isolates.	 The	main	 cluster	 is	 divided	 in	 sub	 clusters.	 Four	
samples	are	outside	the	main	cluster	(Figure	22).	These	four	samples	are	all	of	the	persistent	
type.	Sample	53,	 the	only	virulent	 (TA)	 isolate,	as	defined	by	a	specific	amino	acid	 residue	
characteristics	obtained	from	previous	research,	found	in	this	study	is	located	away	from	the	
main	cluster	near	samples	IoA9	and	13	which	have	the	amino	acid	composition	PA	(see	Table	
48).	
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Figure	 22.	 Non-homologous	 amino	 acid	 alignment	 based	 Neighbour	 Network	 of	 the	 VP2	 protein	 for	
genogroup	V	IPNV	samples.	The	scale	bar	represents	the	split	support	for	the	edges.	Sample	53	(red)	 is	the	
only	virulent	type	(TA).	Green	samples	represent	persistent	type	(PT),	purple	low	virulent	(PA)	and	blue	not	
assigned	types	(AT	and	PS).	
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3.3.2.1.1 Persistency	experiment	
Previous	 studies	 have	 shown	 that	 IPNV	 attenuates	 in	 CHSE-214	 cell	 culture	 after	 several	
passages,	 which	 is	 shown	 in	 amino	 acid	 changes	 at	 VP2	 position	 217	 and	 221	 e.g.	 from	
virulent	(T217,	A221)	to	avirulent	(T217,	T221).	
All	original	diagnostic	cultures	had	been	performed	on	CHSE-214	cells	(1-2	passages).	To	rule	
out,	for	the	additional	pre-sequencing	CHSE-214	cell	culture	(maximum	3	passages),	that	the	
VP2	residues	observed	in	the	IPNV	sequences	determined	here,	were	not	biased	due	to	cell	
culture	 attenuation,	 5	 randomly	 selected	 IPNV	 isolates	 were	 additionally	 cultured	 for	 3	
passages	on	rainbow	trout	gonad	(RTG-2)	cells	which	are	known	not	to	introduce	cell	culture	
attenuation	mutations	in	these	specific	VP2	amino	acid	positions.		
The	analysis	of	 the	whole	genome	sequences	obtained	 from	the	selected	 isolates	cultured	
on	RTG-2	cells	showed	no	differences	in	amino	acid	positions	217	and	221	in	the	VP2	gene	
whether	 grown	 in	 CHSE-214	 or	 RTG-2	 cells,	 and	 independent	 of	 the	 number	 of	 passages	
(Table	50).	
	
Table	 50.	 Amino	 acid	 composition	 of	 five	 randomly	 selected	
samples	 grown	 in	 two	 different	 cell	 lines	 to	 prove	 persistency	
characteristics.	All	Isolates	≥2	passages.	
Sequence	ID	 Amino	acid	position	
217	 221	
IoA068CHSE-214	 P	 T	
IoA068RTG2	 P	 T	
IoA090CHSE-214	 P	 T	
IoA090RTG2	 P	 T	
IoA076CHSE-214	 P	 T	
IoA076RTG2	 P	 T	
IoA035CHSE-214	 P	 T	
IoA035RTG2	 P	 T	
IoA039CHSE-214	 P	 T	
IoA039RTG2	 P	 T	
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3.3.2.2 Analysis	of	features	of	other	IPNV	proteins:	VP1,	VP3,	VP4,	VP5	
VP1	has	a	characteristic	N-terminal	Serine	at	the	5’-end	of	the	RNA-RdRp	complex	which	is	
confirmed	in	the	sequenced	IPNV	samples	(Table	51).	Furthermore,	the	alignment	shows	in	
the	GTP-	binding	motif	(G)	site	242-252	that	samples	belonging	to	the	genogroup	I	have	an	
Isoleucine	I243	whereas	all	other	genogroups	have	a	Valine	V243.	In	the	RdRp	specific	motifs	
I-VI	 (A-F)	amino	acid	 changes	are	observed	 in	 the	motifs	 I	 (F),	 IV	 (B),	V	 (D)	and	VI	 (E)	 that	
differ	between	genogroups.	It	is	known	that	the	RdRp	lacks	the	typical	GDD	motif	and	has	an	
ADN	motif	instead,	which	is	confirmed	for	all	57	IPNV	sequences.	
The	 Neighbour	 Network	 analysis	 of	 non-homologue	 amino	 acids	 of	 the	 VP3	 protein	
(genogroup	V	only)	shows	one	main	cluster.	Nine	samples	are	outside	the	main	cluster	with	
sample	IoA7	(1984)	being	further	away	and	deriving	from	the	isolates	IoA82,	83	and	90,	that	
were	all	sampled	in	the	1990s	(Figure	23).	
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Figure	 23.	 Non-Homologous	 amino	 acid	 alignment	 based	 Neighbour	 Network	 of	 the	 VP3	 protein	 for	
genogroup	V	IPNV	samples.	The	scale	bar	represents	the	split	support	for	the	edges.	
	
The	alignment	of	VP4	 (Table	52)	 shows	 the	main	 conserved	catalytic	 residues	Serine	S179	
and	 Lysine	K220	as	 expected,	 as	well	 as	 the	 catalytic	 residue	 F89	 in	 samples	belonging	 to	
genogroup	 I	 or	 V89	 in	 samples	 belonging	 to	 genogroups	 II,	 III	 and	V.	Other	 catalytic	 sites	
V91,	H93,	L184,	A221,	A223,	H225,	L229,	L231,	I232,	G233	and	D239	do	not	differ	between	
the	genogroups	and	are	therefore	not	explicitly	shown.	
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In	VP5	four	sequences	all	belonging	to	genogroup	V	show	a	truncated	protein.	One	sample	is	
of	the	persistent	type	from	the	1980’s	and	the	other	three	are	of	the	low	virulent	type	from	
the	2000’s	(Figure	24).	
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Table	51.	Amino	acid	 features	of	specific	 IPNV	RdRp	(VP1)	sites	and	motifs.	S	 (Serine),	A	 (Alanine),	D	 (Aspartic	acid),	N	 (Asparagine),	 I	 (Isoleucine),	V	 (Valine),	H	 (Histidine),	Y	 (tyrosine),	G	
(Glycine),	E	(Glutamic	acid),	K	(Lysine),	L	(Leucine),	T	(Threonine).	
	 Terminal	
AA	
GTP	binding	
site	(G)	
(242-252)	
RdRp	specific	
ADN	motif	
(387-389)	
RdRp	specific	
site	I	(F)	
(315-324)	
	
RdRp	specific	site	IV	
(B)	
(462-493)	
	
RdRp	specific	
site	V	(D)	
(502-520)	
	
RdRp	specific	
site	VI	(E)	
(553-568)	
AA	site	 2	 243	 	 316	 			467								486											492	 			503											509	 566	
I	 S	 I	 ADN	 K	 H	 I	 V	 G	 E	 I	
II/III	 S	 V	 ADN	 K	 Y	 L	 H	 E	 T	 V	
V	 S	 V	 ADN	 L	 Y	 I	 H	 E	 A	 V	
	
Table	52.	Amino	acid	features	of	catalytic	sites	of	the	IPNV	protease	(VP4).	S	(Serine),	V	
(Valine),	K	(Lysine),	F	(Phenylalanine).	
	 Main	catalytic	site	 Further	catalytic	site	
AA	site	 179	 220	 89	
I	 S	 K	 F	
II/III	 S	 K	 V	
V	 S	 K	 V	
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Figure	24.	Selected	 region	of	 the	amino	acid	alignment	of	 the	VP5	protein	 for	57	sequenced	 IPNV	samples	
showing	deletions	and	years	when	they	occurred.	Stars	indicate	truncated	proteins.	Deletions	highlighted	in	
red.	Dots	represent	homologous	amino	acids.	Amino	acid	variations	are	highlighted	by	respective	amino	acid	
code	letters.	
	
3.3.3 CAI	analysis	
Codon	 adaptation	 by	 an	 infecting	 virus	 to	 the	 host	 genome	 can	 improve	 virus	 replication	
efficiency	 and	 influence	 virulence.	 In	 order	 to	 assess	 if	 IPNV	 has	 been	 adapting	 its	 codon	
usage	 in	any	of	 the	5	 IPNV	proteins	 to	 that	of	 the	host	organisms	that	used	extensively	 in	
Scottish	 aquaculture,	 salmon	 (Salmo	 salar)	 or	 rainbow	 trout	 (Onchorhynchus	 mykiss),	 to	
optimise	virus	protein	translation,	a	codon	adaptation	analysis	was	performed	for	both	hosts	
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was	performed,	assuming	both	hosts	have	the	same	tRNA	usage,	as	the	both	belong	to	the	
Salmonidae	family	(see	2.6.5	according	to	Nicholas	Di	Paola’s	approach).	
In	 the	 first	 analysis	 a	 CAI	 was	 calculated	 for	 each	 IPNV	 protein	 in	 terms	 of	 codon	 usage	
adaptation	towards	the	salmon	and	the	rainbow	trout	genome	(see	Figure	25).	Proteins	VP2,	
VP3	 and	 VP4	 have	 a	 CAI	 above	 1.00	 which	 indicates	 adaptation	 for	 both,	 salmon	 and	
rainbow	trout	genomes,	although	the	adaptation	in	VP2	and	VP4	seems	to	be	higher	than	in	
VP3.	Furthermore,	VP2	appears	to	have	a	significantly	higher	adaptation	towards	the	salmon	
than	 the	 rainbow	 trout	 genome	 (p=4.867e-05).	 In	 VP5	 we	 observe	 a	 completely	 random	
codon	usage	for	both	hosts	as	the	CAI	 is	below	1.00	 indicating	the	virus	does	not	adapt	to	
the	codon	choice	of	any	of	the	hosts,	although	there	is	a	significant	difference	between	the	
two	hosts	(p=1.544e-08).	The	polymerase	shows	only	a	minor	codon	usage	adaptation.	
Analysing	CAI	over	 time	 (see	Table	53)	 a	 significant	 increase	of	 codon	usage	adaptation	 is	
evident	 for	both	hosts	 in	VP2	and	VP4,	with	 the	highest	 increase	between	 the	1980’s	and	
1990’s.	 (Figure	 26).	 In	 VP3	 a	 significant	 decrease	 in	 codon	 adaptation	 over	 time	 for	 both	
hosts	can	be	observed.	VP5	demonstrates	a	random	codon	usage	constantly	over	time,	but	
with	 significant	 fluctuations	 between	 the	 decades	 for	 both	 hosts.	 The	 polymerase	 shows	
significant	 fluctuations	 over	 time	 (Table	 53)	 but	 does	 not	 show	 signs	 of	 overall	 codon	
adaptation	(Figure	25).	
Finally,	CAI	 values	were	 calculated	 for	 all	 proteins	of	 IPNV	 isolates	presenting	a	persistent	
and	low	virulent	phenotype	in	VP2	(see	Table	54	and	Table	55).	
In	VP2	we	see	significant	differences	between	salmon	and	rainbow	trout	for	low	virulent	as	
well	 as	 persistent	 isolates.	 Significant	 differences	 are	 also	 obvious	 between	 salmon	 and	
rainbow	trout	within	the	persistent	type	of	samples.	 In	VP3	we	see	a	significant	difference	
between	persistent	and	low	virulent	samples	towards	the	rainbow	trout	genome.	VP4	shows	
a	significant	difference	in	the	persistent	type	of	samples	between	the	two	hosts.	RdRp	shows	
a	significant	difference	between	low	virulent	and	persistent	types	for	each	host.	VP5	shows	
significant	 differences	 in	 CAI	 between	 salmon	 and	 rainbow	 trout	 in	 low	 virulent	 and	
persistent	 samples.	 Further	 there	 is	 a	 significant	 difference	 between	 low	 virulent	 and	
persistent	samples	for	salmon	(Fehler!	Verweisquelle	konnte	nicht	gefunden	werden.).	
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Figure	25.	CAI	analysis	of	each	IPNV	protein	to	show	signs	of	codon	usage	adaptation	towards	the	
host	 genome	of	 Atlantic	 salmon	 (Salmo	 salar)	 and	 rainbow	 trout	 (Onchorhynchus	mykiss).	 Values	
above	1.00	show	a	sign	of	codon	usage	adaptation.	Stars	indicate	a	significant	relation.	
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Figure	26.	CAI	analysis	of	each	IPNV	to	show	signs	of	codon	usage	adaptation	towards	the	host	genome	of	
Atlantic	Atlantic	salmon	(Salmo	salar)	and	rainbow	trout	(Onchorhynchus	mykiss)	between	low	virulent	and	
persistent	 type	 of	 samples.	 Values	 above	 1.00	 show	 a	 sign	 of	 codon	 usage	 adaptation.	 Stars	 indicate	 a	
significant	relation;	significance	level	p≤0.05.	
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Table	53.	Significance	levels	of	CAI	threshold	over	time	of	three	decades	by	comparing	two	decades	with	each	
other	for	both	hosts	Salmo	salar	and	Onchorhynchus	mykiss;	significance	level	p≤0.05.	
Protein	 Host	 Comparison	 p-	value	
VP1	 Oncorhynchus	mykiss	 1980s	-	1990s	 2.165e-05	
Salmo	salar	 1980s	-	1990s	 2.165e-05	
Oncorhynchus	mykiss	 2000s	-	2010s	 0.003261	
Salmo	salar	 2000s	-	2010s	 0.003261	
VP2	 Oncorhynchus	mykiss	 1980s	-	1990s	 2.165e-05	
Salmo	salar	 1980s	-	1990s	 2.165e-05	
VP3	 Oncorhynchus	mykiss	 1980s	-	1990s	 2.165e-05	
Salmo	salar	 1980s	-	1990s	 0.0006495	
Oncorhynchus	mykiss	 1990s	-	2000s	 1.083e-05	
Salmo	salar	 1990s	-	2000s	 1.083e-05	
Oncorhynchus	mykiss	 2000s	-	2010s	 0.03717	
Salmo	salar	 2000s	-	2010s	 0.01985	
VP4	 Oncorhynchus	mykiss	 1980s	-	1990s	 2.165e-05	
Salmo	salar	 1980s	-	1990s	 2.165e-05	
Oncorhynchus	mykiss	 2000s	-	2010s	 0.003261	
Salmo	salar	 2000s	-	2010s	 0.003261	
VP5	 Oncorhynchus	mykiss	 1980s	-	1990s	 2.165e-05	
Salmo	salar	 1980s	-	1990s	 2.165e-05	
Oncorhynchus	mykiss	 1990s	-	2000s	 0.003886	
Salmo	salar	 1990s	-	2000s	 0.002879	
Oncorhynchus	mykiss	 2000s	-	2010s	 0.003261	
Salmo	salar	 2000s	-	2010s	 0.003261	
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Table	54.	Significant	differences	in	CAI	values	between	hosts	against	a	sample	variant	persistent	(P)	type	and	
low	virulent	(LV)	type;	significance	level	p≤0.05.	
Protein	 Host	 Comparison	 p-	value	
VP1	 Oncorhynchus	mykiss	 P	-	LV	 0.00037	
Salmo	salar	 P	-	LV	 0.0004383	
VP2	 Oncorhynchus	mykiss	 P	-	LV	 0.014	
Salmo	salar	 P	-	LV	 0.01627	
VP3	 Oncorhynchus	mykiss	 P	-	LV	 0.048	
	
Table	 55.	 Significant	 differences	 in	 CAI	 values	 low	virulent	 (LV)	 and	persistent	 (P)	 type	of	 samples	 against	
host	species;	significance	level	p≤0.05.	
Protein	 Virulence	type	 Comparison	 p-	value	
VP2	 LV	 Oncorhynchus	mykiss	-	Salmo	salar	 8.178e-06	
P	 Oncorhynchus	mykiss	-	Salmo	salar	 0.01589	
VP5	 LV	 Oncorhynchus	mykiss	-	Salmo	salar	 0.0008824	
	 P	 Oncorhynchus	mykiss	-	Salmo	salar	 7.267e-06	
	
3.3.4 Selection	analysis	
To	 identify	 specific	 sites	 in	any	of	 the	 IPNV	proteins	under	a	positive	 selection	pressure,	a	
positive	 selection	 analysis	 using	 the	 HYPHY	 package	 was	 performed.	 Initially,	 the	 SLAC	
(Single	Likelihood	Ancestor	Counting)	model,	with	a	significance	level	of	p≤0.1,	which	is	able	
to	model	variations	in	synonymous	and	non-synonymous	rates	under	the	MG94xREV	codon	
model,	was	applied	(see	2.6.6).	
The	 results	 in	 Table	 56	 show	 that	 only	 one	 site,	 site	 217,	 in	 the	 VP2	 protein	 is	 under	
significant	 positive	 selection.	 A	 total	 of	 6	 substitutions	 at	 this	 site,	 with	 0	 of	 them	 being	
synonymous	and	6	non-synonymous	was	calculated.	The	determination	of	site	217	as	being	
under	positive	selection	pressure	is	supported	by	the	calculated	p-value	of	0.087.	
	
	
	
	
	
	 124	
Table	56.	Results	of	a	positive	selection	analysis	of	all	IPNV	proteins	for	all	57	sequenced	samples	using	SLAC	
on	HYPHY.	
Protein	 Codon	 p-value	
VP1	 FOUND	NO	POSITIVE	SELECTED	SITES	
VP2	 217	 0.087791	
VP3	 FOUND	NO	POSITIVE	SELECTED	SITES	
VP4	 FOUND	NO	POSITIVE	SELECTED	SITES	
VP5	 FOUND	NO	POSITIVE	SELECTED	SITES	
	
Another,	more	detailed	way	 to	 find	 selection	sites	 is	 to	apply	MEME	 (Mixed	Effects	Model	
of	Evolution)	 within	 the	 HYPHY	 package	 under	 the	 MG94xREV	 codon	 model.	 MEME	
hypothesises	 that	sites	have	been	under	episodic	positive	or	diversifying	selection	under	a	
proportion	of	branches.	A	p-value	of	p≤0.1	defines	positive	 selection	at	one	site.	Table	57	
shows	 that	 all	 IPNV	 proteins	 have	 sites	 of	 positive	 selection.	 In	 VP1	 these	 sites	 are	
distributed	 across	 the	 genome	with	 codon	316	 located	 in	 the	 1st	 and	 467	 in	 the	 4th	 RdRp	
specific	motif	respectively.	
VP2	shows	sites	of	selection	within	the	variable	domain.	Sites	217,	248	and	315	are	under	
positive	 selection	which	 represent	 regions	 determining	 the	 virulent	 character	 of	 the	 virus	
(see	 1.1.2.3.2).	 VP3	 shows	 sites	 of	 selection	within	 the	VP3	 and	 the	RNA	binding	domain.	
Sites	in	VP4	are	not	within	the	active	region	of	the	protease.	Sites	2-68	in	VP5	are	all	within	
the	truncated	region	of	the	protein.	
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Table	 57	Results	 of	 site-specific	 positive	 and	diversifying	 selection	 analysis	 of	 all	 IPNV	proteins	 for	 all	 57	 sequenced	 samples	 using	MEME	on	HYPHY,	
applying	the	MG94xREV	codon	model.	P	describes	the	p-value	(p≤0.1)	for	positive	selection	at	one	site.	
VP1	 VP2	 VP3	 VP4	 VP5	
Codon	 p-value	 Codon	 p-value	 Codon	 p-value	 Codon	 p-value	 Codon	 p-value	
50	 0.01	 195	 0.02	 66	 0.10	 37	 0.09	 2	 0.01	
81	 0.00	 208	 0.02	 145	 0.10	 46	 0.01	 13	 0.19	
82	 0.00	 217	 0.00	 	 	 131	 0.04	 17	 0.03	
140	 0.04	 241	 0.00	 	 	 212	 0.09	 36	 0.09	
226	 0.05	 242	 0.03	 	 	 218	 0.05	 53	 0.07	
232	 0.04	 248	 0.00	 	 	 	 	 68	 0.09	
316	 0.00	 315	 0.09	 	 	 	 	 98	 0.08	
358	 0.07	 333	 0.07	 	 	 	 	 106	 0.04	
368	 0.05	 	 	 	 	 	 	 111	 0.08	
467	 0.01	 	 	 	 	 	 	 	 	
687	 0.07	 	 	 	 	 	 	 	 	
699	 0.07	 	 	 	 	 	 	 	 	
737	 0.09	 	 	 	 	 	 	 	 	
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3.3.5 Dinucleotide	composition	
In	order	 to	get	more	 insight	 into	possible	 selection	on	nucleotide	 level	of	 IPNV	sequences	
obtained	from	whole	genome	sequencing,	a	dinucleotide	abundance	calculation,	focusing	on	
the	CG	dinucleotide,	was	performed	for	IPNV	segment	A	and	B	using	the	EMBOSS	COMPSEQ	
online	platform.	As	previously	mentioned	in	1.3.6,	the	motif	CG	or	CpG	is	of	big	interest	as	it	
is	 a	methylation	 cite	 in	 vertebrates	 and	 besides,	 suppressed	 throughout	 the	 DNA	 (Karlin,	
Doerfler,	and	Cardon	1994),	due	to	cytosine	methylation	and	other	reasons	such	as	higher	
energy	of	CpG	in	DNA	and	immune	escape	mechanism	of	a	virus.	
	
Table	58.	Dinucleotide	composition	of	 IPNV	segment	A	and	B	calculated	
with	EMBOSS	compseq	with	focus	on	CG	(bold	italic).	Results	CpGO/E	≤1:	
underrepresented	 dinucleotide;	 CpGO/E	 ≥1:	 overrepresented	
dinucleotide.	
Dinucleotide	 Segment	A	(CpGO/E)	 Segment	B	(CpGO/E)	
AA	 0.91	 0.98	
AC	 1.05	 1.03	
AG	 1.10	 1.01	
AT	 0.91	 0.96	
CA	 1.15	 1.09	
CC	 0.99	 0.98	
CG	 0.72	 0.74	
CT	 1.19	 1.26	
GA	 1.20	 1.15	
GC	 0.76	 0.81	
GG	 1.07	 1.12	
GT	 0.98	 0.89	
TA	 0.56	 0.66	
TC	 1.33	 1.27	
TG	 1.22	 1.26	
TT	 0.83	 0.78	
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Results	 with	 CpGO/E	 ≤1	mean	 that	 the	 dinucleotide	 is	 underrepresented	 in	 the	 sequence,	
CpGO/E	≥1means	the	dinucleotide	is	overrepresented	in	the	sequence.	
The	 results	 show	 that	 for	 both	 segments,	 the	 CG	 dinucleotide	 is	 underrepresented	 (see	
Table	 58,	 bold	 italic)	 compared	 to	 previously	 estimated	mean	 CpGO/E=0.88	 for	 vertebrate	
infecting	dsRNA	viruses,	by	Cheng	et	al.	(Cheng	et	al.	2013).	The	most	abundant	dinucleotide	
is	TC	(bold)	and	the	less	abundant	is	TA	(italic).	
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4 Discussion	
To	observe	possible	changes	in	the	genome	of	IPNV	isolates	from	the	last	three	decades	of	
IPNV,	the	whole	genome	of	57	IPNV	TCID50	isolates	was	sequenced	and	analysed	using	next	
generation	 sequencing	 technology	 on	 the	 Illumina	 MiSeq	 platform.	 Two	 whole	 genome	
sequencing	 protocols,	 the	 Goettingen	 (GOEP)	 and	 the	 Glasgow	 protocol	 (GLAP),	 were	
compared	in	terms	of	terminal	nucleotide	coverage.	Furthermore,	the	whole	genome	of	one	
IPNV	 isolate	 was	 recovered	 from	 whole	 genome	 sequencing	 on	 the	 Oxford	 Nanopore	
Technologies	MinION	sequencer.	
	
4.1 Whole	genome	sequencing	protocols	
4.1.1 Comparing	the	Goettingen	and	the	Glasgow	protocol	
A	 sequencing	 protocol	 for	 virus	 RNA	 had	 been	 developed	 in	 the	 group	 of	 Dr.	Weidmann,	
University	 of	Goettingen,	Germany	 using	 the	 454	 Pyrosequencing	 approach	 (Dilcher	 et	 al.	
2012).	 For	 the	 purpose	 of	 this	 project	 the	 virus	 RNA	 protocol	 was	 transferred	 to	 whole	
genome	 sequencing	 (WGS)	 on	 the	 Illumina	 MiSeq	 next	 generation	 sequence	 (NGS).	 The	
protocol	is	complex	and	costly	so	upon	contacting	the	group	of	Dr.	Emma	Thompson	at	MRC,	
University	of	Glasgow,	UK,	who	had	developed	a	WGS	protocol	 for	sequencing	Hepatitis	C	
Virus	(Thomson	et	al.)	directly	from	whole	blood	samples	(Thomson	et	al.	2016),	protocols	
were	compared	and	it	was	decided	to	test	if	the	Glasgow	protocol	could	simplify	and	speed	
up	 IPNV	 whole	 genome	 sequencing	 in	 comparison	 to	 the	 Goettingen	 protocol.	 Special	
attention	was	on	obtaining	the	full	genome	with	de	novo	assembly	and	to	obtain	terminal	
sequences	without	 the	use	of	 specific	primers,	 to	make	 it	possible	 to	use	 the	protocol	 for	
WGS	of	potentially	any	viral	genome	in	a	sample.	
For	 this	 several	 IPNV	 isolates	 were	 chosen.	 IPNV	 RNA	 was	 processed	 with	 both,	 GOEP	
(2.1.2.1.1)	and	GLAP	(2.1.2.1.2)	and	sequenced	 in	 the	same	way,	according	to	 the	 Illumina	
Nextera	XT	DNA	Library	Preparation	Kit	(2.1.2.3)	as	seen	in	the	overview	(Figure	11).	
The	results	showed	no	significant	difference	in	terms	of	missing	nucleotides	at	the	termini	of	
the	 IPNV	 genome.	 Both	 protocols	 were	 not	 able	 to	 yield	 a	 full	 genome	 after	 a	 de	 novo	
assembly.	 Manual	 editing	 of	 missing	 nucleotides	 was	 achieved	 using	 a	 reference-based	
approach.	 In	 general	 reference-based	 assembly	works	 better	 than	de	novo	 at	 sites	 of	 low	
genome	coverage,	as	in	the	case	of	termini	regions	of	the	IPNV	genome	segments.	The	fact	
that	the	GLAP	had	a	significantly	lower	coverage	and	reads	than	the	GOEP	did	not	lower	its	
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assembly	quality,	as	de	novo	assembly	often	works	better	with	lower	read	numbers	for	short	
sequences	 typically	 produced	 by	 the	 MiSeq.	 As	 the	 genomes	 recovered	 through	 manual	
editing	 from	GLAP	sequencing	were	as	good	as	 those	recovered	 from	GOEP	sequencing,	 it	
was	decided	to	switch	to	the	GLAP,	as	it	was	additionally	cheaper	and	faster.	Compared	to	
GOEP	 it	 did	 not	 have	 a	 ds-cDNA	 amplification	 step,	 which	 potentially	 can	 introduce	
mutations	into	the	viral	genome	sequencing	amplificates.	
Altogether,	 27	 IPNV	 isolates	 were	 sequenced	 using	 the	 GOEP	 and	 30	 isolates	 were	
sequenced	using	 the	GLAP.	Comparison	of	 the	sequencing	 results	 indicated	 that	 the	GOEP	
determined	 significantly	more	 terminal	nucleotides	 (0-60nt	missing)	 than	 the	GLAP	 results	
(0-2495nt	 missing)	 (Table	 63).	 Interestingly,	 both	 protocols	 were	 able	 to	 yield	 full	 length	
genomes	 (4	 samples	each).	However,	 the	data	demonstrated	 that	 the	GLAP	 is	 suitable	 for	
whole	genome	sequencing	of	 IPNV	and	was	 subsequently	used	based	on	qualities	 such	as	
lower	costs,	less	time	consumption	and	fewer	amplification	steps.	
	
4.1.1.1 Improving	GLAP	
To	 improve	 the	 termini	 coverage	 of	 the	 GLAP,	 several	 changes	 were	 introduced	 to	 the	
protocol.	
RNA	from	one	 IPNV	sample	was	processed	 in	different	ways	during	 the	ds-cDNA	synthesis	
step	(2.2)	and	sequenced	as	described	in	2.1.2.3.	
The	bacteriophage	T4	single	strand	DNA	binding	(SSB)	GP32	protein	was	used	to	protect	ss-
cDNA	during	the	ds-cDNA	synthesis,	as	it	is	known	that	GP32	stabilises	ssDNA	intermediates	
and	protects	them	during	the	reaction	from	degradation	(Shereda	et	al.	2008,	Shamoo	et	al.	
1995,	Bittner,	Burke,	and	Alberts	1979).	
Termini	specific	primers	were	used	 in	ds-cDNA	synthesis	to	 increase	the	overall	number	of	
determined	nucleotides	at	the	genome	termini.	
The	 use	 of	 RNase	 H	 after	 ss-cDNA	 synthesis	 was	 not	 part	 of	 the	 original	 GLAP	 but	 was	
considered	 as	 it	 is	 recommended	 in	 the	 SuperScript	 III	 Reverse	 Transcriptase	 original	
protocol.	 It	 was	 assumed	 to	 obtain	 an	 overall	 better	 sequencing	 results	 by	 using	 the	 RT	
enzyme	according	to	the	original	protocol.	
The	use	of	a	template	premix	containing	the	RNA,	the	dNTPs	and	the	random	hexamers	prior	
to	the	RNA	incubation	step	was	a	variation	that	was	suggested	in	personal	correspondence	
with	Dr.	Emma	Thomson.	
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Finally	increasing	the	RNA	incubation	temperature,	up	to	75	°C	and	above,	was	introduced	to	
allow	a	better	unfolding	of	potential	complex	secondary	structures	at	the	genomic	ends,	as	
RNA	 secondary	 structures	 unfold	 completely	 at	 different	 temperatures	 depending	 on	 the	
structure	complexity	(Li,	Vieregg,	and	Tinoco	Jr	2008,	Tinoco	Jr	2004).	
The	results	showed	that	none	of	the	protocol	variations	resulted	in	a	full	IPNV	genome	after	
a	 de	 novo	 assembly	 and	 termini	 were	 still	 missing	 nucleotides	 in	 the	 range	 of	 60-1092	
nucleotides	(Table	38	and	Table	40).	Even	improvements	in	the	RNA	incubation	step	prior	to	
the	 ds-cDNA	 synthesis	 by	 increasing	 the	 RNA	 incubation	 temperature	 did	 only	 improve	
termini	 coverage	 slightly	 (87	 nt	 missing	 compared	 to	 288	 nt	 at	 65	 °C	 RNA	 incubation	
temperature).	Manual	editing	using	a	reference-based	approach	was	still	needed.	
This	 could	 mean	 that	 the	 successful	 unfolding	 of	 the	 secondary	 structure	 of	 the	 IPNV	
genome	termini	might	include	other	factors	such	as	salts	in	the	mix,	that	are	known	to	play	a	
role	in	resolving	secondary	RNA	structures	(Li,	Vieregg,	and	Tinoco	Jr	2008,	Tinoco	Jr	2004).	
Usage	of	RNase	H	after	ss-cDNA	synthesis	did	not	improve	sequencing	results.	This	could	be	
due	 to	 the	 influence	 of	 the	 RNaseH	 in	 the	mix	 that	 was	 used	 for	 the	 following	 ds-cDNA	
synthesis	 step	 as	 according	 to	 the	 protocol	 for	 RNaseH	 a	 clean-up	 step	 had	 not	 to	 be	
performed.	It	might	be	an	option	to	clean	the	ss-cDNA	synthesis	reaction	up	before	using	it	
for	the	ds-cDNA	synthesis	step,	although	this	could	decrease	the	template	concentration.	
Using	a	3’-end	specific	primer	in	both	steps	of	ds-cDNA	synthesis	had	only	a	minimal	effect	
on	 increasing	 the	 number	 of	 terminal	 nucleotides	 determined.	 It	 might	 be	 considered	 to	
work	on	primer	concentration	optimisation	or	optimise	the	primer	sequence	especially	 for	
IPNV	sequencing.	However,	in	general	is	not	of	interest	to	use	a	specific	primer	as	the	goal	is	
to	use	 the	WGS	protocol	 for	possibly	all	 viruses.	Besides,	 reference-based	assembly	 is	 still	
mostly	used	 for	 viral	 genome	assembly	which	means	 that	 sites	with	 rather	poor	 coverage	
can	still	be	assembled	 fully	without	any	gaps	by	providing	 reference	sequences	 if	 they	are	
available.	
Additionally,	the	GOEP	includes	a	step	of	ligating	a	3’-iSP9	adapter	(Maan	et	al.	2007)	to	the	
dsRNA	but	this	adapter	sequence	was	never	found	in	the	obtained	data,	indicating	that	the	
ligation	 did	 not	 work	 for	 IPNV.	 This	 suggested	 that	 RNA	 termini	 maybe	 are	 not	 properly	
accessible	due	to	the	secondary	structure	of	the	terminal	RNAs	of	the	IPNV	genome.	
The	number	of	missing	terminal	nucleotides	was	smaller	when	additionally	using	GP32	in	the	
ds-cDNA	 synthesis	 step	 (60	 missing	 nucleotides)	 or	 during	 both	 steps	 (70	 missing	
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nucleotides)	but	not	in	the	ss-cDNA	step	(124	missing	nucleotides),	indicating	that	it	has	only	
a	 small	 impact	 during	 the	 ds-cDNA	 synthesis	 step	 (see	 Table	 38).	 This	 could	 be	 due	 to	
primary	incomplete	unfolding	of	the	template	RNA	to	begin	with.	The	concentration	of	the	
GP32	 protein	 in	 the	 mix	 was	 possibly	 higher	 or	 lower	 than	 needed	 for	 optimal	 process.	
Another	possibility	could	be	the	need	of	further	SSBs	in	order	to	unwind	the	RNA,	stabilise	
the	primary	RNA	structure	 thus,	optimise	 the	ds-cDNA	synthesis	 in	 terms	of	 recovering	all	
nucleotides	in	the	genome	termini.	
Taken	together,	comparing	two	WGS	protocols	and	improving	the	GLAP	in	order	to	increase	
the	termini	coverage	of	the	IPNV	genome	segments,	showed	that	RNA	secondary	structure	
could	be	the	cause	of	failing	to	achieve	recovering	of	a	full	IPNV	genome.	The	results	made	
clear	that	changes	in	the	GLAP	that	affect	the	secondary	structure	like	the	use	of	the	GP32	
protein	and	higher	RNA	incubating	temperatures	showed,	even	if	not	statistically	significant,	
improvement	 resulting	 in	 fewer	 missing	 terminal	 nucleotides.	 WGS	 of	 betanodavirus	
samples	using	NGS	 (MiSeq)	with	 the	standard	GLAP	showed	a	higher	 terminal	 coverage	 in	
general	than	observed	for	IPNV	(personal	communication	with	Dr.	Benjamin-Lopez	Jimena).	
betanodavirus	also	is	a	bi-segmented	virus	(RNA1	and	RNA2)	and	it	was	observed	that	RNA2	
was	 recovered	 completely	 in	 almost	 every	 sample,	whereas	 RNA1	was	missing	 just	 a	 few	
terminal	 nucleotides,	 thus	 supporting	 the	 idea	 that	 RNA	 secondary	 structure	 is	 the	major	
cause	for	not	recovering	the	terminal	sequences.	
	
4.1.2 MinION	sequencing	
A	 publication	 on	 whole	 genome	 sequencing	 of	 Influenza	 virus	 on	 the	 MinION	 platform	
(Wang	et	al.	2015)	gave	the	idea	to	try	to	sequence	IPNV	on	the	MinION	to	see	if	this	would	
recover	 a	 full	 IPNV	 genome	 after	 a	 reference-based	 assembly,	 without	 any	 missing	
nucleotides	 in	the	terminal	genome	regions.	The	data	 from	the	study	done	by	Wang	et	al.	
showed	 that	 the	whole	 genome	of	 an	 influenza	 virus	was	 >99	%	 identical	 to	 the	 genome	
obtained	by	Sanger	 sequencing,	which	proved	 the	accuracy	of	 the	MinION	device	as	 such.	
Although	 the	 group	 used	 termini	 specific	 primer	 to	 amplify	 the	 viral	 template	 (PCR	
sequencing	approach),	the	sequencing	technology	of	the	MinION	itself	is	very	different.	As	a	
ssDNA	strand	passes	through	a	pore	and	tetranucleotides	are	transduced	into	a	signal,	this	
might	potentially	result	in	better	covered	terminal	regions.	
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RNA	 from	 one	 IPNV	 sample	 was	 processed	 with	 the	 GLAP	 and	 sequenced	 on	 the	MiSeq	
(2.1.2.3)	and	on	the	MinION	(2.4).	Comparing	sequence	yields	showed	no	improvement,	as	
nucleotides	at	the	IPNV	genome	termini	were	missing	with	both	sequencing	approaches.	The	
mean	coverage	of	 the	MinION-obtained	sequence	was	more	 than	30	 times	 lower	 than	 for	
the	MiSeq-obtained	sequence	 (Table	44).	The	number	of	missing	terminal	nucleotides	was	
only	 10	 for	 the	MiSeq	 yield	 compared	 to	MinION	 yield	 with	 36	 (Table	 45),	 although	 the	
genome	assembly	for	the	MinION	data	was	done	using	a	reference	genome	in	the	first	place.	
The	MinION	 technology	allows	 the	 sequencing	of	 very	 long	 fragments.	 It	was	 therefore	of	
interest	 to	 see	 if	 a	 change	 in	 the	 magnetic	 bead	 to	 sample	 ratio	 in	 the	 post	 ds-cDNA	
synthesis	 purification	 step	 could	 increase	 the	 fragment	 size.	 To	 prove	 that,	 one	 randomly	
selected	betanodavirus	sample	was	processed	as	describe	in	3.2.2.1.1	with	a	change	of	the	
beads	to	sample	ratio	from	1x	to	0.6x.	The	library	preparation	protocol	for	the	MinION	could	
be	 improved	 successfully	 in	 terms	 of	 recovering	 longer	 fragments	 shifting	 the	 average	
fragment	size	from	642	bp	to	770	bp.	This	shows	that	the	MinION	sequencing	protocol	can	
be	adapted	to	individual	sequencing	needs.	
MinION	 sequencing	 was	 also	 performed	 with	 betanodavirus	 samples,	 although	 with	 a	
slightly	 changed	 library	 preparation	 protocol	 and	 yielded	 full	 recovery	 of	 RNA2	 whereas	
RNA1	was	still	missing	a	few	terminal	nucleotides.	
The	 use	 of	 two	 different	 NGS	 technologies	 for	 betanodavirus	 as	 well	 as	 for	 IPNV	 WGS	
indicates	that	not	the	ds-cDNA	synthesis	protocol,	the	library	preparation	or	the	sequencing	
technology	 but	 rather	 the	 RNA	 structure	 of	 the	 virus	 is	 the	 factor	 that	 determines	 the	
recovery	of	a	full	genome	with	fully	recovered	terminal	sites.	
Comparing	the	GLAP	to	other	published	WGS	protocols	for	NGS	reveals	that	usually	termini	
specific	primers	for	segment	A	and	B	are	used	in	the	cDNA	synthesis	step	in	order	to	obtain	
the	full	genome	of	Birnaviruses,	as	shown	in	a	study	of	Lu	et	al.	(Lu	et	al.	2015).	
This	study	aimed	at	optimising	a	protocol	avoiding	specific	terminal	primers	in	order	to	have	
a	WGS	protocol	that	can	be	used	for	any	possible	virus.	The	GLAP	was	indeed,	successfully	
used	 to	 sequence	 the	 whole	 genomes	 of	 more	 IPNV	 samples	 from	 Turkey,	 white	 spot	
syndrome	virus	(WSSV,	dsDNA	genome),	piscine	myocarditis	virus	(PMCV,	dsRNA	genome),	
and	 viruses	 from	 the	 Betanodaviridae	 family	 (ssRNA(+)	 genome);	 data	 not	 shown	 as	 it	 is	
unpublished	work	by	Dr.	Benjamin	Lopez	Jimena	and	not	described	in	the	the	introduction	
and	methods	section.	 	
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4.2 Phylogenetic	analysis	interpretation	
To	analyse	the	phylogeny	of	IPNV	isolates	from	Scottish	aquafarms	from	three	decades,	the	
whole	 genome	 of	 57	 IPNV	 isolates	 was	 sequenced	 using	 NGS.	 Phylogenetic	 trees	 were	
calculated	using	the	BEAST	package	and	double	checked	with	phylogenetic	trees	calculated	
via	RAXML	(not	shown).	The	results	showed	that	over	70	%	of	the	sequenced	IPNV	isolates	in	
this	study	belong	to	genogroup	V,	which	was	also	seen	in	studies	in	Finland	between	1985-
2015	 (Holopainen,	 Eriksson-Kallio,	 and	Gadd	2017),	 in	 Scotland	between	1979-2004	 (Bain,	
Gregory,	 and	 Raynard	 2008),	 in	 Ireland	 between	 1993-2013	 (Ruane	 et	 al.	 2015)	 and	 in	
Norway	between	2002-2003	(Mutoloki	and	Evensen	2011).	Only	a	few	IPNV	isolates	belong	
to	the	genogroup	I,	II	or	III.	
In	five	samples	the	results	showed	that	segment	A	belonged	to	genogroup	III	but	segment	B	
to	 the	 genogroup	 II,	 indicating	 reassortment.	 The	 samples	 are	 dated	 from	 1987	 to	 1989.	
Three	samples	(IoA63,	66,	68)	were	extracted	from	salmon	and	in	case	of	IoA64	and	65	the	
host	is	not	known.	
Natural	 reassortment	 in	wild	 IPNV	 isolates	 resulting	 in	a	 combination	of	 serotypes	WB/Ab	
(I/II)	(see	Table	2	for	IPNV	classification)	was	observed	by	Romero-Brey	et	al.,	in	1999	off	the	
Canadian	 east	 coast	 isolated	 from	 Atlantic	 cod	 (Gadus	 morhua),	 Greenland	 halibut	
(Reinhardtius	 hippoglossoides),	 Witch	 flounder,	 (Glyptocephalus	 cynoglossus),	 American	
plaice	 (Hippoglossoides	 platessoides),	 Deepwater	 redfish	 (Sebastes	 mentella),	 Onion-eye	
grenadier	 (Macrourus	 berglax),	 Blue	 antimora	 (Antimora	 rostrata)	 and	 Atlantic	 wolf	 fish	
(Anarhichas	lupus)	(Romero-Brey	et	al.	2009).	More	cases	of	natural	reassortants	were	found	
between	2010	and	2011	in	29	different	wild	fish	in	Spain	and	represented	WB/Ab	(I/II)	and	
WB/Ja	 (I/I)	 combination	 (Moreno	 et	 al.	 2014).	 Cases	 of	 natural	 reassortment	 were	 also	
reported	 in	 IBDV,	 a	 Birnavirus	 infecting	 chicken	 (Wei	 et	 al.	 2006).	 No	 indication	 for	
reassortants	of	the	combination	II/III	in	IPNV	was	found	in	literature.	
Interactions	between	wild	and	 farmed	fish	are	 found	 for	many	 infectious	diseases.	 IPNV	 is	
found	in	wild	fish	near	farming	sites	but	also	up	to	50km	away,	persistently	for	many	years,	
which	indicates	that	it	is	passed	on	from	farmed	to	wild	animals,	through	escaped	animals.	
There	 is	 evidence	 for	 the	 opposite	 route	 as	 several	 pathogens	were	 detected	 in	wild	 fish	
near	farming	sites	before	there	were	any	signs	of	the	disease	in	the	farm	or	even	before	a	
farm	was	built.	Once	IPNV	is	transmitted	from	wild	to	farmed	animals	it	can	be	enriched	in	
the	dense	farmed	population	and	reach	outbreak	potential	and	can	potentially	spill	over	to	
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wild	 populations	 (pathogen	 spill	 back)	 (Wallace,	McKay,	 and	Murray	 2017).	 The	 high	 host	
number	 allowing	 massive	 replication	 is	 a	 suitable	 ground	 for	 selection	 of	 isolates	 with	
specific	 properties,	 and	 reassortants,	 that	 could	 be	 deriving	 from	 cross-transmissions	
between	farmed	and	wild	fish.	
The	detected	IPNV	reassortants	may	have	been	generated	in	wild	fish	and	then	infected	the	
farmed	 salmon	 and	 trout.	 However,	 it	 is	 also	 possible	 that	 the	 reassortant	 strains	 in	 this	
study	derived	from	2	types	of	IPNVs	co-infecting	farmed	salmon	and	trout.	
The	 IPNV	 reassortants	 found	here	 could	 be	 a	 product	 of	 early	 aquaculture	 but	 they	were	
obviously	not	able	to	persist.	Still,	reassortants	could	occur	anytime	due	to	the	use	of	non-
sterilising	 IPNV	vaccines	used	on	farming	sites,	which	allows	 IPNV	replication	 in	vaccinated	
salmon	 and	 acquiring	 with	 different	 IPNV	 genogroups	 (co-infection)	 (Julin,	 Mennen,	 and	
Sommer	2013).	Viruses	with	more	than	one	genomic	segment	possibly	use	reassortment	due	
to	 selection	 pressure	 to	 rearrange	 genomic	 properties	 in	 order	 to	 overcome	 elimination,	
which	is	perfectly	documented	in	human	influenza	virus	(Carrat	and	Flahault	2007,	Shao	et	
al.	2017).	
Only	one	virulent	Sp	isolate	(genogroup	V)	was	found	according	to	the	criteria	published	by	
Santi	et	al	 (Santi,	Vakharia,	and	Evensen	2004b).	The	 two	most	 represented	variants	were	
the	persistent	(58.93	%)	and	the	low	virulent	(32.14	%)	type.	
Similar	results	were	obtained	in	a	study	of	36	IPNV	isolates	from	Scotland	between	1999	and	
2004	by	Bain	et	al.	(Bain,	Gregory,	and	Raynard	2008)	where	41.67	%	of	the	isolates	were	of	
the	persistent,	50.00	%	the	low	virulent	type	and	only	three	isolates	showed	a	virulent	amino	
acid	composition.	Surprisingly	the	low	virulent	P(217)	A(221)	isolates	showed	high	mortality	
in	 field	 and	 challenge	 experiments	 (Bain,	 Gregory,	 and	 Raynard	 2008).	 Furthermore,	 it	 is	
known	that	variants	with	the	persistent	P(217)	T(221)	motif	cause	high	mortality	in	rainbow	
trout	(Ahmadivand	et	al.	2018).	Furthermore,	 it	was	reported	by	Ruane	et	al.	 that	all	 IPNV	
isolates	from	Ireland	(including	clinical	IPNV)	from	1993	to	2013	were	either	P(217)	T(221)	or	
P(217)	A(221)	(Ruane	et	al.	2015).	
Unfortunately,	 there	 is	 no	 information	 available	 if	 the	 isolates	 in	 this	 study	 caused	 an	
outbreak	or	on	the	mortality	induced,	so	it	is	not	possible	to	verify	the	pathogenic	nature	of	
the	 isolates.	 However,	 the	 key	 information	 that	 can	 be	 drawn	 from	 this	 study	 and	 Bain`s	
observation	is	that	pathogenic	IPNV	viruses	are	prevalent	in	vaccinated	farmed	salmon	and	
trout.	
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Interestingly,	 only	 two	 amino	 acid	 flips	 are	 required	 to	 move	 from	 the	 persistent	 to	 the	
virulent	type	in	VP2	(see	Table	59).	This	could	be	of	importance	as	there	could	be	a	potential	
for	 a	 high	 number	 of	 virulent	 strains	 if	 such	 flips	 occur	 due	 to	 stress	 in	 fish	 or	 selection	
mutations,	as	a	high	density	of	hosts	favours	such	phenomena.	
A	 study	 by	 Skjesol	 et	 al.	 in	 2004	 in	 Norway	 demonstrated	 that	 such	 flips	 can	 occur	 from	
pathogenic	to	low	virulent	in	IPNV	isolates	from	field	outbreaks	with	T(217)	A(221)	changing	
to	T(217)	T(221)	 in	CHSE-214	cell	 culture	after	2-3	passages	and	 to	P(217)	A(221)	after	13	
passages	post	infection	(Skjesol	et	al.	2011).	This	shows	that	IPNV	can	accumulate	mutations	
which	 result	 in	 decreased	 replication	 success,	 thus	 favouring	 fish	 survival	 but	 indirectly	
ensuring	its	own	survival	at	low	replication	level.	
The	incidence	of	the	virulence	types	described	here	suggests	that	the	amino	acid	switches	in	
IPNV	can	happen	from	low	virulent/persistent	strains	to	high	virulent	ones.	
	
Table	59	Distribution	of	variants	of	56	sequenced	IPNV	strains	
with	indicated	flips	leading	to	virulent	strains.	
Amino	acid	site	
	 213	(217)	 217	(221)	 	
persistent	 			P	 			T	 58.93	%	
	 	 à	 	
low	virulent	 			P	 			A	 32.14	%	
	 à	 	 	
virulent	 			T	 			A	 1.79	%	
	
It	can	be	assumed	that	 the	high	number	of	persistent	and	 low	virulent	strains	enables	 the	
virus	to	replicate	on	a	certain	level	without	harming	the	host	and	avoiding	a	strong	immune	
response.	 The	 host	 can	 potentially	 shed	 the	 virus	 for	 a	 longer	 period	 and	 over	 bigger	
distances	 (see	 4.3	 for	more).	 This	was	 already	 suggested	 for	 shrimp	 viruses,	where	 it	was	
shown	that	changes	in	the	codon	usage	allow	a	shift	towards	lower	virus	replication	to	avoid	
hosts	immune	response	(Tyagi,	Kumar,	and	Singh	2017).	
Looking	at	the	data	presented	in	this	study,	we	see	that	most	isolates	are	of	the	persistent	
type	and	only	persistent	types	prevail	 in	the	time	before	vaccine	 introduction	 in	1995	(see	
Table	 65).	 After	 1995	 the	 data	 shows	 that	 there	 seemed	 to	 be	 a	 switch	 from	 persistent	
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P(219)	 T(221)	 to	 low	 virulent	 types	 P(217)	 A(221),	 with	 continuous	 increase	 of	 the	 low	
virulent	type	over	the	decades	(see	Figure	27).	Before	1995	highly	virulent	strains	were	not	
detected,	after	1995	one	isolate	from	2011	shows	the	high	virulent	amino	acid	composition	
T(217)	A(221).	
	
	
Figure	 27.	 Distribution	 of	 variants	 of	 56	 sequenced	 IPNV	 strains	 in	 each	
decade.	
	
This	 could	mean	 that	 the	 amino	 acid	 switches	 proposed	 in	 Fehler!	 Verweisquelle	 konnte	
nicht	gefunden	werden.	are	potentially	happening	in	farmed	salmon.	The	first	switch	from	
persistent	to	low	virulent	types	occurred	after	the	introduction	of	the	IPNV	vaccine.	The	next	
change	 could	 have	 been	 triggered	 by	 the	 introduction	 of	 the	 QTL	 fish	 in	 2010	which	 are	
resistant	to	IPNV.	They	specifically	block	the	entry	of	the	T217,	A221	variant	in	infected	fish.	
This	possibly	 introduced	an	enormous	selection	pressure	in	terms	of	the	binding	affinity	of	
IPNV,	 as	 it	 was	 shown	 that	 the	 QTL	 region	 contains	 genes	 coding	 for	 epithelial	 cadherin	
(cdh1)	gene,	which	 is	 involved	 in	virus	 internalization	 into	 the	cell	 (Moen	et	al.	2015),	and	
may	 have	 yielded	 the	 only	 high	 virulent	 isolate	 from	 2011.	 To	 confirm	 this,	 it	 would	 be	
necessary	 to	 study	 more	 recent	 isolates	 as	 this	 assumption	 is	 based	 on	 a	 small	 dataset.	
Recently,	 persistent	P217,	 T221	 types	have	been	 isolated	 from	groups	of	 fish	 carrying	 the	
IPN-QTL	in	northern	Norway	(Oystein	Evensen,	personal	communication).	As	we	know	from	
previous	 research,	 Alanine	 at	 position	 221	 results	 in	 lower	 binding	 affinity	 and	 therefore	
better	 virus	 release	 and	 spreading	 (Mutoloki	 et	 al.	 2016).	 So	 a	mutation	 from	P217,	 T221	
(persistent)	to	P217,	A221	(low	virulent)	would	enable	IPNV	to	replicate	better	in	host	cells,	
selecting	 for	 low	virulent	 types.	 To	understand	whether,	 in	 spite	of	 this,	 T217,	A221	 IPNV	
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types	 are	 currently	 evolving	 in	QTL	 fish	 in	 Scotland,	 it	would	 be	 necessary	 to	 study	more	
recent	isolates.	
However,	 this	 study	 and	 previous	 research	 might	 show	 that	 IPNV	 is	 evolving	 towards	
mutations,	such	as	Alanine	at	position	221,	to	reduce	binding	affinity.	
Another	way	 to	explain	 the	high	prevalence	of	persistent	 strains	 is	 that	 the	 IPNV	vaccines	
commercially	available	from	1995	must	all	be	failed	vaccines.	The	efficiency	of	IPNV	vaccines	
was	assessed	mainly	in	terms	of	their	ability	to	suppress	disease	symptoms	and	improve	fish	
survival.	 In	general	vaccines	can	fail	 for	different	reasons:	(i)	don’t	 induce	optimal	 immune	
response,	(ii)	an	already	existing	infection,	(iii)	not	all	strains	are	included	in	the	vaccine,	(iv)	
not	 100	 %	 efficiency	 against	 the	 agent,	 (v)	 or	 vaccine-vaccine	 interaction	 with	 antigenic	
interaction	in	multivalent	vaccines	(Heininger	et	al.	2012).	
Julin	et	al.	 showed	that	 IPNV	 isolates	extracted	 from	vaccinated	fish	 from	salmon	farms	 in	
Norway	were	almost	all	of	the	high	virulent	type	T(217)	A(221)	and	when	these	isolates	were	
used	 in	 challenge	 experiments	 in	 naïve	 fish	 they	 induced	 mortality	 of	 up	 to	 56	 %,	 even	
isolates	with	 the	 low	virulent	P(217)	A(221)	motif	 induced	a	mortality	of	more	 than	30	%,	
showing	that	vaccinated	fish	harbour	virulent	strains.	One	sample	showed	attenuation	in	the	
passage	experiment	changing	from	high	virulent	T(217)	A(221)	to	avirulent	T(217)	T(221)	and	
when	 challenged	 with	 the	 attenuated	 type,	 it	 showed	 highly	 reduced	 mortality	 (Julin,	
Mennen,	 and	 Sommer	 2013).	 But	 in	 general,	 the	 study	 showed	 that	 field	 isolates	 from	
vaccinated	 fish	 induced	very	high	mortalities	 in	unvaccinated	populations.	 In	one	case	 the	
IPN-vaccine	had	apparently	no	effect	at	all.	
All	of	these	observations	indicate	failure	of	the	IPN-vaccines	in	the	sense	that	they	are	non-
sterilising	vaccines	which	do	not	inhibit	IPNV	replication.	
It	also	shows	that	 IPNV	 is	very	capable	of	changing	the	motifs	that	determine	 its	virulence	
after	passages	of	the	virus,	or	due	to	stress	and	hosts	immune	response.	Julin	et	al.	showed	
that	both,	 infections	with	 the	high	 virulent	or	 low	virulent	 IPNV	 strains	 in	Atlantic	 salmon	
induced	 mortalities	 after	 sea	 water	 transfer,	 considered	 as	 stressful	 for	 fish	 due	 to	
smoltification	 (Julin	et	al.	2015).	Similar	was	shown	by	Mutoloki	et	al.	when	P(217)	T(221)	
isolates	 caused	 subclinical	 infections	 after	 sea	 water	 transfer	 and	 T(217)	 A(221)	 isolates	
clinical	 infections	 (Mutoloki	et	al.	2016).	Finally,	Gadan	et	al.	 showed	that	a	 reversion	of	a	
non-virulent	 T(217)	 T(221)	 IPNV	 strain	 to	 a	 high	 virulent	 T(217)	A(221)	 IPNV	 strain	 can	be	
induced	by	stress	in	salmon	(Gadan	et	al.	2013).	
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Therefore,	 IPNV	 clearly	 shows	 the	 potential	 to	 change	 its	 virulence	 pattern	 in	 both	
directions:	due	to	stress	to	a	high	virulent	type	or	due	to	attenuation	to	a	low	virulent	type,	
making	Fehler!	Verweisquelle	konnte	nicht	gefunden	werden.	indicating	the	emergence	of	
more	and	more	high	virulent	strains	a	possible	scenario.	
Humoral	 and	 cellular	 response	 induced	 by	 vaccines	 are	 usually	 directed	 against	 viral	
epitopes,	 in	 this	 case	 against	 the	 IPNV	 VP2	 epitopes	 (1.1.6).	 RNA	 viruses	 show	 a	 high	
evolution	 rate,	 due	 to	 error	 prone	RdRp,	with	 substitution	 rates	 ranging	 from	10-2	 to	 10-5	
substitutions	(mutations)/site/year,	whereas	non-viral	evolving	rates	are	between	1.2	x	10-8	
and	1.2	x	10-10	substitutions/site/year	(Hanada,	Suzuki,	and	Gojobori	2004,	Silva	et	al.	2013).	
This	 type	 of	 mutation	 rate	 allows	 for	 the	 selection	 of	 variants	 resistant	 to	 control	 via	
vaccination,	i.e.	of	variants	escaping	immune	response	of	the	host.	IPNV	as	an	RNA	virus	has	
therefore	 a	 high	 variability	 and	 mutation	 rate	 (Pereira	 and	 Amorim	 2013,	 Domingo	 and	
Holland	 1997)	 and	 is	 quite	 capable	 of	 creating	 variants	 to	 escape	 vaccines.	 Skjesol	 et	 al.	
observed	that	VP1,	VP2,	VP3	and	VP5	can	acquire	altogether	more	than	14	sites	per	1	kb	and	
that	VP2,	VP3	and	VP5	contain	equal	or	more	non-synonymous	than	synonymous	mutations,	
especially	 in	 the	 hyper	 variable	 region	 of	 VP2,	 indicating	 selection	 towards	 low	 virulent	
variants	(Skjesol	et	al.	2011).	
Although	usually	high	rates	of	non-synonymous	mutations	indicate	better	viral	reproduction	
it	seems	that	IPNV	is	actually	developing	towards	co-existence	with	the	host.	
This	indicates	that	it	is	possible	that	vaccination	escape	variants	are	observed	in	this	study.	It	
is	very	likely	that	the	virulent	isolates	used	for	the	development	of	the	vaccines	did	not	have	
the	P(217)	T(221)	or	P(217)	A(221)	motifs.	The	IPNV	population	was	subsequently	selected	
for	 these	 variants	 in	 order	 to	 overcome	 the	 vaccine	 control.	 Only	 recently	 research	 is	
concentrating	on	the	PT	motif	for	vaccine	development,	as	it	was	shown	to	induce	anti-IPNV	
antibody	production	and	was	able	to	protect	against	IPNV	(Ahmadivand	et	al.	2018).	
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4.3 Codon	adaptation	of	IPNV	to	salmonids	
In	order	to	see	if	IPNV	is	adapting	to	salmonid	host	codon	usage	(S.	salar	and	O.	mykiss),	to	
improve	 IPNV	 replication	 in	 these	 hosts	 and	 to	 undermine	 immune	 response,	 a	 codon	
adaptation	 index	 (CAI)	was	 calculated	 for	each	of	 the	5	 IPNV	proteins	 towards	both	hosts	
over	time	and	for	both,	persistent	and	low	virulent	strains.	
The	 results	 indicate	 that	 the	 major	 capsid	 protein	 VP2	 and	 the	 protease	 VP4	 show	 the	
highest	CAIs	for	adapting	their	codon	usage	to	both	hosts,	although	the	adaptation	of	VP2	in	
S.	salar	is	significantly	higher	than	in	O.	mykiss.	This	is	not	observed	for	VP4	(see	Figure	25).	
This	difference	could	be	explained	by	the	large	number	of	salmon	(162817	tons	produced	in	
2016)	in	comparison	to	rainbow	trout	(8096	tons	produced	in	2016)	farmed	in	Scotland	with	
an	approximate	30	times	higher	salmon	production	per	year	(Munro	and	Wallace	2017).	This	
allows	 for	 a	much	higher	number	of	 IPNV	 replication	 cycles	 in	 the	 salmon	population	and	
consequently	 more	 scope	 for	 codon	 adaptation.	 The	 fact	 that	 VP4	 seems	 not	 to	 fully	
optimise	codon	usage	could	be	explained	with	a	study	done	by	Skjesol,	which	showed	that	
VP4	has	 the	 lowest	mutation/kb	 rate	with	preferred	 synonymous	mutations	 (Skjesol	et	al.	
2011).	The	adaption	of	the	codon	usage	 in	VP2	and	VP4	ensures	an	efficient	translation	of	
the	 capsid	 protein	 essential	 for	 packaging	 and	 the	 protease,	 which	 enables	 maturation.	
Interestingly,	VP2	and	VP4	both	show	an	increase	of	CAI	over	time	(see	Figure	26)	with	the	
biggest	increase	in	salmon	farming	between	the	1980s	and	1990s	of	98.15	%,	compared	to	
74.91	%	 production	 increase	 between	 1990s	 and	 2000s	 and	 16.35	%	 production	 increase	
between	2000s	and	2010s	(according	to	Scottish	Fish	Farm	Annual	Production	Surveys	1980,	
1990,	2000	and	2010).	Still,	this	has	to	be	viewed	critical,	as	the	sample	sizes	varies	between	
the	decades	in	this	study.	
During	this	time	period	the	IPNV	vaccine	was	introduced	and	salmonid	farming	was	growing	
yearly,	thus	putting	a	pressure	on	the	IPNV	genome	and	allowing	for	viral	enrichment	in	the	
dense	 farmed	 population	 with	 a	 suitable	 ground	 for	 selecting	 isolates	 with	 specific	
properties.	
The	CAI	for	the	RdRp	(VP1)	is	very	low	(Figure	25)	which	is	plausible,	as	the	RdRp	is	strongly	
conserved	within	RNA	viruses	(Shwed	et	al.	2002)	and	rarely	adapts	because	changes	in	the	
coding	sequence	could	result	in	non-synonymous	mutations,	leading	to	fatal	changes	in	the	
RdRp	 protein	 structure	 and	 a	 possible	 decrease	 or	 loss	 of	 the	 function	 of	 this	 enzyme.	 It	
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correlates	with	findings	that	the	IPNV	RdRp	has	(following	VP4)	the	lowest	mutation/kb	rate	
with	preferred	synonymous	mutations	(Skjesol	et	al.	2011).	
Previous	 research	 showed	 that	 VP3	 has	 the	 highest	mutation/kb	 rate	 of	 all	 IPNV	proteins	
with	preferred	non-synonymous	mutations	(Skjesol	et	al.	2011).	
In	this	study	the	minor	capsid	protein	VP3	showed	only	minimal	codon	adaptation.	One	of	
the	 functions	 of	 the	 multifunctional	 VP3	 is	 to	 block	 the	 hosts’	 immune	 response	 during	
infection	by	supressing	IFNα	induction.	A	small	amount	of	VP3	will	still	allow	for	a	low	level	
innate	 immune	 response,	 whereas	 a	 bigger	 amount	 of	 VP3	 could	 result	 in	 a	 potentially	
defenceless	host	that	can	even	succumb	to	disease	too	fast.	This	would	be	contra	productive	
for	virus	survival,	as	it	would	be	more	efficient	if	the	host	could	shed	the	virus	for	a	longer	
period	over	longer	distances.	Therefore,	a	non-optimised	VP3	as	observed	here	might	be	an	
important	toggle	to	keep	innate	immune	response	at	bay	for	just	the	right	low	level	of	IPNV	
replication.	
The	CIA	values	for	VP5	are	lower	than	1,	meaning	that	codon	adaptation	is	not	happening.	
This	 is	 quite	 interesting	 as	 VP5	 shuts	 down	 hosts	 apoptosis	 system	 so	 the	 host	 does	 not	
initiate	apoptosis	of	infected	cells	and	together	with	VP4	inhibits	IFN	signalling	(Skjesol	et	al.	
2009,	Hong,	Gong,	and	Wu	2002).	By	this,	 IPNV	enhances	cell	survival	and	undermines	the	
immune	 response	 for	 the	 benefit	 of	 viral	 proliferation.	 VP5	 is	 a	 homologue	 of	 the	 anti-
apoptotic	Bcl-2	 family	 and	 it	 therefore	has	 to	 retain	 the	ability	 to	mimic	 this	 conservative	
protein.	
Previous	 research	 conducted	 by	 Do	 Yew	 et	 al.	 showed	 that	 in	 IBDV	 the	 VP5	 ORF	 has	 a	
different	 base	 usage	 than	 the	 VP2	ORF	 indicating	 that	 through	mutation	 the	 original	 VP5	
ORF	was	overprinted	 to	create	a	novel	gene	 (de	novo	gene)	 (Do	Yew	et	al.	2004)	 (Sabath,	
Wagner,	and	Karlin	2012).	 Similar	 results	were	 shown	 for	 IPNV	 in	a	 study	by	Pavesi	et	al.,	
2013,	 where	 VP2	 showed	 a	 codon	 usage	 more	 similar	 to	 the	 viral	 genome	 than	 to	 VP5	
(Pavesi,	Magiorkinis,	 and	Karlin	2013).	De	novo	genes	are	usually	more	 connected	 to	 viral	
pathogenicity	than	to	structure	and	replication.	My	study	of	CAI	 for	VP2	and	VP5	confirms	
that	VP5	 shows	no	adaptation	 to	 the	hosts	 codon	usage,	due	 to	 its	 unusual	 codon	usage,	
deriving	from	an	overprinting	strategy	and	not	being	essential	for	replication.	Looking	at	this,	
and	 the	 fact	 that	 some	natural	 IPNV	 strains	were	 found	 to	 lack	VP5	 expression	while	 still	
replicating	and	inducing	mortality,	the	protein	appears	to	be	not	essential	for	virus	survival	
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and	 therefore	 there	 is	might	be	no	need	 to	adapt	 the	codon	usage	 for	 this	protein	 to	 the	
hosts’	codon	usage	to	increase	replication	efficiency.	
This	 could	mean	 that	VP5	might	have	evolved	at	 farming	 sites	due	 to	 the	high	 replication	
level	possible	 in	densely	 farmed	populations	and	 the	 selection	pressures	described	above,	
i.e.	to	maintain	low	level	replication	in	vaccinated	hosts.	
Bahir	et	al.	analysed	CAI	values	of	mammalian	viruses	and	showed	that	viral	structural	genes	
show	the	highest	similarity	in	codon	usage	to	the	host	to	optimise	translational	fitness.	
Genes	that	encode	proteins	that	make	up	the	capsid	but	are	not	involved	in	hosts	immune	
system	 interaction	 show	 higher	 CAI	 values	 than	 non-structural	 proteins	 such	 as	 the	 RdRp	
(Bahir	et	al.	2009).	
In	 this	 study	VP2,	which	 is	a	 capsid	protein	but	 is	also	 interacting	with	 the	host’s	 immune	
system,	 shows	 the	 highest	 CAI.	 This	 only	 partly	 correlates	 with	 Bahir’s	 observation.	 As	 a	
capsid	 protein	 VP2	 adapts	 to	 the	 host’s	 codon	 usage	 in	 order	 to	 increase	 translational	
efficiency	but	it	also	contains	epitopes	that	are	recognised	by	the	hosts	immune	system.	The	
selection	analysis	clearly	showed	however	 that	 the	variable	domain	within	VP2	at	position	
183-335	that	plays	a	role	in	immune	system	response	is	under	selection	pressure	and	prone	
to	changes	in	order	to	bypass	the	immune	system.	
A	 study	 by	 Tello	 et	 al.,	 2013	 (Tello,	 Vergara,	 and	 Spencer	 2013),	 analysing	 CAI	 for	 ISAV	
(ssRNA(-)	genome)	proteins	showed	that	the	nucleoprotein	NP,	the	matrix	protein	M1	and	
the	non-structural	protein	1	NS1	had	the	highest	CAI	values.	The	high	CAI	values	of	M1	and	
the	nucleoprotein	 correlate	with	 findings	by	Bahir,	 that	 structural	 genes	 show	 the	highest	
adaptation	 to	 the	 host’s	 codon	 usage.	 NS1	 however	 showed	 higher	 CAI	 values	 than	 the	
matrix	 protein	 M1	 and	 M2	 for	 some	 analysed	 ISAV	 samples	 indicating	 that	 fish/aquatic	
viruses	may	not	follow	the	general	adaptation	models	that	were	suggested	for	mammalian	
viruses.	
A	possible	explanation	could	be	that	the	immune	response	of	fish	differs	to	that	of	mammals	
and	 therefore	 the	 selection	 pressure	 on	 viral	 proteins	 that	 interact	 with	 the	 fish	 hosts	
immune	system	is	different	than	described	for	interaction	with	mammalian	hosts.	
A	similar	observation	was	made	in	a	study	of	CAI	in	shrimp	viruses	(Tyagi,	Kumar,	and	Singh	
2017).	Almost	all	viruses	in	that	study	had	proteins	that	showed	an	adaptation	to	their	host’s	
codon	usage,	as	showed	by	elevated	CAI	values.	In	case	of	the	hepatopancreatic	parvovirus	
and	 infectious	 hypodermal	 and	 hematopoietic	 necrosis	 virus	 only	 non-structural	 proteins	
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had	higher	CAI	values	showing	again	 that	aquatic	viruses	adapt	 to	 their	host	 in	a	different	
way	from	that	shown	for	mammalian	viruses.	Interestingly,	the	only	analysed	dsRNA	shrimp	
infecting	virus	 in	 that	 study	showed	no	codon	usage	adaptation	at	all,	which	 supports	 the	
possibility	 of	 different	 codon	 usage	 preference	 between	 vertebrates	 and	 invertebrates	
infecting	viruses.	
Cheng	et	al.	 looked	at	the	difference	 in	the	CpG	content	of	different	viruses,	which	beside	
the	CAI	 can	be	considered	as	another	adaptation	 feature	and	compared	 it	 to	 that	of	 their	
hosts.	This	revealed	that	invertebrate	infecting	dsRNA	viruses	had	a	higher	CpG	abundance	
than	 vertebrate	 infecting	 dsRNA	 viruses	 but	 only	 because	 the	 CpGO/E	 of	 invertebrates	
themselves	 is	 1.02	 compared	 to	 0.47	 for	 vertebrates	 (Cheng	 et	 al.	 2013).	 This	 suggests	
indeed	 a	 difference	 in	 host	 adaptation	 between	 vertebrates	 and	 invertebrates	 infecting	
dsRNA	 viruses,	 which	 could	 explain	 why	 the	 shrimp	 infecting	 dsRNA	 virus	 did	 not	 show	
elevated	CAI	values	but	IPNV	does.	
Furthermore,	 it	 is	 known	 from	Epstein-Barr	 virus	 (EBV)	 that	 it	 de-optimises	 its	 codon	bias	
when	it	is	in	the	latent	stage	in	order	to	replicate	on	a	non-detectable	level	(Karlin,	Blaisdell,	
and	Schachtel	1990).	A	de-optimisation	was	also	found	in	shrimp	viruses,	by	which	the	virus	
does	 not	 compete	 with	 the	 host	 translational	 system,	 thus	 possibly	 supporting	 a	 low	
replication	strategy	to	avoid	immune	defence	(Tyagi,	Kumar,	and	Singh	2017).	
It	 is	 possible	 that	 IPNV	uses	 a	 similar	mechanism,	 as	most	 proteins	 show	hardly	 any	 host	
codon	 adaptation	 and	 VP5	 suggests	 even	 a	 de-optimisation	 of	 its	 codon	 bias	 due	 to	 CAI	
values	 lower	 than	 1.	 This	 correlates	 with	 the	 finding	 that	 most	 isolates	 belong	 to	 the	
persistent	type.	Basically,	viral	replication	on	a	low	level	ensures	host	survival	and	therefore,	
survival	of	the	virus.	
CpGs	 are	 also	 pathogen	 associated	 pattern	 molecules	 (PAMPs)	 recognised	 by	 innate	
immunity	receptors.	Small	RNA	viruses	show	CpG	suppression	in	their	genome	which	could	
enhance	their	replication	(Karlin,	Doerfler,	and	Cardon	1994).	This	was	observed	in	a	dsRNA	
shrimp	virus	(Tyagi,	Kumar,	and	Singh	2017)	with	the	CpGO/E	value	of	0.61.	
The	CpG	abundance	calculation	done	in	this	study	shows	that	the	CpG	dinucleotide	is	under-
represented	in	both	IPNV	segments	with	a	CpGO/E=0.72	for	segment	A	and	a	CpGO/E=0.74	for	
segment	 B	 (Table	 58;	 CG	 value).	 These	 calculated	 values	 are	 lower	 than	 the	 previously	
estimated	mean	CpGO/E=0.88	for	vertebrate	infecting	dsRNA	viruses,	by	Cheng	et	al.,	which	
in	 that	 study	meant	 a	 normal	 or	 an	 over-representation	 of	 CpG	motifs.	 The	 findings	 here	
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correlate	with	previous	studies	which	showed	that	small	RNA	viruses	show	a	suppression	of	
CpG	 in	order	 to	 escape	 immune	 recognition,	 as	 Toll-like	 receptor	 9	 is	 known	 to	 recognise	
CpG	motifs	in	dsRNA	and	to	initiate	innate	immune	response	(Tyagi,	Kumar,	and	Singh	2017).	
Non-methylated	CpG	have	 an	 immune	 stimulating	 effect	 (Goldberg,	Urnovitz,	 and	 Stricker	
2000,	Chen	et	al.	2001,	Cheng	et	al.	2013),	as	it	was	shown	for	the	Toll-like	receptor	9,	which	
initiated	an	 innate	 immune	response	after	binding	of	CpG	motifs	 (Tyagi,	Kumar,	and	Singh	
2017).	The	immune	escape	suggestion	might	have	been	proven,	for	fish	as	hosts,	in	a	study	
done	 by	 Jorgensen	 et	 al.	 (Jørgensen	 et	 al.	 2001),	 which	 showed	 that	 Atlantic	 salmon	
leucocytes	produce	antiviral	cytokines	after	stimulation	with	unmethylated	CpG.	
Although	the	immune	escape	theory	regarding	the	CpG	underrepresentation	is	ambiguous,	
the	 suppression	 of	 CpG	 in	 IPNV	 may	 suggest	 an	 immune	 escape	 mechanism.	 IPNV	 has	
acquired	 this	 feature	before	 the	year	1982,	as	a	 separate	calculated	CpGO/E	 for	 segment	A	
and	B	for	the	oldest	sample	in	our	study	from	that	year	yielded	0.73	and	0.74,	respectively	
(not	shown	in	results).	
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4.4 Selection	analysis	interpretation	
In	order	to	see	if	sites	of	the	IPNV	genomes	are	under	selection	pressure	a	positive	selection	
analysis	on	each	 IPNV	protein	sequence	alignment	of	 the	57	sequenced	 IPNV	samples	was	
performed	using	two	different	algorithms.	
The	results	from	the	SLAC	calculation	showed	that	only	VP2	has	a	site	(codon	217)	which	is	
under	 positive	 selection	 pressure.	 The	 MEME	 calculation	 on	 the	 other	 hand	 revealed	
possible	sites	under	positive	selection	pressure	in	each	IPNV	protein.	
The	 site	 217	 in	 VP2	 is	 under	 positive	 selection	 pressure	 calculated	with	 both	 approaches.	
This	is	one	of	the	sites	described	by	Santi	et	al.	 important	for	virulence	determination.	The	
fact	that	this	site	is	under	pressure	correlates	with	previous	findings	that	this	site	is	variable	
and	changes	in	the	codons	determine	the	virulence	of	the	virus.	Other	sites	in	VP2	obtained	
with	MEME	show	that	5	of	them	(217,	241,	242,	248	and	315)	are	within	the	variable	domain	
or	 represent	 sites	 that	 determine	 the	 virulence	 character	 of	 the	 virus.	 This	 indicates	 that	
these	 sites	 are	 constantly	 under	 pressure	 to	 change	 in	 terms	 of	 virulence	 behaviour.	 It	
correlates	 with	 the	 fact	 that	 there	 is	 a	 tendency	 to	 changes	 between	 different	 types	 of	
strains	and	the	possibility	to	create	highly	virulent	strains	with	only	two	amino	acid	flips.	As	
described	 above,	 one	 of	 the	 flips	 is	 from	 persistent	 to	 low	 virulent	 strains	 (Fehler!	
Verweisquelle	konnte	nicht	gefunden	werden.).	
As	 this	 site	 is	 under	 pressure	 such	 a	 flip	 is	 very	 likely	 to	 happen.	 The	 variable	 region	 also	
contains	 the	neutralising	epitopes	 so	 it	 is	possible	 that	pressure	coming	 from	the	 immune	
system	results	in	changes	within	this	region	in	order	to	escape	immune	response	resulting	in	
changes	 to	 virulence	 beneficial	 to	 low	 level	 virus	 replication.	 Evidence	 for	 such	 flips	 to	
happen	is	seen	in	the	network	analysis	of	non-homologous	amino	acid	sequences	within	the	
hypervariable	region	(HVR)	of	the	genogroup	V	isolates	of	the	VP2	protein	(Figure	22).	The	
virulent	 (TA)	 isolate	53	separates	 from	the	main	cluster	of	persistent	 (PT)	and	 low	virulent	
(PA)	strains	by	acquiring	the	second	amino	acid	change.	The	network	shows	that	the	main	
cluster	 of	 persistent	 and	 low	 virulence	 isolates	 evolves	 in	 the	 constraints	 of	 a	 certain	
sequence	space	from	which	as	shown	by	samples	72	or	14,	variants	with	specific	new	amino	
acid	patterns	can	emerge	(Table	48).	Because	of	the	pressure	of	the	hosts	immune	system,	
IPNV	 escapes	 through	 low	 virulent	 or	 persistent	 infections,	 and	 the	 main	 cluster	 of	 the	
network	 is	 composed	 of	 these	 types	 of	 isolates.	 But	 factors	 such	 as	 stress,	 not	 sterilising	
vaccines	and	viral	enrichment	in	the	densely	farmed	populations	 lead	to	the	emergence	of	
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isolates	with	changes	 in	the	genome	that	can	 lead	to	a	change	 in	the	virulence	properties,	
even	 towards	 full	 virulence	 as	 seen	 in	 isolate	 53	 from	 2011	 as	 clearly	 indicated	 in	 the	
network	analysis.	
VP1	 (RdRp)	 sites	 calculated	 under	 positive	 selection	 pressure	 were	 mostly	 found	 outside	
conserved	 motifs	 I-VI.	 Only	 site	 316	 which	 is	 in	 the	 motif	 I	 and	 site	 467	 in	 the	 motif	 IV	
experience	 positive	 selection	 pressure.	 These	 conserved	 motifs	 are	 crucial	 for	 the	 RdRp	
function	(Graham	et	al.	2011)	and	it	is	not	surprising	that	there	can	be	only	very	few	or	even	
no	changes	in	the	codons.	
VP3	showed	one	site	under	positive	selection	pressure	within	 the	self-binding	domain	and	
one	within	 the	 dsRNA	binding	 domain.	No	 sites	were	 under	 selection	 pressure	within	 the	
RdRp	 binding	 domain.	 This	 indicates	 that	 this	 region	 is	 quite	 conserved	 as	 it	 binds	 to	 the	
RdRp,	which	 is	a	conserved	protein	 itself,	meaning	 that	changes	 in	 this	 site	can	negatively	
affect	 the	 RdRp	 binding.	 The	 self-binding	 site	 and	 the	 RNA	 biding	 sites	 are	 possibly	more	
flexible	to	changes	as	certain	differences	 in	the	amino	acid	structure	might	not	disturb	the	
binding	efficiency.	
In	 VP4	 no	 catalytic	 active	 sites	 are	 affected	 by	 positive	 selection.	 It	 is	 quite	 obvious	 that	
these	sites	are	very	crucial	to	protease	functioning	and	cannot	undergo	changes.	
In	VP5	the	first	6	sites	under	positive	selection	pressure	are	within	the	truncated	region	of	
the	protein	indicating	high	local	variability.	As	stated	above	VP5	appears	not	being	essential,	
some	IPNVs	have	a	truncated	VP5,	and	some	IPNVs	lack	VP5	but	still	are	capable	to	induce	
mortality.	The	role	of	VP5	remains	to	be	elucidated.	
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4.5 Conclusion	
This	project	made	 it	possible	to	determine	the	phylogeny	and	genomic	changes	of	 IPNV	 in	
Scotland	 by	 sequencing	 and	 analysing	 the	 whole	 genome	 of	 diagnostic	 IPNV	 isolates	
spanning	3	decades	since	1982,	using	next	generation	sequencing	technology.	
Two	 different	 protocols	 were	 compared,	 with	 GLAP	 being	 suitable	 for	 whole	 genome	
sequencing	 of	 viral	 genomes	 on	 the	 next	 generation	 sequencing	 Illumina	MiSeq	 platform.	
During	 the	 protocol	 optimisation	 and	 sequencing	 of	 IPNV	 on	 the	 Oxford	 Nanopore	
Technologies	MinION	platform	it	could	be	shown	that	the	secondary	structure	of	IPNV	RNA	
has	 to	 be	 the	 reason	why	 there	were	 always	 termini	 nucleotides	missing	 after	 a	de	 novo	
IPNV	genome	assembly.	
The	 phylogenetic	 and	 genomic	 analyses	 of	 IPNV	done	 in	 this	 study	 indicate	 that	 selection	
pressure	by	the	hosts	immune	response	and	failed	vaccines	result	in	escape	mechanisms	of	
IPNV	in	farmed	salmon	and	rainbow	trout	which	are	seen	in:	
(i) changes	 within	 the	 hypervariable	 region	 in	 the	 VP2	 protein,	 thus	 changing	
virulence	beneficial	to	low	level	virus	replication	
(ii) adapting	the	codon	usage	of	the	major	capsid	protein	VP2	and	the	VP4	for	a	
better	maturation	
(iii) reassorting	the	dsRNA	segments	between	different	genogroups	
(iv) occurrence	of	a	virulent	(TA)	strain	(IoA53	from	2011)		
These	mechanisms	are	possible	due	to:	
(i) high	mutation	rate	of	IPNV	
(ii) high	virus	replication	and	enrichment	in	dense	fish	populations	on	farms	and	
interactions	with	wild	animals	
(iii) non-sterilising	 IPNV	 vaccines	 which	 enable	 IPNV	 replication	 in	 farmed	
vaccinated	fish.	
The	 high	 prevalence	 of	 persistent	 and	 low	 virulent	 strains	 shows	 that	 IPNV	 is	 evolving	
towards	the	host	by	 lowering	the	replication	 levels	so	the	fish	host	do	not	succumb	to	the	
disease	too	fast	and	the	virus	can	be	shed	over	a	longer	period	of	time	over	longer	distances.	
Still,	 the	 emergence	 of	 virulent	 strains	 from	 the	 persistent	 and	 low	 virulent	 pool	 that	 is	
observed	in	this	study	is	highly	possible	by	flipping	only	1	amino	acid.	
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4.6 Limitations	and	Outlook	
The	samples	studied	here	have	no	clinical	data	available,	 so	 it	was	not	possible	 to	make	a	
correlation	between	different	virulence	variants	and	sub	or	clinical	infections.	
As	geographical	data	was	sparse,	phylogeography	could	not	be	done.	
	
As	 sequencing	of	 IPNV	 showed	 that	RNA	 secondary	 structures	 are	 an	 issue	 in	whole	 virus	
genome	 sequencing,	 it	 would	 be	 of	 interest	 to	 overcome	 this	 problem	 by	 testing	 other	
approaches	 such	 as	 higher	 incubations	 temperatures,	 alternative	 single	 strand	 binding	
proteins,	 secondary	 structure	 relaxing	 additives	 such	 as	 tetramethylammonium	 chloride,	
formamide,	 or	 salts	 already	 established	 in	 RT-PCR,	 to	 improve	 virus	 genome	 sequencing	
without	using	termini	specific	primer.	
In	order	to	verify	the	data	described	here	a	2nd	study	looking	at	IPNV	in	trout	aquaculture	in	
Turkey	has	been	 initiated	and	 it	 remains	to	be	seen	 if	 the	data	obtained	 in	this	new	study	
will	verify	the	observations	made	here.	
Fish	challenge	experiments	should	verify	 if	 isolates	that	have	been	characterised	according	
to	 their	 specific	 amino	 acids	 in	 VP2	 (persistent,	 low	 virulent	 or	 virulent)	 are	 causing	
subclinical	 or	 clinical	 infections.	 On	 the	 other	 hand,	 the	 not	 yet	 assigned	 amino	 acid	
combinations	 need	 to	 be	 characterized	 in	 fish	 experiments	 to	 elucidate	 their	 virulence	
character.	
Since	 IPNV	 QTL	 fish	 are	 dominating	 salmon	 aquaculture,	 an	 effort	 should	 be	 made	 to	
attempt	 isolating	 and	 characterising	 more	 IPNV	 isolates	 evolving	 in	 these	 more	 selective	
conditions.	 Indeed,	 the	 industry	 should	 be	 convinced	 to	 contribute	 to	 a	 new	 surveillance	
effort	 so	 that	 the	emergence	of	new	 IPNV	and	 their	characteristics	are	understood	before	
they	can	cause	any	harm.	
The	data	obtained	in	this	study	shows	the	need	for	a	sterilising	vaccine	and	furthermore,	the	
industry	should	make	an	attempt	to	make	vaccine	data	available	for	science	to	ease	research	
to	improve	aquaculture.	
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III Appendix	
III.1 Figures	and	Tables	
III.1.1 Figures	
	
IoA030	Goettingen	 	 	 	 					IoA030	Glasgow	
	
IoA107	Goettingen	 	 	 	 					IoA107	Glasgow	
Figure	28.	Coverage	plots	of	the	other	two	randomly	selected	samples	processed	with	the	Goettingen	and	the	
Glasgow	protocol.	
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ss-cDNA-3'Primer	 	 	 	 					ds-cDNA-3'Primer	
	
ss/ds-cDNA-3'Primer	
	
RNaseH	treatment	 	 	 	 					dNTPs	and	rand.hex	
	
RNAincub.75C/5min	 	 	 	 						normal	Glasgow	prot.	
Figure	29.	Coverage	plots	of	the	other	protocol	variants.	
	 	
	 150	
	 	
IoA006		 Glasgow	 	 	 					IoA060	 Goettingen	
	 	
IoA007	Glasgow	 	 	 	 					IoA008	Glasgow	
	 	
IoA011	Glasgow	 	 	 	 					IoA061	Goettingen	
	 	
IoA019	Glasgow	 	 	 	 					IoA021	Glasgow	
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IoA062	Goettingen	 	 	 	 					IoA063	Goettingen	
	 	
IoA064	Goettingen	 	 	 	 					IoA065	Goettingen	
	 	
IoA066	Goettingen	 	 	 	 					IoA027	Glasgow	
	 	
IoA032	Glasgow	 	 	 	 					IoA068	Goettingen	
	 	
IoA026	Glasgow	 	 	 	 					IoA069	Goettingen	
	 152	
	 	
IoA070	Goettingen	 	 	 	 					IoA071	Goettingen	
	 	
IoA072	Goettingen	 	 	 	 				IoA073	Goettingen	
	 	
IoA075	Goettingen	 	 	 	 					IoA076	Goettingen	
	 	
IoA081	Glasgow	 	 	 	 					IoA082	Goettingen	
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IoA083	Goettingen	 	 	 	 								IoA084	Glasgow	
	 	
IoA087	Glasgow	 	 	 	 					IoA088	Glasgow	
	 	
IoA090	Goettingen	 	 	 	 					IoA107	Glasgow	
	 	
IoA111	Goettingen	 	 	 	 					IoA001	Glasgow	
	 	
IoA003	Glasgow	 	 	 	 					IoA009	Goettingen	
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IoA010	Glasgow	 	 	 	 					IoA013	Glasgow	
	 	
IoA014	Goettingen	 	 	 	 					IoA018	Glasgow	
	 	
IoA024	Goettingen	 	 	 	 					IoA030	Goettingen	
	 	
IoA031	Glasgow	 	 	 	 					IoA035	Glasgow	
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IoA039	Glasgow	 	 	 	 					IoA051	Glasgow	
	 	
IoA052	Glasgow	 	 	 	 					IoA053	Glasgow	
	 	
IoA054	Glasgow	 	 	 	 					IoA055	Glasgow	
	 	
IoA056	Glasgow	 	 	 	 					IoA057	Glasgow	
	 	
IoA047	Goettingen	 	 	 	 					IoA048	Goettingen	
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IoA049	Goettingen	 	 	 	 					IoA050	Goettingen	
	
IoA058	Glasgow	
Figure	30.	Coverage	plots	of	57	processed	IPNV	samples.	The	coverage	plots	were	created	with	R,	using	the	
NanoOK	tool	as	a	guidance	with	changes	in	the	R	script	for	this	purpose.	
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III.1.2 Tables	
Table	60.	Control	values	of	sequenced	IPNV	samples;	NA=not	assigned.	
	 RNA	 ds-cDNA	 Library	
Sequence	ID	 RNA	conc.	
(ng/µL)	
NanoDrop	
Ct	
value	
qPCR	
	
Mean	conc.	
qPCR	
(genome	
equivalent;	
copies/mL)	
	
dscDNA	
conc.	
(ng/µL)	
NanoDrop	
dscDNA	
conc.	
(ng/µL)	
Qubit	
Average	
fragment	
size	
(bp)	
	
Conc.	
(pg/µL)	
	
Mol.	
(pmol/l)	
	
IOA_IPNV006	 12.28	 NA	 NA	 9.28	 1.08	 258	 3037.91	 18868.1	
IOA_IPNV060	 21.00	 40.62	 9.14E1	 122.29	 115.00	 NA	 NA	 NA	
IOA_IPNV007	 7.14	 20.37	 1.72E7	 10.73	 0.63	 221	 370.37	 2625.7	
IOA_IPNV008	 15.02	 21.26	 9.20E6	 6.77	 0.50	 260	 4297.47	 26478.4	
IOA_IPNV011	 13.95	 36.41	 2.99E1	 7.77	 0.96	 247	 1941.34	 12532.4	
IOA_IPNV061	 162.50	 43.08	 1.56E1	 76.77	 68.50	 NA	 NA	 NA	
IOA_IPNV019	 21.85	 37.43	 2.44E2	 7.62	 0.36	 203	 1155.30	 10354.1	
IOA_IPNV021	 135.77	 23.66	 3.16E6	 8.93	 0.58	 193	 678.74	 6406.6	
IOA_IPNV062	 139.10	 25.44	 5.01E6	 43.00	 38.80	 NA	 NA	 NA	
IOA_IPNV063	 60.80	 41.63	 4.41E1	 67.66	 53.20	 NA	 NA	 NA	
IOA_IPNV064	 353.10	 NA	 NA	 31.04	 26.10	 NA	 NA	 NA	
IOA_IPNV065	 239.70	 NA	 NA	 28.67	 25.40	 NA	 NA	 NA	
IOA_IPNV066	 72.90	 38.48	 4.75E2	 86.81	 75.80	 NA	 NA	 NA	
IOA_IPNV027	 46.74	 24.80	 1.45E6	 8.40	 0.34	 184	 1004.50	 9854.8	
IOA_IPNV032	 57.73	 24.09	 2.70E6	 9.05	 0.80	 178	 605.03	 5936.3	
IOA_IPNV068	 1845.73	 NA	 NA	 32.84	 9.82	 260	 813.00	 4991.0	
IOA_IPNV026	 7.45	 22.07	 5.28E6	 6.13	 0.98	 237	 1168.22	 7825.0	
IOA_IPNV069	 333.15	 NA	 NA	 1.79	 0.72	 NA	 NA	 NA	
IOA_IPNV070	 173.49	 36.69	 5.57E3	 102.13	 47.10	 NA	 NA	 NA	
IOA_IPNV071	 579.64	 25.51	 8.73E8	 53.39	 25.60	 290	 1817.05	 10238.5	
IOA_IPNV072	 1615.24	 24.88	 7E9	 38.75	 11.42	 269	 962.46	 5785.1	
IOA_IPNV073	 434.93	 NA	 NA	 133.50	 41.40	 429	 1672.72	 6424.7	
IOA_IPNV075	 650.39	 23.51	 9.22E7	 88.20	 32.20	 293	 1783.87	 9942.1	
IOA_IPNV076	 685.94	 21.38	 3.63E8	 68.33	 26.20	 267	 2574.63	 15530.1	
IOA_IPNV081	 26.97	 28.84	 5.09E4	 9.01	 0.86	 280	 4878.27	 29337.5	
IOA_IPNV082	 1057.00	 28.84	 3.52E7	 37.43	 14.62	 272	 1148.10	 6791.0	
IOA_IPNV083	 1407.65	 22.62	 2.35E10	 19.87	 6.86	 267	 1297.05	 7827.0	
IOA_IPNV084	 20.02	 17.19	 2.66E8	 7.95	 0.40	 303	 6218.10	 35167.2	
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IOA_IPNV087	 31.00	 16.81	 3.60E8	 11.92	 0.63	 294	 8208.93	 48193.5	
IOA_IPNV088	 3.07	 18.71	 4.01E8	 9.41	 0.18	 305	 5580.07	 31571.5	
IOA_IPNV090	 391.59	 NA	 NA	 141.14	 59.60	 456	 1811.74	 6745.1	
IOA_IPNV107	 863.79	 19.97	 5.24E11	 24.25	 8.68	 NA	 NA	 NA	
IOA_IPNV111	 73.39	 17.25	 2.62E8	 9.03	 0.49	 246	 1746.83	 12334.0	
IOA_IPNV001	 4.51	 20.61	 2.17E7	 6.79	 0.57	 248	 1204.42	 7764.1	
IOA_IPNV003	 2.08	 18.66	 4.19E8	 9.39	 0.21	 309	 6859.15	 38430.9	
IOA_IPNV009	 330.83	 18.32	 3.10E9	 102.73	 44.00	 265	 5085.71	 31114.9	
IOA_IPNV010	 24.79	 17.02	 3.02E8	 12.42	 0.85	 271	 6153.88	 36620.1	
IOA_IPNV013	 11.44	 15.99	 6.49E8	 7.91	 0.86	 253	 2289.94	 14425.3	
IOA_IPNV014	 465.51	 NA	 NA	 172.28	 89.80	 457	 1842.64	 6500.5	
IOA_IPNV018	 29.01	 16.88	 3.61E8	 11.92	 1.25	 250	 1819.34	 11612.7	
IOA_IPNV024	 781.58	 21.25	 3.93E8	 85.56	 34.20	 268	 1649.56	 9887.4	
IOA_IPNV030	 558.97	 22.16	 5.31E8	 76.79	 35.00	 277	 2733.47	 15937.8	
IOA_IPNV031	 11.73	 15.63	 8.48E8	 5.64	 0.64	 250	 2463.72	 15731.5	
IOA_IPNV035	 2.07	 28.29	 3.47E5	 11.72	 0.52	 473	 6378.78	 26009.0	
IOA_IPNV039	 21.20	 18.48	 4.77E7	 17.85	 1.41	 274	 3975.92	 23764.9	
IOA_IPNV051	 11.03	 19.89	 2.35E7	 9.07	 1.31	 273	 1995.74	 11783.0	
IOA_IPNV052	 14.09	 16.12	 3.16E8	 10.47	 2.08	 246	 1424.90	 9282.8	
IOA_IPNV053	 9.48	 23.38	 2.13E6	 9.76	 1.45	 154	 51.26	 544.2	
IOA_IPNV054	 20.85	 15.70	 4.22E8	 11.56	 2.14	 249	 1752.89	 11315.4	
IOA_IPNV055	 16.85	 17.32	 1.39E8	 10.45	 2.80	 253	 1980.77	 12639.1	
IOA_IPNV056	 9.65	 15.54	 4.72E8	 9.16	 0.95	 245	 3959.42	 25968.4	
IOA_IPNV057	 6.27	 17.04	 1.68E8	 6.88	 0.90	 239	 2420.07	 16058.7	
IOA_IPNV047	 458.44	 25.35	 5.33E6	 89.52	 80.30	 NA	 NA	 NA	
IOA_IPNV048	 286.06	 27.14	 7.11E6	 89.85	 50.20	 NA	 NA	 NA	
IOA_IPNV049	 180.96	 31.04	 3.82E5	 86.56	 58.40	 NA	 NA	 NA	
IOA_IPNV050	 231.32	 29.31	 1.39E6	 66.18	 43.20	 NA	 NA	 NA	
IOA_IPNV058	 36.53	 18.96	 8.01E7	 10.05	 1.20	 192	 294.75	 2785.8	
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Table	 61.	 Number	 of	 forward	 and	 reverse	 decontaminated	 reads	 of	 the	 randomly	 selected	 IPNV	 samples	
processed	 with	 the	 Goettingen	 or	 the	 Glasgow	 protocol	 for	 whole	 genome	 sequencing	 using	 NGS	 on	 the	
MiSeq.	
Sequence	ID	 Collection	Year	 Raw	reads	
forward	
Raw	reads	
reverse	
RNA	to	ds-cDNA	protocol	
IOA_IPNV006	 1982	 157513	 159043	 Glasgow	
IOA_IPNV060	 1983	 847250	 847403	 Goettingen	
IOA_IPNV007	 1984	 156883	 157428	 Glasgow	
IOA_IPNV008	 1984	 203001	 206777	 Glasgow	
IOA_IPNV011	 1986	 262412	 263952	 Glasgow	
IOA_IPNV061	 1986	 666022	 666071	 Goettingen	
IOA_IPNV019	 1987	 56400	 58897	 Glasgow	
IOA_IPNV021	 1987	 58105	 59652	 Glasgow	
IOA_IPNV062	 1987	 1130819	 1130831	 Goettingen	
IOA_IPNV063	 1987	 1030840	 1031013	 Goettingen	
IOA_IPNV064	 1987	 716053	 716233	 Goettingen	
IOA_IPNV065	 1987	 921373	 921546	 Goettingen	
IOA_IPNV066	 1988	 645778	 645936	 Goettingen	
IOA_IPNV027	 1989	 34563	 35875	 Glasgow	
IOA_IPNV032	 1989	 51422	 52702	 Glasgow	
IOA_IPNV068	 1989	 108577	 155139	 Goettingen	
IOA_IPNV026	 1990	 116230	 118318	 Glasgow	
IOA_IPNV069	 1992	 97497	 97571	 Goettingen	
IOA_IPNV070	 1992	 84454	 84490	 Goettingen	
IOA_IPNV071	 1992	 1869779	 1871585	 Goettingen	
IOA_IPNV072	 1992	 233195	 239646	 Goettingen	
IOA_IPNV073	 1993	 114205	 114188	 Goettingen	
IOA_IPNV075	 1993	 341263	 348589	 Goettingen	
IOA_IPNV076	 1994	 794345	 796701	 Goettingen	
IOA_IPNV081	 1994	 255231	 276768	 Glasgow	
IOA_IPNV082	 1996	 378916	 378509	 Goettingen	
IOA_IPNV083	 1997	 345097	 346524	 Goettingen	
IOA_IPNV084	 1997	 149023	 156194	 Glasgow	
IOA_IPNV087	 1997	 51928	 83714	 Glasgow	
IOA_IPNV088	 1997	 117249	 138934	 Glasgow	
IOA_IPNV090	 1998	 87701	 87705	 Goettingen	
IOA_IPNV107	 1999	 47114	 48257	 Glasgow	
IOA_IPNV111	 1999	 943838	 947100	 Goettingen	
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IOA_IPNV001	 2000	 275019	 279827	 Glasgow	
IOA_IPNV003	 2002	 568821	 572761	 Glasgow	
IOA_IPNV009	 2003	 803601	 810307	 Goettingen	
IOA_IPNV010	 2003	 102959	 152299	 Glasgow	
IOA_IPNV013	 2004	 762381	 806229	 Glasgow	
IOA_IPNV014	 2004	 87292	 87281	 Goettingen	
IOA_IPNV018	 2004	 156887	 183702	 Glasgow	
IOA_IPNV024	 2005	 441114	 454357	 Goettingen	
IOA_IPNV030	 2006	 931946	 933601	 Goettingen	
IOA_IPNV031	 2006	 405181	 427456	 Glasgow	
IOA_IPNV035	 2007	 196167	 202745	 Glasgow	
IOA_IPNV039	 2008	 548752	 609277	 Glasgow	
IOA_IPNV051	 2010	 102370	 104648	 Glasgow	
IOA_IPNV052	 2011	 177755	 178843	 Glasgow	
IOA_IPNV053	 2011	 2200	 2457	 Glasgow	
IOA_IPNV054	 2011	 284878	 287228	 Glasgow	
IOA_IPNV055	 2012	 194832	 196394	 Glasgow	
IOA_IPNV056	 2012	 185364	 186123	 Glasgow	
IOA_IPNV057	 2013	 132886	 134701	 Glasgow	
IOA_IPNV047	 2014	 449718	 449735	 Goettingen	
IOA_IPNV048	 2014	 82315	 82347	 Goettingen	
IOA_IPNV049	 2014	 94259	 94302	 Goettingen	
IOA_IPNV050	 2014	 80821	 80846	 Goettingen	
IOA_IPNV058	 2014	 65844	 67027	 Glasgow	
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Table	 62.	Mean	 coverage	 (number	 of	 reads/reference	 bases)	 of	 segment	 A	 and	 B	 for	 57	 processed	 IPNV	
samples.	
Sequence	ID	 Collection	Year	 Protocol	 Mean	coverage	
segment	A	
Mean	coverage	
segment	B	
IOA_IPNV006	 1982	 Glasgow	 1057.42	 1627.85	
IOA_IPNV060	 1983	 Goettingen	 11225.5	 68372.8	
IOA_IPNV007	 1984	 Glasgow	 2838.87	 3557.37	
IOA_IPNV008	 1984	 Glasgow	 704.312	 1584.97	
IOA_IPNV011	 1986	 Glasgow	 24625.3	 34155.3	
IOA_IPNV061	 1986	 Goettingen	 3260.57	 4180.43	
IOA_IPNV019	 1987	 Glasgow	 28061.4	 68500.2	
IOA_IPNV021	 1987	 Glasgow	 16605.2	 97132.9	
IOA_IPNV062	 1987	 Goettingen	 42507.8	 39525.6	
IOA_IPNV063	 1987	 Goettingen	 29486.7	 34777.7	
IOA_IPNV064	 1987	 Goettingen	 763.912	 744.757	
IOA_IPNV065	 1987	 Goettingen	 637.947	 1198.1	
IOA_IPNV066	 1988	 Goettingen	 15903.1	 39622.8	
IOA_IPNV027	 1989	 Glasgow	 252.93	 255.255	
IOA_IPNV032	 1989	 Glasgow	 359.017	 475.389	
IOA_IPNV068	 1989	 Goettingen	 1728.51	 2025.94	
IOA_IPNV026	 1990	 Glasgow	 1294.14	 1472.15	
IOA_IPNV069	 1992	 Goettingen	 4041.39	 6344.43	
IOA_IPNV070	 1992	 Goettingen	 2101.18	 7359.07	
IOA_IPNV071	 1992	 Goettingen	 29768.6	 115328	
IOA_IPNV072	 1992	 Goettingen	 228.237	 900.192	
IOA_IPNV073	 1993	 Goettingen	 495.345	 2176.05	
IOA_IPNV075	 1993	 Goettingen	 607.765	 5601.92	
IOA_IPNV076	 1994	 Goettingen	 12416.8	 31406.9	
IOA_IPNV081	 1994	 Glasgow	 7382.67	 8689.62	
IOA_IPNV082	 1996	 Goettingen	 1474.65	 6441.11	
IOA_IPNV083	 1997	 Goettingen	 737.929	 2650.62	
IOA_IPNV084	 1997	 Glasgow	 3585.32	 4951.66	
IOA_IPNV087	 1997	 Glasgow	 1059.14	 1422.46	
IOA_IPNV088	 1997	 Glasgow	 1800.65	 3423.65	
IOA_IPNV090	 1998	 Goettingen	 643.839	 1299.1	
IOA_IPNV107	 1999	 Goettingen	 2022.02	 3144.74	
IOA_IPNV111	 1999	 Glasgow	 5941.4	 56484.6	
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IOA_IPNV001	 2000	 Glasgow	 5924.04	 7736.91	
IOA_IPNV003	 2002	 Glasgow	 5503.64	 5560.97	
IOA_IPNV009	 2003	 Goettingen	 2231.4	 18619.2	
IOA_IPNV010	 2003	 Glasgow	 2225.12	 2286.15	
IOA_IPNV013	 2004	 Glasgow	 421.222	 1631.82	
IOA_IPNV014	 2004	 Goettingen	 15744.5	 28408.6	
IOA_IPNV018	 2004	 Glasgow	 2518.9	 5401.02	
IOA_IPNV024	 2005	 Goettingen	 524.901	 1664.13	
IOA_IPNV030	 2006	 Goettingen	 15076.9	 41065	
IOA_IPNV031	 2006	 Glasgow	 9645.72	 12206.9	
IOA_IPNV035	 2007	 Glasgow	 170.414	 441.67	
IOA_IPNV039	 2008	 Glasgow	 1534.39	 2228.68	
IOA_IPNV051	 2010	 Glasgow	 442.107	 816.657	
IOA_IPNV052	 2011	 Glasgow	 3136.61	 5685.87	
IOA_IPNV053	 2011	 Glasgow	 172.811	 321.778	
IOA_IPNV054	 2011	 Glasgow	 6184.14	 9461.81	
IOA_IPNV055	 2012	 Glasgow	 2255.28	 5646.46	
IOA_IPNV056	 2012	 Glasgow	 3508.96	 5632.67	
IOA_IPNV057	 2013	 Glasgow	 2150.06	 2615.85	
IOA_IPNV047	 2014	 Goettingen	 2593.66	 6378.74	
IOA_IPNV048	 2014	 Goettingen	 1946.87	 7189.44	
IOA_IPNV049	 2014	 Goettingen	 2359.31	 8515.45	
IOA_IPNV050	 2014	 Goettingen	 6574.6	 34302	
IOA_IPNV058	 2014	 Glasgow	 1045.52	 1315.39	
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Table	 63.	 Missing	 nucleotides	 and	 the	 overall	 mapping	 rate	 of	 processed	 IPNV	 samples	 after	 de	 novo	
assembly.	
Sequence	ID	 Segment	A	
(bp)	
Segment	B	
(bp)	
Total	
(bp)	
Mapping	rate	(%)	 RNA	to	ds-cDNA	
protocol	
5’	 3’	 5’	 3’	 	 	 	
IOA_IPNV006	 1	 8	 1	 2	 12	 7.44	 Glasgow	
IOA_IPNV060	 0	 0	 0	 0	 0	 87.85	 Goettingen	
IOA_IPNV007	 1	 26	 1	 20	 48	 31.86	 Glasgow	
IOA_IPNV008	 0	 157	 4	 19	 180	 4.87	 Glasgow	
IOA_IPNV011	 0	 0	 0	 0	 0	 88.31	 Glasgow	
IOA_IPNV061	 1	 2	 1	 2	 6	 15.84	 Goettingen	
IOA_IPNV019	 0	 0	 0	 0	 0	 86.79	 Glasgow	
IOA_IPNV021	 0	 0	 0	 0	 0	 90.82	 Glasgow	
IOA_IPNV062	 0	 0	 0	 0	 0	 82.71	 Goettingen	
IOA_IPNV063	 0	 5	 0	 0	 5	 84.20	 Goettingen	
IOA_IPNV064	 7	 2	 1	 4	 14	 4.59	 Goettingen	
IOA_IPNV065	 32	 0	 2	 5	 39	 7.88	 Goettingen	
IOA_IPNV066	 0	 0	 0	 0	 0	 86.01	 Goettingen	
IOA_IPNV027	 24	 2	 26	 15	 67	 1.67	 Glasgow	
IOA_IPNV032	 92	 2386	 2	 15	 2495	 2.15	 Glasgow	
IOA_IPNV068	 0	 26	 0	 3	 29	 2.71	 Goettingen	
IOA_IPNV026	 1	 105	 1	 32	 139	 7.35	 Glasgow	
IOA_IPNV069	 0	 2	 0	 0	 2	 87.66	 Goettingen	
IOA_IPNV070	 7	 9	 0	 0	 16	 89.77	 Goettingen	
IOA_IPNV071	 0	 0	 0	 0	 0	 88.02	 Goettingen	
IOA_IPNV072	 52	 31	 8	 1	 92	 2.22	 Goettingen	
IOA_IPNV073	 0	 18	 10	 0	 28	 23.02	 Goettingen	
IOA_IPNV075	 0	 10	 0	 0	 10	 72.88	 Goettingen	
IOA_IPNV076	 17	 5	 0	 0	 22	 9.02	 Goettingen	
IOA_IPNV081	 0	 0	 0	 0	 0	 54.22	 Glasgow	
IOA_IPNV082	 1	 18	 0	 0	 19	 27.33	 Goettingen	
IOA_IPNV083	 0	 26	 0	 2	 28	 13.45	 Goettingen	
IOA_IPNV084	 0	 13	 0	 0	 13	 5.38	 Glasgow	
IOA_IPNV087	 1	 2	 1	 28	 32	 24.71	 Glasgow	
IOA_IPNV088	 1	 36	 0	 19	 56	 4.18	 Glasgow	
IOA_IPNV090	 2	 156	 0	 2	 160	 9.92	 Goettingen	
IOA_IPNV107	 0	 8	 0	 8	 16	 22.21	 Glasgow	
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IOA_IPNV111	 0	 7	 0	 0	 7	 68.80	 Goettingen	
IOA_IPNV001	 0	 6	 0	 20	 26	 30.72	 Glasgow	
IOA_IPNV003	 0	 3	 1	 19	 23	 17.88	 Glasgow	
IOA_IPNV009	 0	 9	 0	 0	 9	 16.04	 Goettingen	
IOA_IPNV010	 1	 115	 2	 19	 137	 6.43	 Glasgow	
IOA_IPNV013	 0	 9	 0	 8	 17	 23.09	 Glasgow	
IOA_IPNV014	 0	 23	 1	 2	 26	 42.91	 Goettingen	
IOA_IPNV018	 0	 26	 1	 2	 29	 15.00	 Glasgow	
IOA_IPNV024	 0	 26	 0	 0	 26	 2.20	 Goettingen	
IOA_IPNV030	 0	 10	 0	 0	 10	 69.31	 Goettingen	
IOA_IPNV031	 1	 22	 1	 8	 32	 34.34	 Glasgow	
IOA_IPNV035	 28	 0	 4	 4	 36	 1.06	 Glasgow	
IOA_IPNV039	 1	 5	 2	 2	 10	 2.78	 Glasgow	
IOA_IPNV051	 1	 2	 17	 2	 22	 3.42	 Glasgow	
IOA_IPNV052	 1	 26	 1	 30	 58	 30.84	 Glasgow	
IOA_IPNV053	 43	 157	 23	 35	 258	 4.83	 Glasgow	
IOA_IPNV054	 0	 4	 1	 37	 42	 39.49	 Glasgow	
IOA_IPNV055	 1	 5	 1	 29	 36	 18.84	 Glasgow	
IOA_IPNV056	 1	 26	 1	 15	 43	 30.42	 Glasgow	
IOA_IPNV057	 1	 11	 2	 2	 16	 14.62	 Glasgow	
IOA_IPNV047	 0	 0	 4	 0	 4	 90.12	 Goettingen	
IOA_IPNV048	 0	 9	 0	 0	 9	 90.55	 Goettingen	
IOA_IPNV049	 0	 11	 10	 0	 21	 90.21	 Goettingen	
IOA_IPNV050	 2	 10	 0	 30	 42	 89.80	 Goettingen	
IOA_IPNV058	 1	 1	 2	 15	 19	 12.09	 Glasgow	
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Table	64.	Sequenced	IPNV	isolates	and	their	genogroups	according	to	segment	A	and	segment	B	phylogeny;	
NA=not	assigned.	
Sequence	ID	 Collection	Year	 Serotype	 Genogroup	(segment	A)	 Genogroup	(segment	B)	
IOA_IPNV006	 1982	 NA	 III	 III	
IOA_IPNV060	 1983	 NA	 I	 I	
IOA_IPNV007	 1984	 NA	 V	 V	
IOA_IPNV008	 1984	 NA	 V	 V	
IOA_IPNV011	 1986	 NA	 III	 III	
IOA_IPNV061	 1986	 Sp	 I	 I	
IOA_IPNV019	 1987	 NA	 III	 III	
IOA_IPNV021	 1987	 NA	 V	 V	
IOA_IPNV062	 1987	 NA	 V	 V	
IOA_IPNV063	 1987	 Ab	 III	 II	
IOA_IPNV064	 1987	 Ab	 III	 II	
IOA_IPNV065	 1987	 Ab	 III	 II	
IOA_IPNV066	 1988	 Ab	 III	 II	
IOA_IPNV027	 1989	 NA	 V	 V	
IOA_IPNV032	 1989	 NA	 V	 V	
IOA_IPNV068	 1989	 Ab	 III	 II	
IOA_IPNV026	 1990	 NA	 V	 V	
IOA_IPNV069	 1992	 Ab	 III	 III	
IOA_IPNV070	 1992	 Sp	 V	 V	
IOA_IPNV071	 1992	 Sp	 V	 V	
IOA_IPNV072	 1992	 Sp	 V	 V	
IOA_IPNV073	 1993	 Sp	 V	 V	
IOA_IPNV075	 1993	 Sp	 V	 V	
IOA_IPNV076	 1994	 Sp	 V	 V	
IOA_IPNV081	 1994	 NA	 I	 I	
IOA_IPNV082	 1996	 Sp	 V	 V	
IOA_IPNV083	 1997	 Sp	 V	 V	
IOA_IPNV084	 1997	 Sp	 V	 V	
IOA_IPNV087	 1997	 Sp	 V	 V	
IOA_IPNV088	 1997	 Sp	 V	 V	
IOA_IPNV090	 1998	 Sp	 V	 V	
IOA_IPNV107	 1999	 Sp	 V	 V	
IOA_IPNV111	 1999	 Sp	 V	 V	
IOA_IPNV001	 2000	 Sp	 V	 V	
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IOA_IPNV003	 2002	 Sp	 V	 V	
IOA_IPNV009	 2003	 Sp	 V	 V	
IOA_IPNV010	 2003	 Sp	 V	 V	
IOA_IPNV013	 2004	 Sp	 V	 V	
IOA_IPNV014	 2004	 Sp	 V	 V	
IOA_IPNV018	 2004	 Sp	 V	 V	
IOA_IPNV024	 2005	 Sp	 V	 V	
IOA_IPNV030	 2006	 Sp	 V	 V	
IOA_IPNV031	 2006	 Sp	 V	 V	
IOA_IPNV035	 2007	 Sp	 V	 V	
IOA_IPNV039	 2008	 Sp	 V	 V	
IOA_IPNV051	 2010	 NA	 V	 V	
IOA_IPNV052	 2011	 NA	 V	 V	
IOA_IPNV053	 2011	 NA	 V	 V	
IOA_IPNV054	 2011	 NA	 V	 V	
IOA_IPNV055	 2012	 NA	 V	 V	
IOA_IPNV056	 2012	 NA	 V	 V	
IOA_IPNV057	 2013	 NA	 V	 V	
IOA_IPNV047	 2014	 Sp	 V	 V	
IOA_IPNV048	 2014	 Sp	 V	 V	
IOA_IPNV049	 2014	 Sp	 V	 V	
IOA_IPNV050	 2014	 Sp	 V	 V	
IOA_IPNV058	 2014	 NA	 V	 V	
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Table	65.	Detailed	VP2	residue	characteristics	of	sequenced	IPNV	isolates	compared	to	the	virulent	reference	
strain	excluding	IoA032;	NA=not	assigned.	Amino	acid	positions	identified	in	previous	studies	as	important	in	
terms	of	viral	virulence	are	listed,	with	a	focus	on	the	positions	217	and	221	(underlined).	
Sequence	ID	 Collection	
Year	
Genogroup	
by	
genotyping	
Amino	acid	position	
	
217				221						247							252						281						282				319											Variant	
Santi	et	al.,	
2004	
2000	 V	 T	 A	 T	 V	 T	 N	 A	 Virulent	
IOA_IPNV006	 1982	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV060	 1983	 I	 A	 T	 E	 N	 T	 A	 A	 NA	
IOA_IPNV007	 1984	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV008	 1984	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV011	 1986	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV061	 1986	 I	 A	 T	 E	 N	 T	 A	 A	 NA	
IOA_IPNV019	 1987	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV021	 1987	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV062	 1987	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV063	 1987	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV064	 1987	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV065	 1987	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV066	 1988	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV027	 1989	 V	 P	 T	 A	 N	 T	 N	 V	 Persistent	
IOA_IPNV068	 1989	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV026	 1990	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV069	 1992	 III	 P	 T	 P	 A	 T	 A	 A	 Persistent	
IOA_IPNV070	 1992	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV071	 1992	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV072	 1992	 V	 P	 A	 A	 T	 T	 N	 A	 Low	virulent	
IOA_IPNV073	 1993	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV075	 1993	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV076	 1994	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV081	 1994	 I	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV082	 1996	 V	 A	 T	 E	 N	 T	 A	 A	 NA	
IOA_IPNV083	 1997	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV084	 1997	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV087	 1997	 V	 P	 A	 A	 I	 T	 N	 A	 Low	virulent	
IOA_IPNV088	 1997	 V	 P	 A	 A	 I	 T	 N	 A	 Low	virulent	
IOA_IPNV090	 1998	 V	 P	 A	 A	 I	 T	 N	 A	 Low	virulent	
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IOA_IPNV107	 1999	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV111	 1999	 V	 P	 A	 A	 I	 T	 N	 A	 Low	virulent	
IOA_IPNV001	 2000	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV003	 2002	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV009	 2003	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV010	 2003	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV013	 2004	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV014	 2004	 V	 P	 S	 A	 V	 T	 N	 A	 NA	
IOA_IPNV018	 2004	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV024	 2005	 V	 P	 T	 A	 V	 T	 N	 A	 Persistent	
IOA_IPNV030	 2006	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV031	 2006	 V	 P	 T	 A	 V	 T	 N	 A	 Persistent	
IOA_IPNV035	 2007	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV039	 2008	 V	 P	 T	 A	 N	 T	 N	 A	 Persistent	
IOA_IPNV051	 2010	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV052	 2011	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV053	 2011	 V	 T	 A	 A	 V	 T	 N	 A	 Virulent	
IOA_IPNV054	 2011	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV055	 2012	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV056	 2012	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV057	 2013	 V	 P	 T	 A	 V	 T	 N	 A	 Persistent	
IOA_IPNV047	 2014	 V	 P	 T	 A	 V	 T	 N	 A	 Persistent	
IOA_IPNV048	 2014	 V	 P	 T	 A	 V	 T	 N	 A	 Persistent	
IOA_IPNV049	 2014	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
IOA_IPNV050	 2014	 V	 P	 T	 A	 V	 T	 N	 A	 Persistent	
IOA_IPNV058	 2014	 V	 P	 A	 A	 V	 T	 N	 A	 Low	virulent	
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III.1.3 Data	processing	–	Additional	Appendix	
V.1.1	MiSeq	reads	process	shows	the	detailed	workflow,	provided	by	Dr.	Stefanie	Wehner,	of	
how	 the	 data,	 generated	 with	 the	 MiSeq,	 was	 processed	 in	 order	 to	 obtain	 whole	 IPNV	
genomes.	
V.1.2	Workflow	for	coverage	plots	generation	shows	the	detailed	workflow,	provided	by	Dr.	
Stefanie	Wehner,	of	how	coverage	plots	were	generated	 for	each	sequenced	 IPNV	sample	
on	the	MiSeq.	
V.2	MinION	data	process	shows	the	detailed	workflow,	provided	by	Dr.	Stefanie	Wehner,	of	
how	the	data	generated	with	the	MinION	was	processed	to	obtain	a	full	IPNV	genome.	
V.3	 Genome	 annotation	 shows	 the	 detailed	 process	 of	 IPNV	 genome	 annotation	 for	
sequenced	IPNV	samples	on	the	MiSeq.	It	was	provided	by	Dr.	Michaël	Bekaert.	
V.4	CAI	shows	the	detailed	workflow,	provided	by	Nicholas	Di	Paola,	of	how	the	CAI	for	each	
IPNV	protein,	based	on	the	single	protein	alignment	from	all	sequenced	IPNV	isolates,	was	
calculated,	with	corresponding	statistical	analysis	and	graphical	output.	
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III.2 Abbreviations	and	Acronyms	
°C	 Celsius	degree	
A	 Adenine	
bp	 Base	pare	
C	 Cytosine	
CaCl2	 Calcium	Chloride	
cDNA	 Complementary	DNA	
CO2	 Carbon	dioxide	
Cp	 Crossing	point	
CPE	 Cytopathic	effect	
CpG	 5'—Cytosine—phosphate—Guanine—3'		
Ct	 Threshold	Cycle	
DNA	 Deoxyribonucleic	acid	
dNTP	 Desoxyribonucleosidtriphosphate	
ds	 Double	stranded	
EDTA	 Ethylenediaminetetraacetic	acid	
EMEM	 Eagle's	Minimum	Essential	Medium	
FBS	 Fetal	bovine	serum	
G	 Guanine	
h	 Hour	
HCl	 Hydrochloric	acid	
HPLC	 High-performance	liquid	chromatography	
iSP9	 Integrated	C9	(phosphoramidite)	spacer	
kbp	 Kilo	base	pair	
kg	 Kilo	gram	
L	 Litre	
M	 Molar	
mg	 Mille	gram	
min	 Minute	
mL	 Mille	litre	
mM	 Mille	molar	
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MnCl2	 Manganese	(II)	chloride	
mol	 Mole	
MW	 Molecular	weight	
N	 Normality	
NaCl	 Sodium	chloride	
ng	 Nano	gram	
nM	 Nano	molar	
OD	 Optical	density	
PBS	 Phosphate	buffered	saline	
PCR	 Polymerase	chain	reaction	
PEG	 Polyethylene	glycol	
qPCR	 Quantitative	polymerase	chain	reaction	
RNA	 Ribonucleic	acid	
RT-qPCR	 Real-time	quantitative	PCR	
sec	 Second	
ss	 Single	stranded	
T	 Thymine	
TAE	 Tris-Acetic	acid-EDTA-buffer	
TC	 Tissue	culture	flask	
Tris	 Tris	(hydroxymethyl)	aminomethane	
U	 Uracil	
V	 Volt	
WP	 Well	plate	
µL	 Micro	litre	
µM	 Micro	molar	
RNase	H	 Ribonuclease	H	
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III.3 Material	
III.3.1 Primer,	Probes,	Adaptors	
3’	iSP9	adaptor	
(Oligonucleotide)	
5’-P-GACCTCTGAGGATTCTAAACXTCCAGTTTAGAATCC-OH-3’	
X=	C9-phosphoamiditespacer		
	
qPCR	forward	
primer	
5’-GCCTACCCCCCGTTCCT	
qPCR	reverse	
primer	
5’-CCCGTCACTGTTGTTGAGTTGA	
qPCR	probe	 5’-6FAM-ACTCTCTACGAGGGAAACGCCGAC--BBQ	
WTA2	adaptor	 5’-GTGGTGTGTTGGGTGTGTTTGGG	
S501	 5’-TAGATCGC		
S502	 5’-CTCTCTAT		
S503	 5’-TATCCTCT		
S504	 5’-AGAGTAGA		
S505	 5’-GTAAGGAG		
S506	 5’-ACTGCATA		
S507	 5’-AAGGAGTA		
S508	 5’-CTAAGCCT		
N701	 5’-TAAGGCGA		
N702	 5’-CGTACTAG		
N703	 5’-AGGCAGAA		
N704	 5’-TCCTGAGC		
N705	 5’-GGACTCCT		
N706	 5’-TAGGCATG		
N707	 5’-CTCTCTAC		
N708	 5’-CAGAGAGG		
N709	 5’-GCTACGCT		
N710	 5’-CGAGGCTG		
N711	 5’-AAGAGGCA		
N712	 5’-GTAGAGGA		
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Nextera®	
transposase	
sequences	
5’-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG		
																																																												(a)	Read	1	-->	
	
5’-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG		
																																																												(d)	Read	2	-->	
Nextera®	Index	
Kit	-	PCR	primers	
5’-AATGATACGGCGACCACCGAGATCTACAC[i5]TCGTCGGCAGCGTC		
																								(c)	i5	Index	read	-->	
5’-CAAGCAGAAGACGGCATACGAGAT[i7]GTCTCGTGGGCTCGG		
																																																																														<--	i7	Index	read	(b)	
IPNV	A	 5’-CGACGACCCCG	
IPNV	B	 5’-GCTCCR(A	or	G)CGCC	
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III.3.2 Chemicals	
10	M	NaOH	BioUltra	 Sigma	Aldrich	
Agarose	Molecular	Grade	 Bioline	
Chloroform,	Chromasolv	for	HPLC	 Sigma	Alrdich	
DNA	decontamination	reagent	250	mL	 Sigma	Aldrich	
Dulbecco’s	Phosphate	Buffered	Solution	(1x;	-CaCl2;	-
MgCl2),	500	mL	
Gibco	
Ethanol	for	molecular	biology	 Sigma	Aldrich	
Ethidium	bromide	 Thermo	Fisher	Scientific	
Ethylenediaminetetraacetic	acid	disodium	salt	dihydrate	 Sigma	Aldrich	
FBS	batch	number:	41F6547K	 Gibco	
Hank’s	Balanced	Salt	Solution	(1x;	-CaCl2;	-MgCl2),	500	mL	 Gibco	
HCl	 VWR	CHemicals	
L-glutamine,	200	mM	(100x),	100	mL	 Gibco	
Minimum	Essential	Medium	(1x;	+Eagle’s	Salt;	+L-
glutamine),	500	mL	
Gibco	
Minimum	Essential	Medium	Non-Essential	Amino	Acids	
(100x),	100	mL	
Gibco	
MyOne	C1	strepatavidine	beads	 Life	Technologies	
NaCl	 Sigma	Aldrich	
peqGold	Trifast	 PeqLab	
Poly	ethylene	glycol,	BioUltra,	8000,	1	kg	 Sigma	Aldrich	
Presept	(100x	2.5	g)	 Division	of	Ethicon,	Inc.	
Propan-2-ol	 Fisher	Scientific	
RNase	A	(20	mg/mL)	 PeqLab	
RNase	away,	250	mL	 Sigma	Aldrich	
TAE	(50x),	1	L	 Fisher	Bio	Reagents	
Tris	 Sigma	Aldrich	
Trypan	Blue	Solution,	0,4	%,	100	mL	 Sigma	Aldrich	
Trypsin	EDTA,	0,05	%	(1x),	500	mL	 Gibco	
Virkon	Desinfectant	(5	kg)	 SLS	
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Molecular	grade	water	 Sigma-	Aldrich	
isopropanol	 Sigma	Aldrich	
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III.3.3 Kits	
Agencourt	AMPure	XP	beads	 Beckman	Coulter	
Agencourt	RNAdvance®	Blood	Kit	 Beckman	Coulter	
Agilent	RNA	6000	Nano	Kit	 Agilent	Technologies	
DNA	Gel	Loading	Dye	 Thermo	Scientific	
dNTP	Mix	(2.5	mM)	 Life	Technologies	
Flow	cell	wash	Kit	EXP-WSH002	 Oxford	Nanopore	
Technologies	
GeneRuler	100	bp	Plus	DNA	Ladder	 Thermo	Scientific	
GeneRuler	Express	Marker	 Thermo	Scientific	
Glycogen	35	mg/mL,	1	mL	 PeqLab	
High	Sensitivity	DNA	Kit	 Agilent	Technologies	
Light	Cycler	480	RNA	Master	Hydrolysis	Probes	(Version	
07)	
Roche	
MasterPure	Complete	DNA	&	RNA	Purification	Kit	 Epicenter	
MiSeq	Reagent	Kit	v3	150	cycles	 Illumina	
Molecular	grade	water	 Sigma	Aldrich	
Nanopore	Sequencing	Kit	SQK-NSK007	R9	version	 Oxford	Nanopore	
Technologies	
NEBNext	mRNA	Second	Strand	Synthesis	Module	 NEB	
Nextera	XT	DNA	Library	Preparation	Kit	 Illumina	
Nextera	XT	Index	Kit	(24	indices)	 Illumina	
Pellet	Paint	Precipitant	 Merck	Milipore	
PhiX	Control	v3	 Illumina	
Protector	Rnase	Inhibitor	(2000	U)	 Roche	
QIAquick	PCR	Purification-Kit		 Qiagen	
Qiagen	RNeasy-MinElute	Cleanup	Kit	 Qiagen	
Qubit	dsDNA	HS	assay		 Life	Technologies	
Random	Hexamers	(50	µM)	 Life	Technologies	
RNaseOUT	Recombinant	Ribonuclease	Inhibitor	(5000	U)	 Life	Technologies	
SuperScript	III	Reverse	Transcriptase	(10000	U)	 Life	Technologies	
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T4	RNA	Ligase	1		 NEB	
Turbo	DNA-free	Kit	Ambion	 Life	Technologies	
WTA2	Complete	Whole	Transcriptome	Amplification	Kit	 Sigma	Aldrich	
T4	gene	32	protein	(100	µg)	 Roche	
RNase	H	(2	U/µL)	 Life	Technologies	
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III.3.4 Consumables	
0.2	mL	Thin	Wall	Tube	Flat	Cap	 Alpha	Laboratories	
1.5	mL	APEX	Tough	Microtube	Natural	 Alpha	Laboratories	
Biosphere	Filter	Tips,	long,	10	µL	 Sarstedt	
DNA	LoBind	Microcentrifuge	tubes	1.5	mL	 Eppendorf	
epDualfilter	TIPS	0.1-10	μl	 Eppendorf	
Gilson	pipette	1000	µL,	200	µL,	100	µL,	20	µL,	10	µL,	2	µL	 Gilson	
Lens	cleaning	tissue	 GE	Healthcare	
Light	Cycler	480	multiwell	plate	96,	white	 Roche	
Light	Cycler	480	Sealing	foil	 Roche	
Maxymum	Recovery,	Filter	tips:	1000	µL,	200	µL,	100	µL,	
20	µL	
Axygen	
Microcentrifuge	tubes	with	flat	cap,	2	mL	 VWR	
Minisart	High-Flow	single	use	syringe	filter,	0.2	µm	 Sartorius	
Qubit	Assay	Tubes,	0.5	mL	 Life	Technologies	
Research	plus	pipette	1000	µL,	100	µL,	10	µL,	2.5	µL	 Eppendorf	
Serological	pipette:	10	mL,	25	mL	 Sarstedt	
Spectrum	Desinfectant	Wipes		 Advanced	Sterilized	Products	
Syringe,	20	mL	 Therumo	
Tissue	culture	flask,	canted	neck,	non-pyrogenic,	non	
cytotoxic:	25	cm2,	75	cm2,	175	cm2	
Sarstedt	
Tissue	culture	plate	with	24	wells,	flat	bottom,	with	lid	 Sarstedt	
DynaMag-2	Magnet	 Life	Technologies	
Qubit	assay	tubes	 Life	Technologies	
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III.3.5 Devices	
Agilent	2100	Bioanalyzer	 Agilent	Technologies	
B.S.5726	Class	II	Flow	Cabinet	 Peteric	Ltd	
Easy	Breeze	Gel	Dryer	 Hoefer	Scientific	Instruments	
Electrophoresis	Apparatus	GPS	200/400	 LKB/	Pharmacia	
Flow	cabinet	TC-48	 Gelaire	
Fluorescence	microscope	TH4-200	 Olympus	
Heating	Block	QBD1		 Grant	
HU6	Mini	Horizontal	Gel	Unit	 SCIE-PLAS	
Inverted	Research	Microscope	IMT-2	 Olympus	
MinION	MKI	 Oxford	Nanopore	
Technologies	
MiSeq	 Illumin	
MyFuge	12	Mini	Centrifuge	 Benchmark	Scientific	
NanoDrop	ND-1000	 Thermo	Fisher	Scientific	
Pipetus,	0,1	mL	-	200	mL	 Hirschmann	
Refrigerated	Microcentrifuge	5418	R	 Eppendorf	
Refrigirated	Centrifuge	4-16KS	 Sigma	
Research	CO2	Incubator	GA2010	 Leec	
Research	CO2	Incubator	GA3000	 Leec	
Rotator,	Vortex	and	Blotter	Intelli-Mixer	RM-2S	 ELMI	
Thermocycler	TGradient	 Biometra	
Tube	shaker	Lab	dancer	 IKA	
WT16	Mini	Rocking	Platform	 Biometra	
Light	Cycler	480	II	 Roche	
Qubit	2.0	 Life	Technologies	
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